US20100034786A1 - Use of PI3K M-TOR and Akt Inhibitors to Induce FOXP3 Expression and Generate Regulatory T Cells - Google Patents
Use of PI3K M-TOR and Akt Inhibitors to Induce FOXP3 Expression and Generate Regulatory T Cells Download PDFInfo
- Publication number
- US20100034786A1 US20100034786A1 US12/518,739 US51873907A US2010034786A1 US 20100034786 A1 US20100034786 A1 US 20100034786A1 US 51873907 A US51873907 A US 51873907A US 2010034786 A1 US2010034786 A1 US 2010034786A1
- Authority
- US
- United States
- Prior art keywords
- cells
- cell
- foxp3
- pi3k
- inhibitor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 230000014509 gene expression Effects 0.000 title claims abstract description 140
- 108091007960 PI3Ks Proteins 0.000 title claims description 187
- 210000003289 regulatory T cell Anatomy 0.000 title claims description 128
- 239000003197 protein kinase B inhibitor Substances 0.000 title claims description 7
- 102000010400 1-phosphatidylinositol-3-kinase activity proteins Human genes 0.000 title 1
- 102100027581 Forkhead box protein P3 Human genes 0.000 title 1
- 101000861452 Homo sapiens Forkhead box protein P3 Proteins 0.000 title 1
- 210000001744 T-lymphocyte Anatomy 0.000 claims abstract description 223
- 239000003112 inhibitor Substances 0.000 claims abstract description 117
- 230000000638 stimulation Effects 0.000 claims abstract description 99
- 230000011664 signaling Effects 0.000 claims abstract description 81
- 238000000034 method Methods 0.000 claims abstract description 74
- 230000005764 inhibitory process Effects 0.000 claims abstract description 62
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 35
- 230000004936 stimulating effect Effects 0.000 claims abstract description 20
- 230000001939 inductive effect Effects 0.000 claims abstract description 16
- 108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 claims description 185
- 102000003993 Phosphatidylinositol 3-kinases Human genes 0.000 claims description 185
- 210000004027 cell Anatomy 0.000 claims description 177
- 108091008874 T cell receptors Proteins 0.000 claims description 172
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims description 168
- 229940043441 phosphoinositide 3-kinase inhibitor Drugs 0.000 claims description 78
- 239000012828 PI3K inhibitor Substances 0.000 claims description 74
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 claims description 69
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 claims description 67
- 229960002930 sirolimus Drugs 0.000 claims description 67
- 108091008611 Protein Kinase B Proteins 0.000 claims description 44
- CZQHHVNHHHRRDU-UHFFFAOYSA-N LY294002 Chemical compound C1=CC=C2C(=O)C=C(N3CCOCC3)OC2=C1C1=CC=CC=C1 CZQHHVNHHHRRDU-UHFFFAOYSA-N 0.000 claims description 25
- 229940126638 Akt inhibitor Drugs 0.000 claims description 4
- 230000006698 induction Effects 0.000 description 93
- 102000013530 TOR Serine-Threonine Kinases Human genes 0.000 description 61
- 108010065917 TOR Serine-Threonine Kinases Proteins 0.000 description 61
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 55
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 52
- 230000000694 effects Effects 0.000 description 47
- 230000004913 activation Effects 0.000 description 42
- 238000011282 treatment Methods 0.000 description 40
- 210000001165 lymph node Anatomy 0.000 description 36
- 108010044467 Isoenzymes Proteins 0.000 description 28
- 101710204747 Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform Proteins 0.000 description 27
- 102100036056 Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform Human genes 0.000 description 27
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 24
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 24
- 239000012823 PI3K/mTOR inhibitor Substances 0.000 description 23
- 230000026731 phosphorylation Effects 0.000 description 23
- 238000006366 phosphorylation reaction Methods 0.000 description 23
- 230000004044 response Effects 0.000 description 22
- 102100038332 Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform Human genes 0.000 description 20
- 101710093328 Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform Proteins 0.000 description 20
- 238000000338 in vitro Methods 0.000 description 20
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 description 19
- 102100036052 Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform Human genes 0.000 description 19
- 101710096503 Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform Proteins 0.000 description 19
- 101001024630 Drosophila melanogaster RNA cytidine acetyltransferase Proteins 0.000 description 18
- 101000652705 Drosophila melanogaster Transcription initiation factor TFIID subunit 4 Proteins 0.000 description 18
- 101000873927 Homo sapiens Squamous cell carcinoma antigen recognized by T-cells 3 Proteins 0.000 description 18
- 101000996915 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) Nucleoporin NSP1 Proteins 0.000 description 18
- 102100035748 Squamous cell carcinoma antigen recognized by T-cells 3 Human genes 0.000 description 18
- 150000001875 compounds Chemical class 0.000 description 18
- 230000033228 biological regulation Effects 0.000 description 15
- 210000004698 lymphocyte Anatomy 0.000 description 15
- 239000000427 antigen Substances 0.000 description 14
- 102000036639 antigens Human genes 0.000 description 14
- 108091007433 antigens Proteins 0.000 description 14
- 238000013459 approach Methods 0.000 description 14
- 230000007812 deficiency Effects 0.000 description 14
- 238000002474 experimental method Methods 0.000 description 13
- 208000023275 Autoimmune disease Diseases 0.000 description 12
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 description 12
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 description 12
- 102100027268 Interferon-stimulated gene 20 kDa protein Human genes 0.000 description 12
- 230000032823 cell division Effects 0.000 description 12
- 230000001965 increasing effect Effects 0.000 description 12
- 238000010212 intracellular staining Methods 0.000 description 12
- 102000004169 proteins and genes Human genes 0.000 description 12
- 108090000623 proteins and genes Proteins 0.000 description 12
- 238000012360 testing method Methods 0.000 description 12
- 238000012546 transfer Methods 0.000 description 12
- 230000003915 cell function Effects 0.000 description 11
- 230000002950 deficient Effects 0.000 description 11
- 230000028993 immune response Effects 0.000 description 11
- 230000002093 peripheral effect Effects 0.000 description 11
- 230000009711 regulatory function Effects 0.000 description 11
- 102000009308 Mechanistic Target of Rapamycin Complex 2 Human genes 0.000 description 10
- 108010034057 Mechanistic Target of Rapamycin Complex 2 Proteins 0.000 description 10
- 230000008901 benefit Effects 0.000 description 10
- 239000012636 effector Substances 0.000 description 10
- 210000003162 effector t lymphocyte Anatomy 0.000 description 10
- 238000001727 in vivo Methods 0.000 description 10
- 230000005784 autoimmunity Effects 0.000 description 9
- 230000002829 reductive effect Effects 0.000 description 9
- 102000008135 Mechanistic Target of Rapamycin Complex 1 Human genes 0.000 description 8
- 108010035196 Mechanistic Target of Rapamycin Complex 1 Proteins 0.000 description 8
- 102100025751 Mothers against decapentaplegic homolog 2 Human genes 0.000 description 8
- 101710143123 Mothers against decapentaplegic homolog 2 Proteins 0.000 description 8
- FCKJZIRDZMVDEM-UHFFFAOYSA-N N-(7,8-dimethoxy-2,3-dihydro-1H-imidazo[1,2-c]quinazolin-5-ylidene)pyridine-3-carboxamide Chemical compound COC1=C(C2=NC(=NC(=O)C3=CN=CC=C3)N4CCNC4=C2C=C1)OC FCKJZIRDZMVDEM-UHFFFAOYSA-N 0.000 description 8
- 108091000080 Phosphotransferase Proteins 0.000 description 8
- 230000004069 differentiation Effects 0.000 description 8
- 210000003630 histaminocyte Anatomy 0.000 description 8
- 230000037361 pathway Effects 0.000 description 8
- 102000020233 phosphotransferase Human genes 0.000 description 8
- 108090000765 processed proteins & peptides Proteins 0.000 description 8
- 230000002441 reversible effect Effects 0.000 description 8
- 150000003384 small molecules Chemical class 0.000 description 8
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 8
- 241000699670 Mus sp. Species 0.000 description 7
- 210000000612 antigen-presenting cell Anatomy 0.000 description 7
- 206010009887 colitis Diseases 0.000 description 7
- 230000006870 function Effects 0.000 description 7
- 230000003472 neutralizing effect Effects 0.000 description 7
- 238000003753 real-time PCR Methods 0.000 description 7
- 230000019491 signal transduction Effects 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 6
- 108010000605 Ribosomal Proteins Proteins 0.000 description 6
- 102000002278 Ribosomal Proteins Human genes 0.000 description 6
- 230000000975 bioactive effect Effects 0.000 description 6
- 230000024245 cell differentiation Effects 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 230000007170 pathology Effects 0.000 description 6
- 230000001105 regulatory effect Effects 0.000 description 6
- 210000001541 thymus gland Anatomy 0.000 description 6
- 230000009261 transgenic effect Effects 0.000 description 6
- 101150076297 ywhaz gene Proteins 0.000 description 6
- 102100037263 3-phosphoinositide-dependent protein kinase 1 Human genes 0.000 description 5
- 108010052946 Activin Receptors Proteins 0.000 description 5
- 102000018918 Activin Receptors Human genes 0.000 description 5
- 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 description 5
- 101000600756 Homo sapiens 3-phosphoinositide-dependent protein kinase 1 Proteins 0.000 description 5
- 101001117146 Homo sapiens [Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 1, mitochondrial Proteins 0.000 description 5
- 108010002350 Interleukin-2 Proteins 0.000 description 5
- 108010029485 Protein Isoforms Proteins 0.000 description 5
- 102000001708 Protein Isoforms Human genes 0.000 description 5
- 102100024908 Ribosomal protein S6 kinase beta-1 Human genes 0.000 description 5
- 101710108924 Ribosomal protein S6 kinase beta-1 Proteins 0.000 description 5
- 230000006044 T cell activation Effects 0.000 description 5
- 102000040945 Transcription factor Human genes 0.000 description 5
- 108091023040 Transcription factor Proteins 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 238000007912 intraperitoneal administration Methods 0.000 description 5
- 239000003446 ligand Substances 0.000 description 5
- 238000012423 maintenance Methods 0.000 description 5
- 206010039073 rheumatoid arthritis Diseases 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- IWCQHVUQEFDRIW-UHFFFAOYSA-N 3-[1-[[4-(6-phenyl-8H-imidazo[4,5-g]quinoxalin-7-yl)phenyl]methyl]piperidin-4-yl]-1H-benzimidazol-2-one Chemical compound O=c1[nH]c2ccccc2n1C1CCN(Cc2ccc(cc2)-c2[nH]c3cc4ncnc4cc3nc2-c2ccccc2)CC1 IWCQHVUQEFDRIW-UHFFFAOYSA-N 0.000 description 4
- 101150107888 AKT2 gene Proteins 0.000 description 4
- 230000007730 Akt signaling Effects 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 102000002254 Glycogen Synthase Kinase 3 Human genes 0.000 description 4
- 108010014905 Glycogen Synthase Kinase 3 Proteins 0.000 description 4
- 101000761737 Homo sapiens Ubiquitin-conjugating enzyme E2 L3 Proteins 0.000 description 4
- 108010074338 Lymphokines Proteins 0.000 description 4
- 102000008072 Lymphokines Human genes 0.000 description 4
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 4
- -1 PI-103 compound Chemical class 0.000 description 4
- 229940124780 PI3K delta inhibitor Drugs 0.000 description 4
- 102100033810 RAC-alpha serine/threonine-protein kinase Human genes 0.000 description 4
- 229940124639 Selective inhibitor Drugs 0.000 description 4
- 102100024861 Ubiquitin-conjugating enzyme E2 L3 Human genes 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 101150045355 akt1 gene Proteins 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 239000011324 bead Substances 0.000 description 4
- 230000000903 blocking effect Effects 0.000 description 4
- 230000001419 dependent effect Effects 0.000 description 4
- 238000000684 flow cytometry Methods 0.000 description 4
- 230000003832 immune regulation Effects 0.000 description 4
- 210000000987 immune system Anatomy 0.000 description 4
- 230000036039 immunity Effects 0.000 description 4
- 238000003119 immunoblot Methods 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 239000000411 inducer Substances 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 230000002265 prevention Effects 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- QDLHCMPXEPAAMD-QAIWCSMKSA-N wortmannin Chemical compound C1([C@]2(C)C3=C(C4=O)OC=C3C(=O)O[C@@H]2COC)=C4[C@@H]2CCC(=O)[C@@]2(C)C[C@H]1OC(C)=O QDLHCMPXEPAAMD-QAIWCSMKSA-N 0.000 description 4
- QDLHCMPXEPAAMD-UHFFFAOYSA-N wortmannin Natural products COCC1OC(=O)C2=COC(C3=O)=C2C1(C)C1=C3C2CCC(=O)C2(C)CC1OC(C)=O QDLHCMPXEPAAMD-UHFFFAOYSA-N 0.000 description 4
- FWYYZGLCNUZWPF-UHFFFAOYSA-N 8-(2-methylphenoxy)-2-(4-morpholinyl)-1H-quinolin-4-one Chemical compound CC1=CC=CC=C1OC1=CC=CC2=C1NC(N1CCOCC1)=CC2=O FWYYZGLCNUZWPF-UHFFFAOYSA-N 0.000 description 3
- 102100034540 Adenomatous polyposis coli protein Human genes 0.000 description 3
- 101000924577 Homo sapiens Adenomatous polyposis coli protein Proteins 0.000 description 3
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 3
- 108010034219 Insulin Receptor Substrate Proteins Proteins 0.000 description 3
- 102100025087 Insulin receptor substrate 1 Human genes 0.000 description 3
- 108010002335 Interleukin-9 Proteins 0.000 description 3
- 102000005650 Notch Receptors Human genes 0.000 description 3
- 108010070047 Notch Receptors Proteins 0.000 description 3
- 108090000315 Protein Kinase C Proteins 0.000 description 3
- 102000003923 Protein Kinase C Human genes 0.000 description 3
- 101710113459 RAC-alpha serine/threonine-protein kinase Proteins 0.000 description 3
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 3
- 239000012190 activator Substances 0.000 description 3
- 210000003719 b-lymphocyte Anatomy 0.000 description 3
- 230000003197 catalytic effect Effects 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 230000001010 compromised effect Effects 0.000 description 3
- 230000004940 costimulation Effects 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 230000001506 immunosuppresive effect Effects 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 210000002501 natural regulatory T cell Anatomy 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- 108010068338 p38 Mitogen-Activated Protein Kinases Proteins 0.000 description 3
- 230000002085 persistent effect Effects 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 210000004989 spleen cell Anatomy 0.000 description 3
- 210000004988 splenocyte Anatomy 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 102100040685 14-3-3 protein zeta/delta Human genes 0.000 description 2
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 2
- 108010013238 70-kDa Ribosomal Protein S6 Kinases Proteins 0.000 description 2
- NGAGMBNBKCDCDJ-UHFFFAOYSA-N 8-phenyl-2-(1-piperazinyl)-1-benzopyran-4-one Chemical compound C1=CC=C2C(=O)C=C(N3CCNCC3)OC2=C1C1=CC=CC=C1 NGAGMBNBKCDCDJ-UHFFFAOYSA-N 0.000 description 2
- 101001082110 Acanthamoeba polyphaga mimivirus Eukaryotic translation initiation factor 4E homolog Proteins 0.000 description 2
- 101150051155 Akt3 gene Proteins 0.000 description 2
- 238000011740 C57BL/6 mouse Methods 0.000 description 2
- 102000004631 Calcineurin Human genes 0.000 description 2
- 108010042955 Calcineurin Proteins 0.000 description 2
- 229930105110 Cyclosporin A Natural products 0.000 description 2
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 2
- 108010036949 Cyclosporine Proteins 0.000 description 2
- 101001082109 Danio rerio Eukaryotic translation initiation factor 4E-1B Proteins 0.000 description 2
- HKVAMNSJSFKALM-GKUWKFKPSA-N Everolimus Chemical compound C1C[C@@H](OCCO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 HKVAMNSJSFKALM-GKUWKFKPSA-N 0.000 description 2
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 2
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 2
- 101000964898 Homo sapiens 14-3-3 protein zeta/delta Proteins 0.000 description 2
- 101001018097 Homo sapiens L-selectin Proteins 0.000 description 2
- 101000950669 Homo sapiens Mitogen-activated protein kinase 9 Proteins 0.000 description 2
- 206010021143 Hypoxia Diseases 0.000 description 2
- 206010062016 Immunosuppression Diseases 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- 108010055717 JNK Mitogen-Activated Protein Kinases Proteins 0.000 description 2
- 102100033467 L-selectin Human genes 0.000 description 2
- 108091054455 MAP kinase family Proteins 0.000 description 2
- 102000043136 MAP kinase family Human genes 0.000 description 2
- 102100037809 Mitogen-activated protein kinase 9 Human genes 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical group C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- 101150097381 Mtor gene Proteins 0.000 description 2
- 241000699660 Mus musculus Species 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 102000038030 PI3Ks Human genes 0.000 description 2
- 102000001253 Protein Kinase Human genes 0.000 description 2
- 108091005735 TGF-beta receptors Proteins 0.000 description 2
- CBPNZQVSJQDFBE-FUXHJELOSA-N Temsirolimus Chemical compound C1C[C@@H](OC(=O)C(C)(CO)CO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 CBPNZQVSJQDFBE-FUXHJELOSA-N 0.000 description 2
- 102000016715 Transforming Growth Factor beta Receptors Human genes 0.000 description 2
- 102000009618 Transforming Growth Factors Human genes 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 229940125528 allosteric inhibitor Drugs 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- 206010003246 arthritis Diseases 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 230000020411 cell activation Effects 0.000 description 2
- 239000006143 cell culture medium Substances 0.000 description 2
- 230000011712 cell development Effects 0.000 description 2
- 230000005754 cellular signaling Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 229960001265 ciclosporin Drugs 0.000 description 2
- 239000011436 cob Substances 0.000 description 2
- 108091008034 costimulatory receptors Proteins 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000002900 effect on cell Effects 0.000 description 2
- 230000003028 elevating effect Effects 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 229960005167 everolimus Drugs 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 2
- 230000007954 hypoxia Effects 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 229940043355 kinase inhibitor Drugs 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 229940124302 mTOR inhibitor Drugs 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 239000003628 mammalian target of rapamycin inhibitor Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000003278 mimic effect Effects 0.000 description 2
- 239000003226 mitogen Substances 0.000 description 2
- 229960004857 mitomycin Drugs 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- QTHCAAFKVUWAFI-OCKHKDLRSA-N n-[(z)-(6-bromoimidazo[1,2-a]pyridin-3-yl)methylideneamino]-n,2-dimethyl-5-nitrobenzenesulfonamide Chemical compound C=1N=C2C=CC(Br)=CN2C=1\C=N/N(C)S(=O)(=O)C1=CC([N+]([O-])=O)=CC=C1C QTHCAAFKVUWAFI-OCKHKDLRSA-N 0.000 description 2
- 150000002894 organic compounds Chemical class 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 108060006633 protein kinase Proteins 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000000284 resting effect Effects 0.000 description 2
- 238000003757 reverse transcription PCR Methods 0.000 description 2
- 239000012679 serum free medium Substances 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 229960000235 temsirolimus Drugs 0.000 description 2
- 108091008023 transcriptional regulators Proteins 0.000 description 2
- 238000011830 transgenic mouse model Methods 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- NCGICGYLBXGBGN-UHFFFAOYSA-N 3-morpholin-4-yl-1-oxa-3-azonia-2-azanidacyclopent-3-en-5-imine;hydrochloride Chemical compound Cl.[N-]1OC(=N)C=[N+]1N1CCOCC1 NCGICGYLBXGBGN-UHFFFAOYSA-N 0.000 description 1
- UZOVYGYOLBIAJR-UHFFFAOYSA-N 4-isocyanato-4'-methyldiphenylmethane Chemical compound C1=CC(C)=CC=C1CC1=CC=C(N=C=O)C=C1 UZOVYGYOLBIAJR-UHFFFAOYSA-N 0.000 description 1
- 102100034135 Activin receptor type-1C Human genes 0.000 description 1
- 102000002659 Amyloid Precursor Protein Secretases Human genes 0.000 description 1
- 108010043324 Amyloid Precursor Protein Secretases Proteins 0.000 description 1
- 102000006306 Antigen Receptors Human genes 0.000 description 1
- 108010083359 Antigen Receptors Proteins 0.000 description 1
- 101100028391 Arabidopsis thaliana PI4KB1 gene Proteins 0.000 description 1
- 208000003950 B-cell lymphoma Diseases 0.000 description 1
- 102100021738 Beta-adrenergic receptor kinase 1 Human genes 0.000 description 1
- 102000007350 Bone Morphogenetic Proteins Human genes 0.000 description 1
- 108010007726 Bone Morphogenetic Proteins Proteins 0.000 description 1
- 108091007962 Class I PI3K catalytic Proteins 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 241000272201 Columbiformes Species 0.000 description 1
- 108010024986 Cyclin-Dependent Kinase 2 Proteins 0.000 description 1
- 102100032857 Cyclin-dependent kinase 1 Human genes 0.000 description 1
- 101710106279 Cyclin-dependent kinase 1 Proteins 0.000 description 1
- 102100036239 Cyclin-dependent kinase 2 Human genes 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 102100030011 Endoribonuclease Human genes 0.000 description 1
- 101710199605 Endoribonuclease Proteins 0.000 description 1
- 208000009386 Experimental Arthritis Diseases 0.000 description 1
- 208000007882 Gastritis Diseases 0.000 description 1
- 102000019058 Glycogen Synthase Kinase 3 beta Human genes 0.000 description 1
- 108010051975 Glycogen Synthase Kinase 3 beta Proteins 0.000 description 1
- 208000009329 Graft vs Host Disease Diseases 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 1
- 102100032742 Histone-lysine N-methyltransferase SETD2 Human genes 0.000 description 1
- 101000799189 Homo sapiens Activin receptor type-1B Proteins 0.000 description 1
- 101000799193 Homo sapiens Activin receptor type-1C Proteins 0.000 description 1
- 101000751445 Homo sapiens Beta-adrenergic receptor kinase 1 Proteins 0.000 description 1
- 101100005713 Homo sapiens CD4 gene Proteins 0.000 description 1
- 101000654725 Homo sapiens Histone-lysine N-methyltransferase SETD2 Proteins 0.000 description 1
- 101000977771 Homo sapiens Interleukin-1 receptor-associated kinase 4 Proteins 0.000 description 1
- 101000595746 Homo sapiens Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform Proteins 0.000 description 1
- 101001059454 Homo sapiens Serine/threonine-protein kinase MARK2 Proteins 0.000 description 1
- 101000601441 Homo sapiens Serine/threonine-protein kinase Nek2 Proteins 0.000 description 1
- 101000770770 Homo sapiens Serine/threonine-protein kinase WNK1 Proteins 0.000 description 1
- 102000003746 Insulin Receptor Human genes 0.000 description 1
- 108010001127 Insulin Receptor Proteins 0.000 description 1
- 102100023533 Interleukin-1 receptor-associated kinase 4 Human genes 0.000 description 1
- 102000019145 JUN kinase activity proteins Human genes 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 208000030289 Lymphoproliferative disease Diseases 0.000 description 1
- 101150018665 MAPK3 gene Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 101150024075 Mapk1 gene Proteins 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 101100087591 Mus musculus Rictor gene Proteins 0.000 description 1
- 101100268066 Mus musculus Zap70 gene Proteins 0.000 description 1
- 238000000636 Northern blotting Methods 0.000 description 1
- 102100032315 RAC-beta serine/threonine-protein kinase Human genes 0.000 description 1
- 101710156940 RAC-beta serine/threonine-protein kinase Proteins 0.000 description 1
- 102100032314 RAC-gamma serine/threonine-protein kinase Human genes 0.000 description 1
- 101710103995 RAC-gamma serine/threonine-protein kinase Proteins 0.000 description 1
- 101710113029 Serine/threonine-protein kinase Proteins 0.000 description 1
- 102100028904 Serine/threonine-protein kinase MARK2 Human genes 0.000 description 1
- 102100037703 Serine/threonine-protein kinase Nek2 Human genes 0.000 description 1
- 102100031463 Serine/threonine-protein kinase PLK1 Human genes 0.000 description 1
- 102100029064 Serine/threonine-protein kinase WNK1 Human genes 0.000 description 1
- 102000007374 Smad Proteins Human genes 0.000 description 1
- 108010007945 Smad Proteins Proteins 0.000 description 1
- 230000006052 T cell proliferation Effects 0.000 description 1
- 230000005867 T cell response Effects 0.000 description 1
- 102000046299 Transforming Growth Factor beta1 Human genes 0.000 description 1
- 101800002279 Transforming growth factor beta-1 Proteins 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 238000002679 ablation Methods 0.000 description 1
- 206010000210 abortion Diseases 0.000 description 1
- 231100000176 abortion Toxicity 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 230000030741 antigen processing and presentation Effects 0.000 description 1
- 238000010420 art technique Methods 0.000 description 1
- 239000002439 beta secretase inhibitor Substances 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 229940112869 bone morphogenetic protein Drugs 0.000 description 1
- 210000004970 cd4 cell Anatomy 0.000 description 1
- 238000000423 cell based assay Methods 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000006369 cell cycle progression Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000010001 cellular homeostasis Effects 0.000 description 1
- 101150113535 chek1 gene Proteins 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000000139 costimulatory effect Effects 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000002224 dissection Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000013020 embryo development Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000010363 gene targeting Methods 0.000 description 1
- 238000012252 genetic analysis Methods 0.000 description 1
- 208000024908 graft versus host disease Diseases 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 210000004524 haematopoietic cell Anatomy 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 235000003642 hunger Nutrition 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 150000002484 inorganic compounds Chemical class 0.000 description 1
- 229910010272 inorganic material Inorganic materials 0.000 description 1
- 230000031261 interleukin-10 production Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000031146 intracellular signal transduction Effects 0.000 description 1
- 238000000021 kinase assay Methods 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 210000005210 lymphoid organ Anatomy 0.000 description 1
- 201000001268 lymphoproliferative syndrome Diseases 0.000 description 1
- 239000003120 macrolide antibiotic agent Substances 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000000897 modulatory effect Effects 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 230000005937 nuclear translocation Effects 0.000 description 1
- 229940127017 oral antidiabetic Drugs 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 102000002574 p38 Mitogen-Activated Protein Kinases Human genes 0.000 description 1
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 description 1
- 238000004634 pharmacological analysis method Methods 0.000 description 1
- 230000009038 pharmacological inhibition Effects 0.000 description 1
- 230000004983 pleiotropic effect Effects 0.000 description 1
- 108010056274 polo-like kinase 1 Proteins 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000009822 protein phosphorylation Effects 0.000 description 1
- 102000027426 receptor tyrosine kinases Human genes 0.000 description 1
- 108091008598 receptor tyrosine kinases Proteins 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 230000000452 restraining effect Effects 0.000 description 1
- 210000003705 ribosome Anatomy 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 102000009076 src-Family Kinases Human genes 0.000 description 1
- 108010087686 src-Family Kinases Proteins 0.000 description 1
- 230000037351 starvation Effects 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- QFJCIRLUMZQUOT-UHFFFAOYSA-N temsirolimus Natural products C1CC(O)C(OC)CC1CC(C)C1OC(=O)C2CCCCN2C(=O)C(=O)C(O)(O2)C(C)CCC2CC(OC)C(C)=CC=CC=CC(C)CC(C)C(=O)C(OC)C(O)C(C)=CC(C)C(=O)C1 QFJCIRLUMZQUOT-UHFFFAOYSA-N 0.000 description 1
- 206010043778 thyroiditis Diseases 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 230000023750 transforming growth factor beta production Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 230000009752 translational inhibition Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
- A61K39/4621—Cellular immunotherapy characterized by the effect or the function of the cells immunosuppressive or immunotolerising
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4632—T-cell receptors [TCR]; antibody T-cell receptor constructs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/46433—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
- C12N5/0637—Immunosuppressive T lymphocytes, e.g. regulatory T cells or Treg
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/99—Enzyme inactivation by chemical treatment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K2035/122—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells for inducing tolerance or supression of immune responses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/40—Regulators of development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
- C12N2501/51—B7 molecules, e.g. CD80, CD86, CD28 (ligand), CD152 (ligand)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
- C12N2501/515—CD3, T-cell receptor complex
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/60—Transcription factors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/70—Enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/999—Small molecules not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/11—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from blood or immune system cells
Definitions
- the invention relates to new uses of phosphatidyl inositol-3-kinase (PI3K) inhibitors.
- PI3K phosphatidyl inositol-3-kinase
- the invention relates to new methods for induction of Foxp3 expression in T cells.
- Treg cells Regulatory T cells
- Immune interventions aimed at restraining effector T cells (to limit autoimmunity and immune pathology) or boosting immune responses (e.g. against tumours) require approaches that change the balance between Treg cells and effector T cells.
- Current approaches are slow, inefficient, rely on the use of bioactive peptides purified from biological sources, or on the expansion of pre-existing Treg cells.
- transcriptional regulator Foxp3 an intracellular protein and member of the forkhead/winged-helix family of transcriptional regulators, is characteristic of Treg cells.
- TGFbeta Treatment of T cells with the bioactive peptide TGFbeta is known to induce de novo expression of Foxp3 (Chen et al., 2003 J. Exp. Med. vol 198, pp 1875-1886).
- rapamycin (sirolimus) has been used to manipulate the expansion of pre-existing Treg cells expressing Foxp3 (Zheng et al., 2003 Immunity vol 19 p 503; Battaglia et al., 2005 Blood vol 105 p 4743).
- such treatments have been shown not to induce the de novo expression of Foxp3, which is a problem.
- Battaglia et al states ‘The presence of CD4 CD25 Tr cells . . .
- rapamycin-exposed T-cell cultures may be due to either a de novo induction of CD25 Tr cells from CD25 T cells or to a selective expansion of the naturally occurring CD4 CD25 FoxP3 Tr-cell subset already present in limited amounts at the beginning of the culture (ie, the 10% of CD4 CD25bright T cells usually found in a na ⁇ ve spleen).
- CD4 T cells depleted of the CD25 Tr cells were cultured for 3 weeks in the presence or absence of rapamycin.
- CD4 CD25 T cells activated in the presence of rapamycin gave rise to a population of T cells that failed to suppress cell proliferation in vitro ( FIG. 4A ).
- prior art techniques are typically operating via stimulation or activation of existing Tregs which can enhance Foxp3 expression in cells already expressing it, or are based on blocking non-Tregs, leading to expansion/selection or over-representation of Tregs in the population. These outcomes are the same as rapamycin treatment as noted above.
- Another example is the use of TGFbeta which typically enhances an already present level of Foxp3 expression. No such approaches lead to de novo Foxp3 expression/de novo Tregs.
- Inhibitors of the PI3K isoenzyme p110gamma are under evaluation for the treatment of autoimmune diseases based on mechanisms distinct from Treg cells.
- WO2004/032867A3 discloses molecules preferentially associated with effector T cells or regulatory T cells and methods of their use. This document presents population level studies. PI3K inhibitors are mentioned on page 76 of this document and in FIG. 23A . The effects on Foxp3 expression (if any—high doses of inhibitor according to this document are probably cytotoxic and the low doses arguably show no significant effect) appear to be due to an expansion of Foxp3 expressing cells, or an enhancement in expression of Foxp3 in Foxp3 expressing cells. There is no evidence of de novo Foxp3 expression in the teachings of WO2004/032867A3.
- US2004/0072766 discloses methods for modulating T cell responses by manipulating intracellular signal transduction.
- the methods disclosed in this document involve the addition of stimulators and inhibitors together i.e. at once or simultaneously. No de novo Poxp3 expression is generated in this approach.
- Foey et al (Arthritis Res 2002 vol 4 pp 64-70) disclose that cytokine stimulated T cells induce macrophage IL-10 production dependent on phosphatidyl inositol 3-kinase and p70S6K and the implications for rheumatoid arthritis. This relates to the study of macrophages in the presence of T cells. The T cells were fixed to separate the effects before and after contact. Thus, the cells are fixed and no longer alive when the PI3K inhibitors are added in these methods. Thus no de novo Foxp3 expression is produced by these methods.
- rapamycin and LY294002 co-operate to inhibit T cell proliferation.
- This example in common with other studies, involves exposing T cells to inhibitors in order to study aspects of their biology such as proliferation. The inhibitors are added before stimulation, typically at least 30 minutes prior to stimulation. Cell numbers or other parameters are then examined. No de novo Foxp3 expression is generated by such techniques.
- US2005/0261317 disclose inhibitors of human PI3K delta. This document merely examines certain neutrophils, B cells and certain exocytotic cells, and is not connected with T cells or Tregs. The data presented are merely aimed at validating that the PI3K inhibitors disclosed actually block the relevant functions.
- US2004/0126781 discloses methods of preventing immune-mediated abortion by inhibiting a CD28-mediated costimulatory signal. These methods involve blocking of CD28 with soluble ligand. Blocking of CD28 with soluble ligand is clearly mutually exclusive with stimulation/activation of T cells.
- the present invention seeks to overcome problem(s) associated with the prior art.
- Foxp3 expression has been associated with regulatory T cell function. In certain settings, Foxp3 expression has been shown to be necessary and sufficient to induce regulatory T cell function. Indeed, Foxp3 expression has in some circumstances been regarded as an indicator or identifier of regulatory T cells as compared to other sub-populations of T cells. In the prior art, the only known way of inducing Foxp3 expression pharmacologically has been by treating a population of T cells with the bioactive peptide TGF ⁇ .
- the present inventors have surprisingly discovered a new technique for induction of Foxp3 expression.
- This new method involves the use of PI3-K inhibitors which have not previously been shown to induce Foxp3 expression.
- a key finding of the present inventors is with regard to the timing of treatments to the target cells. Specifically the inventors have found that the inhibitors (such as PI3K inhibitors) must be added to the cells only after they have been stimulated. Thus the stimulation/activation step must be followed by incubation or a time delay before inhibitors are contacted with the cells. Addition of inhibitors simultaneously with or even before activation does not lead to de novo Foxp3 expression. It is thus a key teaching of the invention that the inhibitors should be added after stimulation/activation. These important timings are discussed in more detail below.
- the inhibitors such as PI3K inhibitors
- the present invention is based on these surprising findings.
- the invention provides a method of inducing Foxp3 expression in a T cell comprising
- the invention in another aspect, relates to a method of inducing Foxp3 expression in a previously stimulated T cell comprising inhibiting signalling in said T cell via PI3K alpha or PI3K delta or m-TOR or Akt, wherein said inhibition is commenced 10 to 22 hours after the stimulation.
- the invention relates to a method of treating a subject in need of regulatory T cell(s) comprising
- said inhibition is commenced about 17 to 19 hours after the stimulation.
- said inhibition is commenced about 18 hours after the stimulation.
- the inhibiting signalling step comprises inhibiting signalling via PI3K alpha or PI3K delta.
- Suitably inhibiting signalling via PI3K alpha or PI3K delta comprises contacting said cell with PI3K inhibitor, and wherein said inhibitor inhibits PI3K alpha and/or PI3K delta.
- said method(s) further comprise withdrawing said stimulation no later than at the time of inhibiting signalling.
- the invention relates to a method for generating a regulatory T-cell comprising
- the invention in another aspect, relates to a method for generating a regulatory T-cell comprising treating a stimulated CD8 ⁇ T cell with phosphatidyl inositol 3 kinase (PI3K) inhibitor wherein said inhibitor inhibits PI3K alpha and/or PI3K delta.
- PI3K phosphatidyl inositol 3 kinase
- the invention in another aspect, relates to a method for generating a regulatory T-cell comprising treating a stimulated T cell with phosphatidyl inositol 3 kinase (PI3K) inhibitor wherein said inhibitor inhibits PI3K alpha and/or PI3K delta.
- PI3K phosphatidyl inositol 3 kinase
- the invention provides a method for generating a regulatory T-cell comprising treating a stimulated T cell with m-TOR inhibitor.
- the m-TOR inhibitor may be any known m-TOR inhibitor such as rapamycin (sirolimus), or an analogue thereof such as RAD001 (everolimus), CCI-779 (temsirolimus), AP23573, or a combined m-TOR/p110alpha inhibitor such as PI103.
- rapamycin sirolimus
- an analogue thereof such as RAD001 (everolimus), CCI-779 (temsirolimus), AP23573, or a combined m-TOR/p110alpha inhibitor such as PI103.
- m-TOR inhibitor is rapamycin.
- Stimulation may be by any suitable means which renders the T cell sensitive to the action of PI3K inhibitors and/or m-TOR inhibitors for Treg production as described herein.
- stimulation of the T cell is by stimulation of the TCR receptor. In some embodiments this stimulation may be a persistent or enduring stimulation, which means that the stimulation is not necessarily withdrawn at the time of action of PI3K and/or m-TOR inhibitors.
- a stimulated T cell is a T cell which has been stimulated via the T cell receptor. More preferably stimulation of the T cell is by stimulation of the TCR receptor followed by withdrawal of said TCR receptor stimulation. In another embodiment stimulation may be via CD3. In either case, preferably a costimulatory receptor such as CD28 is also stimulated.
- CD28 is stimulated at the same time as stimulation of the TCR or CD3 receptor(s).
- stimulation is via simultaneous stimulation of TCR and/or CD3, and of CD28, preferably followed by withdrawal of stimulation via TCR and CD3.
- Withdrawal of stimulation may refer to the simple removal of signal, or may refer to more active methods such as blocking costimulation of CD3/CD28 at the time of addition of inhibitor(s).
- Preferred embodiments of the invention may further comprise a signal deprivation step e.g. as set out in the examples section.
- the invention provides a method for generating a regulatory T-cell comprising (i) stimulating a T cell; (ii) optionally withdrawing said stimulation; and (iii) inhibiting signalling via PI3K alpha or PI3K delta and/or via m-TOR and/or via Akt in said T cell.
- step (ii) comprises withdrawing said stimulation.
- Stimulation of said T cell may be via stimulation of the TCR receptor or via CD3, and a costimulatory receptor such as CD28.
- stimulation is via the T cell receptor followed by withdrawal of said stimulation via the T cell receptor.
- the invention provides a method of treating a subject in need of regulatory T cell(s) comprising
- stimulating said T cell comprises contacting said T cell with anti-TCR or anti-CD3 antibody.
- stimulating said T cell further comprises contacting said T cell with anti-CD28 antibody, preferably contacting said T cell with anti-TCR or anti-CD3 antibody, and with anti-CD28 antibody simultaneously.
- the mode of presentation of such antibodies may be chosen by the operator, for example this may be accomplished using plate-bound antibodies or by using beads coated with antibodies such as anti-CD3/anti-CD28 antibodies, or by any other means of presentation known to the operator.
- stimulation may be by contact of the target cells such as peripheral T cells with antigen presenting cells, such as antigen presenting cells contacted with specific peptide antigen.
- said stimulation may be enduring or persistent meaning that the stimulation is not withdrawn at the time of m-TOR/PI3K/Akt inhibition.
- the stimulation may be withdrawn at the time of m-TOR/PI3K/Akt inhibition, may be withdrawn before the time of m-TOR/PI3K/Akt inhibition, suitably the stimulation may be withdrawn at the time of m-TOR/PI3K/Akt inhibition.
- the invention provides a method of inducing Foxp3 expression in a previously stimulated T cell comprising inhibiting signalling in said T cell via PI3K alpha or PI3K delta and/or m-TOR and/or Akt.
- the invention provides a method of inducing Foxp3 expression in a T cell comprising stimulating a T cell; withdrawing said stimulation; and inhibiting signalling in said T cell via PI3K alpha or PI3K delta and/or m-TOR and/or Akt.
- said method comprises inducing Foxp3 expression in a T cell by stimulating a T cell via the T cell receptor; withdrawing said stimulation via the T cell receptor; and inhibiting signalling in said T cell via PI3K alpha or PI3K delta and/or m-TOR and/or Akt.
- the invention provides a method as described above wherein inhibiting signalling via PI3K alpha or PI3K delta and/or m-TOR and/or Akt comprises inhibiting signalling via PI3K alpha or PI3K delta.
- inhibiting signalling via PI3K alpha or PI3K delta comprises contacting said cell with PI3K inhibitor.
- said inhibitor inhibits PI3K alpha and/or PI3K delta.
- inhibiting signalling via PI3K alpha or PI3K delta or m-TOR or Akt comprises inhibiting signalling via m-TOR, preferably inhibiting signalling via m-TOR comprises contacting said cell with rapamycin.
- the invention provides use of a PI3K inhibitor in the induction of differentiation of a T cell into a regulatory T cell wherein said inhibitor inhibits PI3K alpha and/or PI3K delta.
- the invention provides use of a PI3K inhibitor in the induction of Foxp3 expression wherein said inhibitor inhibits PI3K alpha and/or PI3K delta.
- the invention provides use of a PI3K alpha inhibitor or a PI3K delta inhibitor for the manufacture of a medicament for deficiency of regulatory T cells.
- the deficiency of regulatory T cells is an autoimmune disorder or an immune pathology.
- said deficiency is rheumatoid arthritis or diabetes, preferably type I diabetes, colitis, or a lymphoproliferative disorder where the presence of Treg cells indicates a favourable prognosis, preferably a B cell lymphoma.
- the invention provides a PI3K alpha inhibitor for use in the treatment of a deficiency of regulatory T cells.
- the invention provides a PI3K delta inhibitor for use in the treatment of a deficiency of regulatory T cells.
- the invention provides a M-TOR inhibitor for use in the treatment of a deficiency of regulatory T cells.
- the invention provides an Akt inhibitor for use in the treatment of a deficiency of regulatory T cells.
- the invention provides a kit comprising a TCR stimulant and an inhibitor of PI3K alpha or delta and/or an inhibitor of m-TOR and/or an inhibitor of Akt.
- the invention provides a kit as described above wherein said TCR stimulant comprises anti-TCR or anti-CD3, and anti-CD28.
- said anti-TCR/anti-CD3/anti-CD28 agents are antibodies to TCR/CD3/CD28 respectively.
- the invention provides a kit as described above further comprising an m-TOR inhibitor such as rapamycin.
- a m-TOR inhibitor may be advantageously used in expansion of the Foxp3 expressing T cells generated by use of the TCR stimulant/PI3K inhibitor of the kits of the invention.
- a m-TOR inhibitor may advantageously increase the efficiency of Foxp3 induction.
- the invention provides a kit as described above further comprising an Akt inhibitor.
- the inhibitor is a PI3K inhibitor.
- said PI3K inhibitor comprises LY294002; preferably said PI3K inhibitor comprises a class IA PI3K inhibitor such as PIK-90 (alpha/m-TOR), PI-103 (alpha/gamma) or YM-024 (alpha/delta).
- the starting population of cells (target cells) in which Foxp3 is to be induced are depleted of pre-existing Tregs.
- the starting population of cells is depleted of CD25+ cells. If a population of cells comprises less than 1% Tregs we consider it to be depleted of Tregs or effectively free of Tregs.
- the starting population of cells does not comprise Tregs.
- the method of the invention comprises a further step of such depletion; suitably such step is carried out before stimulation.
- the starting population of cells (target cells) in which Foxp3 is to be induced are enriched for na ⁇ ve T cells.
- the starting population is enriched for CD62L cells and/or enriched for CD45Rb cells.
- the starting population is enriched for CD62L cells and enriched for CD45Rb cells.
- the method of the invention comprises a further step of such enrichment; suitably such step is carried out before stimulation.
- activation and inhibition of the cells are chronologically separated. Simultaneous activation and inhibition does not lead to de novo Foxp3 expression. Suitably activation and inhibition are not performed simultaneously according to the present invention. This has happened in the prior art and does not lead to de novo Foxp3 expression.
- the ‘0’ timepoint is indicative of prior art treatments—this represents 0 hours between stimulation/activation and addition of inhibitors i.e. inhibitors added at the same time as activation/stimulation. It is very clear that this treatment is ineffective at induction of de novo Foxp3 expression.
- treatments according to the present invention involving a delay or incubation between stimulation and inhibition are effective for induction of de novo Foxp3 expression.
- This does not mean that inhibitors cannot be added with activators still present, but means that activation must precede inhibition or that inhibition must occur after activation.
- the time of separation can be very important and is a key contribution to the art.
- the time between activation and inhibition may be specifically chosen for particular application(s) as taught herein. Exemplary timings are when inhibitor treatment is applied approx. 12-18 hours after activation, suitably about 18 hours after activation. This is discussed in more detail below.
- the methods of the invention are applied to induce Foxp3 without a requirement for expansion of the cells.
- na ⁇ ve CD4 T cells During their differentiation from hematopoietic stem cells, na ⁇ ve CD4 T cells have undergone considerable restriction of their developmental potential, but a number of options remain open to them, namely Th1, Th2, Th17, and Treg.
- Th lineage is important for effective immune responses to specific pathogens, while the balance between effector and regulatory functions is critical to ensure immune competence while avoiding excessive immune pathology and autoimmunity.
- Natural regulatory T cells are characterised by the expression of the signature transcription factor Foxp3 and persistent expression of Foxp3 is both necessary and sufficient for regulatory T cell function. Tregs arise ‘naturally’ in the thymus and can arise from naive peripheral CD4 T cells.
- Foxp3 expression is induced when newly activated T cells are deprived of TCR signals.
- Foxp3 induction is selectively potentiated by inhibitors of the PI3K/mTOR axis and appears to be independent of TGFbeta, the classical inducer of Treg differentiation.
- the invention provides use of PI3-K/mTOR inhibitors, preferably PI3K inhibitors, which synergise with TCR signal deprivation to induce Foxp3 in newly activated CD4 T cells.
- Tregs effector or regulatory T cells
- Activation of naive CD4 T cells reveals their potential to become effector or regulatory T cells (Tregs). While effectors mediate immune responses, Tregs balance effector T cells, maintain homeostasis and prevent immune pathology.
- PI3K/mTOR preferably small molecule inhibitors of PI3K.
- Selective inhibition of class I PI3K catalytic subunits identifies p111 alpha and p110delta—but not p110gamma or p110beta—as regulators of Foxp3.
- Foxp3 induction is independent of exogenous TGFbeta and resistant to neutralising TGFbeta antibodies and pharmacological antagonists of Smad signaling.
- PI3-K's are a family of enzymes having numerous different individual isoenzymes.
- the invention relates to the use of PI3-K inhibitors, preferably class I PI3K inhibitors, in the induction of Foxp3 expression.
- PI3-K inhibitors preferably class I PI3K inhibitors
- PI3-K ⁇ does not act via regulatory T cells.
- PI3-K ⁇ can have modulatory effects.
- PI3-K ⁇ is not exerting its effects by action in regulatory T cells, and therefore inhibition of or inhibitors of PI3-K ⁇ are specifically disclaimed from the present invention.
- references to PI3-K inhibitors should be construed as references to class IA PI3-K inhibitors which are not specific for PI3-Kbeta.
- references to PI3-K inhibitors should be construed as not referring to any compound which acts to inhibit PI3-K ⁇ activity.
- a compound acts to inhibit a particular PI3K activity, such as PI3-K ⁇ activity, may be easily determined. For example, one way in which inhibition of PI3-K ⁇ may be determined is set out in the examples. Moreover, it may be determined whether a compound is a PI3K isoform specific or selective inhibitor, such as a PI3-K ⁇ specific or selective inhibitor, by testing according to methods described herein or in the prior art. The standard test is to produce the kinase and to test it in vitro with the inhibitor in a titration experiment with different concentrations of inhibitor and a suitable test substrate capable of being phosphorylated by the kinase being tested. Furthermore, PI3K inhibitors are typically characterised with reference to their specificity by the manufacturer/supplier or in the literature connected with the compound of interest.
- references to PI3-K should be construed as relating to PI3-K's, preferably class I PI3K's, preferably class IA PI3K's, preferably class IA PI3K's except for gamma, most preferably a class IA PI3-K selected from the group consisting of PI3-K ⁇ , PI3-K ⁇ , PI3-K ⁇ .
- PI3-K ⁇ has a limited role or no role in Foxp3 induction. Therefore, preferably the PI3-K is not PI3-K ⁇ , and preferably the PI3-K inhibitor is not specific or selective for PI3-K ⁇ .
- the PI3-K inhibitor is an inhibitor which is specific for or selective for PI3-K ⁇ .
- the PI3-K inhibitor is an inhibitor which is selective for or specific for PI3-K ⁇ .
- the target cells in which it is desired to produce Foxp3 expression may be any cells.
- the cells are haematopoietic cells, preferably the cells are cells of the T cell lineage, preferably the cells are thymocytes or lymphocytes, preferably the cells are a population of lymphocytes such as peripheral lymphocytes (e.g. peripheral blood lymphocytes) comprising a sub-population of mature T cells.
- the target cells are T cells, preferably mature na ⁇ ve T cells.
- the techniques used are the same as for peripheral T cells.
- the target cells are not CD8+ T cells.
- CD8+ T cells do not express Foxp3 after activation and PI3K inhibition.
- the target cell(s) do not comprise CD8+ T cells.
- the target cell(s) are depleted for CD8+ T cells, or are essentially free of CD8+ T cells.
- target cells are na ⁇ ve T cells.
- the target cells are not transgenic cells.
- Transgenic cells can be genetically unstable.
- Transgenic cells can be subject to regulatory problems when contemplating their reintroduction to a subject.
- target cells are naturally occurring cells previously collected from a subject of interest.
- target cell When the cells to be treated only comprise a sub-population of target cells (T cells), e.g. when the treatment is conducted on peripheral lymphocytes, then clearly the term ‘target cell’ must be interpreted accordingly to refer to the T cells within the overall population of cells being treated.
- a population of peripheral lymphocytes may comprise B cells, T cells and other cells.
- the whole population of peripheral lymphocytes may be treated, but of course it will be appreciated by the skilled reader that only a proportion of them (i.e. the T cells) are in fact target cells. Since the aim is typically to generate Tregs, the target cells will be non-Treg cells.
- the target cells are T cells which do not express Foxp3 before the treatment(s) of the invention.
- the invention relates to taking a population of one or more T cells, treating them with a PI3-K inhibitor, and obtaining regulatory T cells.
- the population of T cells are stimulated via the T cell receptor (TCR) or the TCR-associated CD3 complex of signalling proteins.
- TCR signal is in fact transmitted via the associated proteins.
- TCR T cell receptor
- CD3 e.g the TCR associated protein(s)
- This stimulation is then preferably withdrawn.
- the cells are treated with a PI3-K inhibitor.
- regulatory T cells are obtained. Specifically, treatment of the PI3-K inhibitor induces Foxp3 expression and this leads to a regulatory T cell fate or differentiation into a regulatory T cell.
- TCR stimulation can advantageously be manipulated to improve the effects.
- the T cells have been recently activated when they are treated with PI3-K inhibitor.
- Activation refers to stimulation via the T cell receptor.
- percent is meant stimulation or activation within the preceding two days.
- inhibitor treatment such as PI3-K inhibitor treatment is applied within 48 hours of activation.
- inhibitor treatment such as PI3-K inhibitor treatment is provided within 3-47 hours of stimulation, preferably within 47 hours of stimulation, preferably within 30 hours of stimulation, preferably at around 18 hours from stimulation, preferably at 18 hours from stimulation.
- inhibitor treatment such as PI3-K inhibitor treatment is provided at least 3 hours after stimulation, preferably at least 4 hours after stimulation, preferably more than 9 hours after stimulation, preferably at least 10 hours after stimulation, preferably about 18 hours after stimulation, preferably at 18 hours after stimulation.
- the technical benefits of these timings are optimisation and/or maximisation of the Foxp3 induction.
- the time from stimulation is the time from withdrawal of signalling via the T cell receptor.
- inhibitor treatment such as PI3-K inhibitor treatment is provided in a range of 3-47 hours from stimulation, preferably from 4-47 hours from stimulation, preferably from 4-30 hours from stimulation, preferably from 10-30 hours from stimulation, preferably from 12-25 hours from stimulation, preferably from 15-25 hours from stimulation, preferably from 17-19 hours from stimulation, preferably at around 18 hours from stimulation, preferably at 18 hours from stimulation.
- the technical benefits of these timings are optimisation and/or maximisation of the Foxp3 induction.
- the inhibitor treatment such as PI3-K inhibitor treatment is provided at a time of 10 to 22 hours after stimulation, preferably 12 to 20 hours after stimulation, preferably 12 to 18 hours after stimulation, preferably 17 to 19 hours after stimulation, preferably about 18 hours after stimulation, preferably 18 hours after stimulation.
- This has the advantage of excellent Foxp3 induction. Indeed, the technical benefit of these timings is illustrated in the examples section, e.g. with reference to FIG. 1C .
- Regulatory T cells are an important component of a healthy immune system. Regulatory T cells are involved in keeping effector T cells in check, and in prevention of “self recognition” which can be a major factor in autoimmune disease.
- Regulatory T cells have numerous acknowledged biomarkers known in the art. These include CD4+, CD25+, and Foxp3+. In particular, according to the present invention a regulatory T cell must show Foxp3 expression (Foxp3+).
- a regulatory T cell must preferably display regulatory function. Exhibition of regulatory function may be determined by any suitable method known in the art. In particular, examples of such tests are set out in the example section. Specifically, the tests embodied in FIG. 3 are regarded as standard in vitro tests for regulatory T cell function.
- the invention relates to the induction of Foxp3 in T cells together with contacting those T cells with said lymphokines; contacting with said lymphokines may be accomplished by contacting with cells producing said lymphokines such as mast cells.
- the cells producing said lymphokines e.g. mast cells
- PI3 KP110 ⁇ knockout animals do not have mast cell dependent responses, and show reduced Treg function.
- the PI3K inhibitors of the invention may be any compound or compounds capable of inhibiting PI3K, preferably class I PI3K, preferably class IA PI3K.
- the PI3K inhibitors may be biological macromolecules or may be small organic or inorganic compounds.
- the PI3K inhibitors are small organic compounds, preferably synthetic compounds.
- PI3-K inhibitors may act on more than one isoenzyme. If a PI3-K inhibitor happens to act upon one of the PI3-K subtypes which we disclose do not directly cause induction of Foxp3 expression, this does not exclude it from the present invention.
- the important characteristic of a PI3-K inhibitor as used herein is that it does act to inhibit one of the PI3-K isoenzymes which are disclosed as important for the induction of Foxp3 expression. Therefore, a PI3-K inhibitor according to the present invention must preferably display activity to inhibit the action of PI3-K ⁇ and/or PI3-K ⁇ .
- the PI3-K inhibitor of the invention is specific for a given PI3-K isoenzyine.
- the PI3-K inhibitor of the invention is specific for PI3-K ⁇ and/or PI3-K ⁇ .
- the inhibitor is specific for PI3-K ⁇ .
- the inhibitor is specific for PI3-K ⁇ .
- Inhibitors which reduce the activity of both PI3-K ⁇ and PI3-K ⁇ are particularly preferred; most preferred are inhibitors which reduce the activity of PI3-K ⁇ and PI3-K ⁇ but do not reduce the activity of other isoenzymes such as PI3-K ⁇ and/or PI3-K ⁇ .
- the inhibitor is specific for PI3-Kalpha or delta, preferably the inhibitor is specific for PI3-Kalpha and delta, since these are the predominant activities in regulation of Foxp3.
- PI3K inhibitors which are approved for clinical use and which inhibit PI3K alpha and/or PI3K delta. Even more preferred are such inhibitors which also do not reduce the activity of other isoenzymes such as PI3-K ⁇ and/or PI3-K ⁇ .
- small molecule inhibitors of PI3K can be produced synthetically and have superior pharmacological properties (analogous to the difference between insulin and oral antidiabetics).
- synthetic PI3K inhibitor compounds such as those with selectivity for individual PI3K isoenzymes, offers the technical advantage that side effects of bioactive peptides can be minimised or eliminated.
- PI3-K inhibitors A new generation of PI3-K inhibitors has recently been characterised at the biochemical, structural, and biological level and shown to have selectivity for PI3-K isoenzymes in preference over an extensive range of other kinases (Knight et al., 2006 Cell vol 125 pp 733-747).
- Selective class IA PI3K inhibitors are preferred inhibitors of the invention. Preferred inhibitors are shown in the examples section; most preferred are the alpha and delta PI3K inhibitors of the examples section.
- m-TOR inhibitors include rapamycin, wortmannin, and synthetic compounds such as PIK-90.
- Preferred m-TOR inhibitors are disclosed above and in the examples section. Most preferred is rapamycin.
- Akt Protein kinase B or Akt
- PKB alpha Akt1
- Akt2 PKB beta
- Akt3 PKB gamma
- Akt inhibitors include the allosteric inhibitor Akti-1/2.
- Rapamycin is not a PI3K inhibitor.
- rapamycin it is demonstrated in the art that ‘no protein kinase tested was inhibited significantly by rapamycin at 1 microM, a concentration 10-20-fold higher than that required to inhibit mTor in cell-based assays (Bioch. J. 351:95-105, 2000)’, the standard work on inhibitor specificity.
- Foxp3 expression has been induced according to the invention, it may be advantageous to combine the methods taught herein with methods promoting expansion of those cells.
- regulatory T cells in which Foxp3 expression has been induced are subsequently expanded.
- this is accomplished by rapamycin treatment.
- this may be accomplished as in Battaglia et al 2005 Blood Volume 105 page 4743.
- the invention finds broad application in clinical settings where the de novo generation of Treg cells is desirable, such as the prevention and/or the treatment of autoimmune diseases.
- m-TOR inhibition may be important for maintenance of in vitro regulatory function.
- the invention finds application in the induction of regulatory T cells for a specific antigen.
- the antigen is first selected and then Foxp3 induction takes place in T cells capable of responding to the specific antigen.
- regulatory T cells control immune systems. In particular, they hold T effector cells in check. Deficiencies in regulatory T cells are associated with auto-immune diseases such as rheumatoid arthritis. Thus, by making regulatory T cells, typically by induction of Foxp3 expression as disclosed herein, such immune damage can be stopped, prevented or reduced.
- the invention may advantageously be applied to the generation of regulatory T cells in vitro. In the prior art, this has been accomplished by treatment with TGF ⁇ .
- the present invention provides a convenient alternative to this method. Furthermore, the invention provides the advantage of avoiding exposure to the bioactive TGF ⁇ peptide.
- the invention finds application in the ex vivo production of regulatory T cells.
- a population of T cells would be taken from a patient. These would then be treated according to the methods of the present invention to induce regulatory T cells. These regulatory T cells may then be reintroduced into that patient to provide the therapeutic effect.
- immuno suppression finds application in immuno suppression.
- immuno suppression may be applied following organ transplantation or graft versus host disease.
- the invention also finds application in autoimmune disease generally.
- the invention finds application in autoimmune diseases such as gastritis, thyroiditis, inflammatory bowel disease, ulcerative colitis, autoimmune diabetes, multiple sclerosis or other autoimmune diseases.
- the invention finds application in suppression of allograft rejection, and examples of arthritis such as rheumatoid arthritis or collagen induced arthritis.
- the invention finds application in combating certain cancers, specifically those cancers which are themselves comprised of lymphocytes such as B-cell malignancies (e.g. leukaemia, lymphoma etc.) as discussed herein.
- lymphocytes such as B-cell malignancies (e.g. leukaemia, lymphoma etc.) as discussed herein.
- methods of the invention are in vitro.
- methods of the invention do not involve the human or animal body.
- references to induction of Foxp3 expression should be understood to mean induction of de novo Foxp3 expression.
- Suitably enhancement of existing Foxp3 expression, or expansion of cells already expressing Foxp3, are not part of the present invention.
- the invention relates to producing Foxp3 expression in cell(s) which were not expressing Foxp3 before the treatments/methods of the invention.
- expression of Foxp3 is necessary and sufficient for Treg production from an appropriate target cell.
- incubation of a cell cause to express Foxp3 de novo according to the present invention leads to Treg production.
- FIG. 1 shows TCR signal deprivation induces Foxp3 expression by newly activated T cells in synergy with inhibitors of the PI3-K/mTOR pathway
- naive CD62LhiCD4+CD25 ⁇ LN T cells were stimulated with plate bound anti TCR and anti CD28 for 18 hours and cultured for an additional two days in the presence of TCR antibody (continued TCR signalling) or in the absence of TCR antibody (TCR signal deprivation).
- naive CD4 T cells were labelled with CFSE and stimulated with plate bound anti TCR and anti CD28 as in a) and transferred to the indicated conditions after 18 hours.
- the expression of Foxp3 protein was evaluated by intracellular staining 2 days later. CFSE profiles are shown for Foxp3- and Foxp3+ cells.
- Foxp3 induction is most effective 18 hours after the activation of naive CD4 T cells.
- FIG. 2 shows TCR signaling controls mTOR activity in newly activated CD4 T cells
- naive LN T cells were stimulated with plate bound anti TCR and anti CD28 for 1 or 18 hours, or for 1 hour with anti CD28 alone (no TCR signaling). Phosphorylation of S6 ribosomal protein was determines at the single cell level using intracellular staining and flow cytometry.
- naive LN cells were activated as in a). After 18 hours, rapamycin (25 nM) or Ly294002 (10 ⁇ M) were added for one additional hour, or the cells were cultured for the indicated time in the absence of anti TCR. pS6 levels were determined as in a).
- FIG. 3 shows induction of Foxp3 by TCR signal deprivation and PI3K/mTOR inhibitors is stable and results in the acquisition of regulatory function.
- naive CD4 T cells were activated for 18 hours and cultured for an additional 2 days either with anti-TCR (control, ⁇ 1% Foxp3+) or without anti-TCR and in the presence of rapamycin and Ly294002 (Foxp3 induced, 28% Foxp3+). Graded numbers of Foxp3 induced or control cells were added to fresh, CFSE labelled CD4 LN T cells in the presence of APC and soluble anti CD3 and the effect on cell division (CFSE profile) was recorded 48 h later.
- FIG. 4 shows Foxp3 expression in response to TCR signal deprivation and PI3-K/mTOR inhibition in vivo
- naive CD4 T cells were labelled with CFSE and stimulated with plate bound anti TCR and anti CD28 and transferred i.v. to syngeneic, immunocompetent hosts after 18 hours with or without rapamycin and Ly294002 i.p. as indicated.
- CFSE ⁇ endogenous
- CFSE+ the inset displays a greater number of events
- FIG. 5 shows differential involvement of p110 isoenzymes in Foxp3 induction
- Naive LN cells were activated as in FIG. 1 and PI3-K inhibitors were added after 18 hours.
- the p110 isoform specificity of each inhibitor at the concentration used is shown (left panel).
- the percentage of Foxp3+ cells in cultures deprived of TCR signaling (14% in this experiment) was subtracted to indicate the net effect of PI3-K inhibitors (red A values in each scatter plot).
- Cells were labeled with CFSE prior to activation to monitor cell division (left panel).
- IC50 values determined in vitro Camps et al., 2005; Knight et al., 2006 are indicated for relevant enzymes (right panel).
- FIG. 6 Foxp3 induction by inhibitors of PI3K/mTOR signaling is independent of TGF ⁇
- naive LN T cells were activated in serum free AIM-V medium (Invitrogen) for 18 hours and whole cell extracts were subjected to SDS gel electophoresis and western blotting after exposure of the cells to TGF ⁇ (1 ng/ml) for (90 minutes, lane 1), TCR signal deprivation (90 minutes, lane 2), or TCR signal deprivation plus rapamycin and Ly294002 (90 minutes, lane 3 or 8 hours, lane 4). The blot was sequentially probed with anti pSmad2 (S465/467) and anti Smad2/3.
- naive LN T cells activated as in a) were deprived of TCR signals and TGF ⁇ and PI3-K/mTOR inhibitors were added as indicated below the graph.
- FIG. 7 shows TCR signal deprivation and inhibitors of the PI3K/mTOR pathway induce Foxp3 expression by newly activated T cells.
- naive CD62L hi CD4+ CD25 ⁇ LN T cells were stimulated with plate bound anti-TCR and soluble anti-CD28 for 18 hours and cultured for an additional two days with TCR antibody (continued TCR signaling) or without TCR antibody (TCR signal deprivation).
- naive CD4 T cells were labelled with CFSE and stimulated with plate bound anti TCR and anti CD28 as in a) and transferred to the indicated conditions after 18 hours.
- the expression of Foxp3 protein was evaluated by intracellular staining 2 days later. Cell recovery was between 67 and 108% of input.
- CFSE profiles are shown for Foxp3 ⁇ and Foxp3+ cells.
- naive LN CD4 T cells were activated as in a) for the indicated number of hours, after which the cells were deprived of TCR signals and exposed to rapamycin and LY294002. The percentage of Foxp3 expressing cells was determined 2 days later (mean of 2 experiments).
- Foxp3 expression was induced in naive CD4 T cells by TCR signal deprivation, rapamycin and LY294002. The cells were re-stimulated weekly in the presence of IL-2 and Foxp3 expression was monitored. Natural Treg cells are shown for comparison.
- naive CD4 T cells were activated for 18 hours and cultured for an additional 2 days either with anti-TCR (control, ⁇ 1% Foxp3 + ) or without anti-TCR and in the presence of rapamycin and LY294002 (Foxp3 induced, 28% Foxp3 + ). Graded numbers of Foxp3 induced or control cells were added to fresh, CFSE labelled CD4 LN T cells in the presence of APC and soluble anti CD3 and the effect on cell division (CFSE profile) was recorded 48 h later.
- naive CD45RB hi CD4 + CD25 ⁇ LN cells were transferred intravenously into syngeneic Rag deficient recipients, either freshly isolated ex vivo, activated under control conditions with continued TCR activation, or deprived of TCR signals and treated with rapamycin and LY294002 after 18 hours. Colitis scores were determined after eight weeks.
- CD4 single positive, CD25 negative thymocytes were activated, TCR signals were withdrawn, rapamycin/LY294002 added after 18 hours and Foxp3 expression analysed 2 days later as in b).
- FIG. 8 shows differential involvement of p110 isoenzymes in Foxp3 induction
- naive LN cells were activated as in FIG. 1 and PI3K inhibitors were added after 18 hours.
- the p110 isoform specificity of each inhibitor at the concentration used is shown alongside the percentage of Foxp3+ cells.
- FIG. 9 shows Foxp3 induction by PI3K/mTOR signaling is independent of TGF ⁇ .
- naive LN T cells were activated in serum free AIM-V medium for 18 hours and whole cell extracts were subjected to SDS gel electophoresis and immunoblotting after exposure of the cells to TGF ⁇ (1 ng/ml) for (90 minutes, lane 1), TCR signal deprivation (90 minutes, lane 2), or TCR signal deprivation, rapamycin and LY294002 (90 minutes, lane 3 or 8 hours, lane 4). The blot was stripped and probed probed with anti pSmad2 (S465/467) and anti Smad2/3.
- naive LN T cells activated as in a) were deprived of TCR signals and TGF ⁇ and PI3K/mTOR inhibitors were added as indicated. Cultures were supplemented with neutralising anti TGF ⁇ (3 ⁇ g/ml) or the Smad kinase inhibitor SB431542.
- FIG. 10 shows the impact of TCR signaling on the PI3K/mTOR/Akt network in newly activated CD4 T cells.
- naive LN CD4 T cells were stimulated with plate bound anti TCR and anti CD28 for 1 or 18 hours, or for 1 hour with anti CD28 alone (no TCR signaling). S6 phosphorylation was determined by intracellular staining and flow cytometry.
- naive LN cells were activated as in a). After 18 hours, rapamycin (25 nM) or LY294002 (10 ⁇ M) were added for one additional hour, or the cells were cultured for the indicated time in the absence of anti TCR.
- pS6 levels were determined as in a).
- immunoblotting confirmed declining pS6 in response to TCR signal deprivation and rapamycin detected at the single cell level in b). TGF ⁇ also reduced pS6.
- pAkt S473 was visible 1 hour, not 18 hours after T cell activation but reappeared in response to TCR signal deprivation, rapamycin, and TGF ⁇ .
- PI3K activates Akt via PDK1
- Akt inhibits TSC1/2
- this activates mTOR relieves translational inhibition via 4EBP/eIF4E and stimulates ribosomal activity via S6K1/eIF4E.
- e) network models of the PI3K/mTOR axis distinguishes mTORC1 and mTORC2.
- mTORC1-dependent S6K1 activity blocks the activation of mTORC2 by PI3K via IRS1.
- Akt activity depends on both PDK1 (T308) and mTORC2 (S473) (Jacinto et al., 2006; Sabatini, 2006).
- FIG. 11 shows Foxp3 expression in response to TCR signal deprivation and PI3K/mTOR inhibition in vivo.
- FIG. 12 shows Foxp3 induction by PI3K/mTOR inhibitors in the presence of continued availability of TCR ligands.
- Naive CD4 T cells were activated with CD3/CD28 beads (Dynal, 4 ⁇ l/10 6 cells).
- the indicated PI3K/mTOR inhibitors were added (1 ⁇ M) at 18 hours without removing the beads and Foxp3 expression was assessed two days later.
- FIG. 13 shows Foxp3 induction in response to physiological TCR ligands and PI3K/mTOR inhibition.
- CD4 LN cells from Rag1 deficient H2 b AND TCR transgenic mice were labeled with CFSE and cultured with BM-derived B10.
- BR (H2 k ) antigen presenting cells pre-loaded with the indicated concentrations of pigeon cytochrome-C peptide 81-104.
- PIK90 (1 ⁇ M) was added after 18 hours without removing the antigen presenting cells or the antigenic peptide. Foxp3 expression was analysed two days later.
- sorted LN CD4+ CD25 ⁇ CD62Lhi T cells were cultured at 1-3 ⁇ 106/ml with plate bound anti-TCR ⁇ (H57, Pharmingen, 200 ng/ml) and anti-CD28 (2 ⁇ g/ml, Pharmingen). After 18 hours the cells were either left in place for continued TCR stimulation or moved to uncoated wells with the indicated additives.
- CD4 T cells cultured as indicated were titrated into round bottom wells containing either 1 ⁇ 105 CFSE labeled total LN cells or 5 ⁇ 104 CFSE labeled CD4+ CD25 ⁇ T cells and 1 ⁇ 105 mitomycin-C treated (25 ⁇ g/ml, 20 min, 37° C.) T cell depleted splenocytes with the indicated concentrations of anti CD3 (2C11, Pharmingen).
- CD4 T cell CFSE profiles were recorded between 48 and 72 hours later.
- RNAbee Tel-Test, Friendswood, Tex.
- Real-time PCR analysis was carried out on an OpticonTMDNA engine (MJ Research Inc.; 95° C. for 15 min followed by 40 cycles of 94° C. for 15 s, 60° C. for 30 s and 72° C.
- Ywhaz forward CGTTGTAGGAGCCCGTAGGTCAT Ywhaz reverse: TCTGGTTGCGAAGCATTGGG Ubc forward: AGGAGGCTGATGAAGGAGCTTGA Ubc reverse: TGGTTTGAATGGATACTCTGCTGGA Foxp3 forward: ACTCGCATGTTCGCCTACTTCAG Foxp3 reverse: GGCGGATGGCATTCTTCCAGGT
- activators and inhibitors of signal transduction pathways included inhibitors of calcineurin, which block the nuclear translocation of NFAT (cyclosporin A and FK-506), activators and inhibitors of relevant MAPKs (mitogen activated kinases, including JNK/SAPK/p38 and upstream kinases), a wide range of inhibitors and pseudosubstrates of PKC isoenzymes, GSK3 (glycogen synthase kinase-3), HIF-1 ⁇ (hypoxia inducible factor), Notch (using the ⁇ -secretase inhibitor L-685458) and BMP (bone morphogenetic proteins, which are relatives of TGF ⁇ .
- TCR signaling was required for PI3K/mTOR inhibitors to induce Foxp3, and co-stimulation markedly enhanced the efficiency of Foxp3 induction (from 3 to 9% for TCR signal withdrawal, from 7 to 46% for TGF ⁇ , from 10 to 25% for rapamycin and from 4 to 44% for Ly294002, average of two experiments.
- naive CD4 T cells we labelled naive CD4 T cells with CFSE prior to their activation.
- Foxp3 expression was induced within 24-48 hours in response to TCR signal deprivation and PI3-K/mTOR inhibitors.
- CD62LhiCD4+CD25 ⁇ LN cells were activated, deprived of TCR signals and cultured in the presence of rapamycin and Ly294002.
- Graded numbers of the resulting population (28% Foxp3+by intracellular staining) were added to fresh, CFSE labelled CD4 LN T cells and efficiently blocked their response to soluble anti CD3 (2C11, 1 ⁇ g/ml) as assessed by the cell division profile ( FIG. 3 b , top panel).
- control cells ⁇ 1% Foxp3+ did not block anti CD3-induced division of CFSE labeled responder cells ( FIG. 3 b , bottom panel).
- TCR signal deprivation predisposes newly activated T cells to Foxp3 expression in synergy with inhibition of the PI3-K/mTOR axis, indicating that PI13-K/mTOR signaling antagonises Foxp3 induction in newly activated T cells in vitro and in vivo.
- PI3-K inhibitors A new generation of PI3-K inhibitors has recently been characterised at the biochemical, structural, and biological level and shown to have selectivity for PI3-K isoenzymes in preference over an extensive range of other kinases (Camps et al., Nat. Med. 2005, 11:936-943; Knight et al., 2006 ibid.).
- CFSE labeling was used to assess cell cycle progression as a measure of activation and viability, and the induction of Foxp3 was assayed at the single cell level ( FIG. 5 a, b ), along with S6 phosphorylation ( FIG. 5 b ).
- p110 ⁇ and p110 ⁇ do not detectably affect Foxp3 expression.
- TGX115 had a slight impact on Foxp3 expression at 10 ⁇ M, where it inhibits both p110 ⁇ and p110 ⁇ .
- TGX115 selectively inhibits p110 ⁇ , it did not affect Foxp3 expression, indicating that p110 ⁇ plays no significant role in regulating Foxp3 in this setting.
- the p110 ⁇ tilde over ( ⁇ ) ⁇ specific inhibitor AS-605240 affected Foxp3 only at concentration far in excess of its IC50 for p110 ⁇ (0.008 ⁇ M), ruling out a role for p110 ⁇ in the regulation of Foxp3 ( FIG. 5 a, b ).
- the inhibitor IC-87114 induced Foxp3 10-15% of cells over and above TCR deprivation alone down to 0.01 ⁇ M. At these concentrations, IC-87114 selectively inhibits p110 ⁇ , demonstrating a significant contribution of the p110 ⁇ isoenzyme to the regulation of Foxp3.
- the PI-103 compound strongly induced Foxp3, elevating the frequency of Foxp3 expressing cells by >20% above TCR signal deprivation alone.
- the p110 ⁇ tilde over ( ⁇ ) ⁇ specific inhibitor PIK75 could not be used to test this suggestion due to toxicity over the duration of our assay (data not shown).
- Conclusive evidence came from the analysis of PIK90, which strongly induced Foxp3 at 0.1 ⁇ M, where it selectively inhibits p110 ⁇ and p110 ⁇ ( FIG. 5 a, b ).
- TGF ⁇ is known as a powerful inducer of Foxp3 expression in conventional CD4 T cells in vitro and we therefore asked whether TGF ⁇ mediates the induction of Foxp3 by TCR signal deprivation of newly activated T cells and PI3-K/mTOR inhibitors. Since cell culture medium supplemented with FCS contains TGF ⁇ , we carried out the experiments described in this section in serum free lymphocyte culture medium (AIM-V, Invitrogen). Real time RT-PCR detected no increase in TGF- ⁇ 1, the predominant TGF ⁇ isoform in the immune system, but TGF- ⁇ regulation is known to be complex and RNA levels do not necessarily correlate with the amount of secreted protein.
- AIM-V serum free lymphocyte culture medium
- TGF ⁇ RII TGF ⁇ receptor II
- SB-431542 is a potent and specific inhibitor of transforming growth factor-beta superfamily type I activin receptor-like kinase (ALK) receptors ALK4, ALK5, and ALK7.
- ALK transforming growth factor-beta superfamily type I activin receptor-like kinase
- TCR signaling and PI3-K/mTOR activity antagonises the induction of Foxp3 in newly activated T cells. Without wishing to be bound by theory, this finding has important implications for understanding immune regulation, as it links the choice between effector and regulatory T cell fate to the termination of TCR signaling. Effective immune responses reduce antigen load and create conditions where the availability of antigen becomes limiting. Our results indicate how immune regulation may be linked to the involution phase of immune responses, which is important for T cell homeostasis and for limiting immune pathology.
- PI3K/mTOR axis potentiates Foxp3 induction triggered by deprivation of TCR signals.
- the involvement of PI3K/mTOR is selective, since blockade PKC, N-FAT, GSK-3, MAPK, Notch and others does not results in Foxp3 induction in the systems of the examples.
- PI3-K activity persists for many hours following T cell activation and our findings demonstrate that the PI3K/mTOR axis is critical in preventing the induction of Foxp3 in newly activated T cells.
- the class I PI3-kinases are subdivided into two groups, A and B, based on the selective involvement of p110 isoezymes, the catalytic subunits of PI3-K.
- the expression of p110 ⁇ and p110 ⁇ subunits is mainly restricted to leukocytes, whereas p110 ⁇ and p110 ⁇ are ubiquitously expressed and essential for embryonic development.
- p110 ⁇ the single member of Class IB, is important for T cell development and activation and a major target for the treatment of inflammatory responses and autoimmune disease.
- the link between PI3K signaling and disease has provided a major driver for the development and introduction into the clinic of selective inhibitors of PI3-K subunits.
- p110 ⁇ deficient mice not only show defects in lymphocyte activation, they also develop inflammatory bowel disease, the hallmark of Treg deficiency.
- a potential explanation for this is suggested by the dependence of Treg tolerance on mast cell-derived IL-9 and the essential role of p110 ⁇ for mast cell function. Consistent with these data, Treg function is impaired in the periphery of p110 ⁇ deficient mice. This notwithstanding, the differentiation of Tregs is increased in the p110 ⁇ deficient thymus in agreement with our findings.
- PI3-K inhibitors and rapamycin have been used to repress unwanted immune responses but the mechanisms by which PI3-K/mTOR inhibitors regulate immunity are largely unknown.
- a link between PI3-K inhibitors and autoimmunity was suggested by the finding that mice heterozygous for Pten, an antagonist of PI3-K signaling, developed autoimmunity as well as other observations.
- PI3-Ks regulate numerous processes in multiple cell types and potential mechanisms for the involvement of PI3-Ks in autoimmunity include the increased survival of T cells and the recruitment and activation of antigen presenting cells, mast cells and other inflammatory cell types. Rapamycin had previously been reported to affect regulatory T cell numbers positively or negatively in long term assays.
- Our findings establish the regulation of Foxp3 as a mechanism by which PI3-K/mTOR inhibitors modulate immunity.
- the class IB PI3-K isoenzyme p110 ⁇ functions predominantly downstream of G protein-coupled receptors (rather than src tyrosine kinases), and PI3-K ⁇ does not significantly regulate Foxp3.
- PI3-K ⁇ plays an important role in T cell development and activation and has recently been recognised as a target for the treatment of autoimmune disease.
- Inhibitors of PI3-K ⁇ are effective drugs in the prevention and in the treatment of autoimmunity, but—as we demonstrate—not via the induction of Foxp3 in newly activated T cells.
- TGF ⁇ is a potent inducer of Foxp3 in naive CD4 T cells and we therefore asked whether TGF ⁇ is involved in the induction of Foxp3 by TCR signal deprivation of newly activated T cells and PI3-K/mTOR inhibitors. We found no evidence that newly activated T cells increase TGF ⁇ production in response to TCR signal deprivation and inhibition of PI3K/mTOR. Foxp3 induction was efficient in serum free medium, which excludes a requirement for serum-derived TGF ⁇ .
- TCR signal deprivation and PI3-K/mTOR inhibitors do not result in detectable phosphorylation of Smad2 and that Foxp3 induction by TCR signal deprivation and PI3-K/mTOR inhibitors is independent of exogenous TGF ⁇ resistant to neutralising anti-TGF ⁇ and resistant to SB431542. They are therefore consistent with a model in which PI3-K/mTOR inhibitors induce Foxp3 by a pathway independently of TGF ⁇ .
- Activation reveals the potential of naive CD4 T cells to differentiate towards a range of T helper (Th) cell types, or, alternatively, to adopt a regulatory T cell (Treg cell) fate.
- Th T helper
- Treg cell regulatory T cell
- PI3K phosphatidyl inositol 3 kinase
- Th subsets such as Th1, Th2 and Th17
- Treg cell fate The choice of Th lineage is important for effective immune responses to specific pathogens, while the balance between effector and regulatory functions is critical to ensure immune competence while avoiding excessive immune pathylogy and autoimmunity.
- Natural regulatory T cells are characterised by the expression of the signature transcription factor Foxp3 and stable high level expression of Foxp3 is both necessary and sufficient for regulatory T cell function.
- Treg cells arise in the thymus and from naive peripheral CD4 T cells.
- TGF ⁇ instructs Foxp3 expression in vitro but, like IL-2, is important for the maintenance of Treg cells in vivo rather than for Treg cell differentiation. Since the molecular basis of the choice between effector and regulatory T cell fate is unknown in the prior art, we set out to identify signals that induce Foxp3 expression and regulatory T cell function in naive CD4 T cells.
- Inhibitors of PI3K and mTOR markedly potentiated Foxp3 induction ( FIG. 7 b ), whereas inhibitors of calcineurin/NFAT (cyclosporin A and FK-506), mitogen activated kinases (MAPKs JNK, SAPK, p38 and upstream kinases), protein kinase-C isoenzymes, glycogen synthase kinase-3, hypoxia inducible factor, and ⁇ -secretase/Notch did not.
- the LY294002 derivative LY303511 does not inhibit PI3K due to a single atom substitution in the morpholine ring and did not induce Foxp3 expression.
- TGF ⁇ was used as a positive control ( FIG. 7 b ).
- naive CD4 T cells we labelled naive CD4 T cells with CFSE prior to activation. No cell division had occurred after 18 hours, when the cells were exposed to inhibitors.
- Rapamycin and LY294002 slightly reduced the number of cell divisions that occurred during the next 24-48 hours, yet substantially enhanced the frequency of Foxp3 expression ( FIG. 7 b ) and Foxp3 was expressed in many cells that had not undergone cell division ( FIG. 7 b ).
- TCR signal deprivation and PI3K/mTOR inhibitors induce Foxp3 expression in naive CD4 T cells.
- T cell activation was required for Foxp3 induction ( FIG. 7 c ) and costimulation markedly enhanced its efficiency.
- Foxp3 expression was mitotically heritable and maintained through several rounds of restimulation ( FIG. 7 d ).
- Foxp3 expression was accompanied by regulatory T cell function, since Foxp3-induced cells (36% Foxp3 + ) efficiently blocked cell division of CFSE labelled CD4 LN T cells in response to soluble anti CD3 ( FIG. 7 e , top panel), while control activated cells (1% Foxp3 + ) did not ( FIG. 7 e , bottom panel).
- CD45RB hi CD4 T cells cause colitis when transferred to lymphocyte deficient (Rag ⁇ / ⁇ ) mice whereas colitis was markedly less severe when Foxp3 had been induced in a proportion of CD45RB hi CD4 T cells (28% Foxp3 + ) prior to transfer ( FIG. 7 f ).
- peripheral CD4 T cells can give rise to ‘adaptive’ Treg cells, their physiological relevance compared to Treg cells that arise ‘naturally’ in the thymus is an area of interest.
- TCR signal transduction To address whether manipulations of TCR signal transduction drive Foxp3 expression in thymocytes, we activated CD4 single positive, CD25 negative thynocytes for 18 hours and added PI3K/mTOR inhibitors ( FIG. 7 f ). Analysis of Foxp3 expression 2 days later demonstrated the induction of Foxp3 in a sizeable fraction of thymocytes.
- PI3K inhibitors have recently been characterised at the biochemical, structural, and biological level. Selectivity of these compounds for PI3K isoenzymes has been extensively validated by in vitro kinase assays and cell-based experiments (see Table 1) and by directly comparing the effects of pharmacological and genetic ablation on insulin signaling and lymphocyte activation. We utilised these compounds to define the involvement of PI3K catalytic subunits in the control of Foxp3.
- the TGX115 compound had a slight impact on Foxp3 expression at 10 ⁇ M, where it inhibits both p110 ⁇ and p110 ⁇ but did not affect Foxp3 expression at 0.1 ⁇ M, where it selectively inhibits p110 ⁇ .
- the p110 ⁇ -specific inhibitor AS-605240 affected Foxp3 only at concentrations far in excess of its IC 50 for p110 ⁇ (0.008 ⁇ M; indicating that p110 ⁇ and p110 ⁇ play no significant role in regulating Foxp3 in this setting ( FIG. 5 a, b ).
- the IC-87114 compound consistently induced Foxp3 in 10-15% of cells over and above TCR deprivation alone at concentrations where it selectively inhibits p110 ⁇ (0.01 ⁇ M), demonstrating a significant contribution of p110 ⁇ to the regulation of Foxp3.
- the PI-103 compound strongly induced Foxp3, elevating the frequency of Foxp3 expressing cells by >20%.
- the p110 ⁇ -specific inhibitor PIK75 could not be used to test this suggestion due to toxicity over the duration of the assay.
- Conclusive evidence for a role of p110 ⁇ came from the analysis of PIK90, which strongly induced Foxp3 at 0.1 ⁇ M, where it selectively inhibits p110 ⁇ and p110 ⁇ ( FIG. 8 a, b ).
- IC87114 is extremely p110 ⁇ selective, esp. at 1 ⁇ M, so the 15% induction at that concentration is clearly due to 6.
- TGX-115 has very little effect even at 10 ⁇ M (where minor 6 inhibition is obtained), so beta is likely of limited or peripheral importance.
- the a inhibitors 103 and 90 show dramatic induction above IC87114 at low doses, showing that ⁇ plays a significant role.
- the window between ⁇ and ⁇ for those compounds is not very large though, so the key observation is that they have more activity than IC87114 does at fully 6 inactivating doses (10 ⁇ M).
- the interpretation of the AS-605240 data depends on what the cellular IC50 for that compound is for ⁇ ; at 10 ⁇ M some ⁇ inhibition is obtained with this compound. Thus it is very unlikely that gamma would be coupled to TCR signaling in this context.
- TGF ⁇ is a powerful inducer of Foxp3 expression in conventional CD4 T cells in vitro and we addressed its role in our system.
- the binding of TGF ⁇ binding to ALK5 and TGF ⁇ receptor 11 (TGF ⁇ RII) results in the phosphorylation of receptor-associated Smad2 and -3, which provides a sensitive indicator of TGF ⁇ signaling.
- pSmad2 S465/467 was readily detectable in response to TGF ⁇ ( FIG. 9 a lane 1) but not in response to TCR signal deprivation ( FIG. 9 a , lane 2), or PI3K/mTOR inhibition ( FIG. 9 a , lanes 3 and 4).
- TGF ⁇ antibodies and SB 431542 which blocks TGF ⁇ activin receptor-like kinases, reduced Foxp3 induction by TGF ⁇ (by 85% and 96%, respectively), but had no effect on Foxp3 induction by PI3K/mTOR inhibitors ( FIG. 9 b ), demonstrating that TGF ⁇ is dispensable for the induction of Foxp3 by TCR signal deprivation and PI3K/mTOR inhibition.
- Akt/PKB serine/threonine protein kinase Akt/PKB is rapidly phosphorylated in response to signaling through TCR/CD28 but, in contrast to pS6, pAkt (S473) was no longer detected 18 h after initiation of TCR/CD28 signaling ( FIG. 10 c ). Akt (S473) phosphorylation was restored, however, when 18 h activated T cells were deprived of TCR signals, which resulted in increasing levels of pAkt at 1, 3, and 8 hours and a reciprocal decline in pS6 levels ( FIG. 10 c ). Exposure to rapamycin for 1 hour had a similar effect.
- Akt phosphorylation in response to TCR signal deprivation and rapamycin treatment is incompatible with a traditional linear signaling pathway ( FIG. 10 d ) but consistent with a network model in which Akt activity is controlled both by PDK1 and by mTORC2.
- mTORC2 mTOR/rictor/Sin1
- S6K1 mTOR/raptor
- IRS1 insulin receptor substrate 1
- FIG. 10 e withdrawal of TCR signaling lowers mTORC1 and S6K1 activity
- FIG. 10 b which reduces feedback inhibition of mTORC2 and explains the observed increase in pAkt (S473) ( FIG. 10 c ).
- short-term treatment with rapamycin blocks mTORC1-dependent feedback inhibition of mTORC2, resulting in Akt (S473) phosphorylation ( FIG. 10 c, e ).
- TGF ⁇ also results in reduced pS6 and increased pAkt S473, and in this regard mimics TCR signal deprivation and mTOR inhibition ( FIG. 10 c ).
- Foxp3 was also inducible by PI3K/mTOR inhibition in Rag1 deficient AND TCR transgenic CD4 LN cells stimulated by antigen presenting cells and specific peptide, demonstrating that it is advantageously now possible to generate antigen specific Treg cells using PI3K/mTOR inhibitors.
- Akt signaling is reportedly compromised in Treg cells and their targets, raising the possibility that regulatory T cell function involves alterations in PI3K/mTOR/Akt signaling.
- TCR engagement or compromised TCR signaling may occur in situations relevant to immune regulation, such as antigen presentation by non-professional APCs, low antigen dose during the involution phase of immune responses or mosaic antigen expression. This is consistent with the selection of Treg cells by epithelial cells ectopically expressing tissue-specific antigens in the thymus and in lymph nodes.
- Example 8 Mice, cell sorting and culture. Animal work was carried out according to the Animals (Scientific Procedures) Act, UK. Lymph node (LN) cells or thymocytes from wild type were stained, analysed and sorted by flow cytometry as described (Thompson et al., 2007 Immunity Vol 26 pp 335-344) from wild type (C57BL/6, BALB/c or C57BL/6 ⁇ 129) mice or from Rag1 deficient H2b AND TCR transgenic mice. Antigen presenting cells were derived from bone marrow in the presence of GM-CSF and incubated with antigenic peptide. Intracellular staining for Foxp3 protein was done as advised by the manufacturers (eBiosciences.com).
- the phosphorylation status of S6 ribosomal protein was determined using anti pS6 Ser235/236 (Cell Signaling cat.no. 2211, http://www.cellsignal.com) using the eBioscience Foxp3 staining kit and anti rabbit IgG-FITC or IgG-Cy5 (Jackson ImmunoResearch).
- Foxp3 expression sorted LN CD4 + CD 25 ⁇ CD62L hi T cells were cultured at 1-3 ⁇ 10 6 /ml with plate bound anti-TCR ⁇ (H57, Pharmingen, 200 ng/ml) and soluble or plate-bound anti-CD 28 (2 ⁇ g/ml, Pharmingen).
- CD4 T cells cultured as indicated were titrated into round bottom wells containing either 1 ⁇ 10 5 CFSE labeled total LN cells or 5 ⁇ 10 4 CFSE labeled CD4 + CD25 ⁇ T cells and 1 ⁇ 10 5 mitomycin-C treated (25 ⁇ g/ml, 20 min, 37° C.) T cell depleted splenocytes with the indicated concentrations of anti CD3 (2C11, Pharmingen).
- CD4 T cell CFSE profiles were recorded between 48 and 72 hours later.
- CD4 + C125 ⁇ CD45RB hi naive CD4 cells were transferred into lymphocyte deficient (Rag ⁇ / ⁇ ) hosts and colitis was scored as described (Powrie et al., 1993 Int. Immunol. Vol S pp 1461-1471).
- RNAbee Tel-Test, Friendswood, Tex.
- Real-time PCR analysis was carried out on an OpticonTM DNA engine (MJ Research Inc.; 95° C. for 15 min followed by 40 cycles of 94° C. for 15 s, 60° C. for 30 s and 72° C.
- Ywhaz forward CGTTGTAGGAGCCCGTAGGTCAT
- Ywhaz reverse TCTGGTTGCGAAGCATTGGG
- Ubc forward AGGAGGCTGATGAAGGAGCTTGA
- Ubc reverse TGGTTTGAATGGATACTCTGCTGGA
- Foxp3 forward ACTCGCATGTTCGCCTACTTCAG
- Foxp3 reverse GGCGGATGGCATTCTTCCAGGT
Abstract
The invention relates to a method of inducing Foxp3 expression in a T cell comprising (i) stimulating a T cell (ii) inhibiting signalling via PBK alpha or PBK delta or m-TOR or Akt in said T cell, wherein said inhibition is commenced 10 to 22 hours after the stimulation of (i). The invention also relates to certain uses of PBK inhibitors, PBK inhibitors for particular uses, and kits.
Description
- The invention relates to new uses of phosphatidyl inositol-3-kinase (PI3K) inhibitors. In particular, the invention relates to new methods for induction of Foxp3 expression in T cells.
- Regulatory T cells (Treg cells) are essential for preventing autoimmunity and immune pathology, which are caused by effector T cells in the absence of Treg cells. Immune interventions aimed at restraining effector T cells (to limit autoimmunity and immune pathology) or boosting immune responses (e.g. against tumours) require approaches that change the balance between Treg cells and effector T cells. Current approaches are slow, inefficient, rely on the use of bioactive peptides purified from biological sources, or on the expansion of pre-existing Treg cells.
- Expression of the transcriptional regulator Foxp3, an intracellular protein and member of the forkhead/winged-helix family of transcriptional regulators, is characteristic of Treg cells.
- Treatment of T cells with the bioactive peptide TGFbeta is known to induce de novo expression of Foxp3 (Chen et al., 2003 J. Exp. Med. vol 198, pp 1875-1886).
- Certain in vivo immunisation protocols have been reported to induce Foxp3 expression in T cell receptor transgenic T cells (Kretschmer et al., 2005 Nature Immunol. vol 6 p 1219). This approach requires knowledge of both the specificity for antigen and the MHC restriction of the target T cells, so that the antigen used for immunisation can be selected accordingly. This condition is met by artificial experimental systems in which T cells carry transgenic T cell receptors. It is a problem with this approach that this condition is not met for naturally occurring autoimmune diseases.
- The mTOR inhibitor rapamycin (sirolimus) has been used to manipulate the expansion of pre-existing Treg cells expressing Foxp3 (Zheng et al., 2003 Immunity vol 19 p 503; Battaglia et al., 2005 Blood vol 105 p 4743). However, such treatments have been shown not to induce the de novo expression of Foxp3, which is a problem. For example, Battaglia et al (ibid) states ‘The presence of CD4 CD25 Tr cells . . . in rapamycin-exposed T-cell cultures may be due to either a de novo induction of CD25 Tr cells from CD25 T cells or to a selective expansion of the naturally occurring CD4 CD25 FoxP3 Tr-cell subset already present in limited amounts at the beginning of the culture (ie, the 10% of CD4 CD25bright T cells usually found in a naïve spleen). To address this question, CD4 T cells depleted of the CD25 Tr cells were cultured for 3 weeks in the presence or absence of rapamycin. In contrast to CD4 T cells (
FIG. 3A ), CD4 CD25 T cells activated in the presence of rapamycin gave rise to a population of T cells that failed to suppress cell proliferation in vitro (FIG. 4A ). Accordingly, FoxP3 expression was enhanced in CD4 T cells exposed to rapamycin but not in CD4 CD25 rapamycin-treated T cells (FIG. 4B)’. Furthermore, the protocols employed rely on multiple rounds of in vitro stimulation over several weeks, which has the drawback of being very labour intensive. Negative effects of rapamycin on Treg cell numbers have also been reported in the art. Rapamycin is not a synthetic compound and can therefore suffer from problems of impurities and/or variation or formulation problems. - Thus, prior art techniques are typically operating via stimulation or activation of existing Tregs which can enhance Foxp3 expression in cells already expressing it, or are based on blocking non-Tregs, leading to expansion/selection or over-representation of Tregs in the population. These outcomes are the same as rapamycin treatment as noted above. Another example is the use of TGFbeta which typically enhances an already present level of Foxp3 expression. No such approaches lead to de novo Foxp3 expression/de novo Tregs.
- Gene targeting of the PI3K isoenzyme p110delta results in increased Treg cell numbers in the thymus, but in decreased Treg cell numbers in peripheral lymphoid organs. This is accompanied by inflammatory bowel disease, which is often linked to Treg cell deficiencies. No clear conclusions about a relationship between PI3K signalling and Foxp3 expression can be drawn from these studies.
- Inhibitors of the PI3K isoenzyme p110gamma are under evaluation for the treatment of autoimmune diseases based on mechanisms distinct from Treg cells.
- WO2004/032867A3 discloses molecules preferentially associated with effector T cells or regulatory T cells and methods of their use. This document presents population level studies. PI3K inhibitors are mentioned on page 76 of this document and in
FIG. 23A . The effects on Foxp3 expression (if any—high doses of inhibitor according to this document are probably cytotoxic and the low doses arguably show no significant effect) appear to be due to an expansion of Foxp3 expressing cells, or an enhancement in expression of Foxp3 in Foxp3 expressing cells. There is no evidence of de novo Foxp3 expression in the teachings of WO2004/032867A3. The underlying principle of this document is in attempting to tilt the balance of the immune system, for example to try to generally reduce autoimmunity or to try to generally enhance responses. There is no teaching of, and no suggestion towards, making new Tregs. Their method at best teaches that resting cells (PBL) are simultaneously activated (CD3/CD28) and inhibited (LY294002), i.e. activation and stimulation at the same time. In common with other prior art studies (e.g. Battaglia (ibid.)), and in common with the inventors' own studies, such treatments do not generate de novo Foxp3 expression/de novo Tregs. - US2004/0072766 discloses methods for modulating T cell responses by manipulating intracellular signal transduction. The methods disclosed in this document involve the addition of stimulators and inhibitors together i.e. at once or simultaneously. No de novo Poxp3 expression is generated in this approach.
- Foey et al (Arthritis Res 2002 vol 4 pp 64-70) disclose that cytokine stimulated T cells induce macrophage IL-10 production dependent on phosphatidyl inositol 3-kinase and p70S6K and the implications for rheumatoid arthritis. This relates to the study of macrophages in the presence of T cells. The T cells were fixed to separate the effects before and after contact. Thus, the cells are fixed and no longer alive when the PI3K inhibitors are added in these methods. Thus no de novo Foxp3 expression is produced by these methods.
- Breslin et al disclose that rapamycin and LY294002 co-operate to inhibit T cell proliferation. This example, in common with other studies, involves exposing T cells to inhibitors in order to study aspects of their biology such as proliferation. The inhibitors are added before stimulation, typically at least 30 minutes prior to stimulation. Cell numbers or other parameters are then examined. No de novo Foxp3 expression is generated by such techniques.
- US2005/0261317 disclose inhibitors of human PI3K delta. This document merely examines certain neutrophils, B cells and certain exocytotic cells, and is not connected with T cells or Tregs. The data presented are merely aimed at validating that the PI3K inhibitors disclosed actually block the relevant functions.
- US2004/0126781 discloses methods of preventing immune-mediated abortion by inhibiting a CD28-mediated costimulatory signal. These methods involve blocking of CD28 with soluble ligand. Blocking of CD28 with soluble ligand is clearly mutually exclusive with stimulation/activation of T cells.
- The present invention seeks to overcome problem(s) associated with the prior art.
- Foxp3 expression has been associated with regulatory T cell function. In certain settings, Foxp3 expression has been shown to be necessary and sufficient to induce regulatory T cell function. Indeed, Foxp3 expression has in some circumstances been regarded as an indicator or identifier of regulatory T cells as compared to other sub-populations of T cells. In the prior art, the only known way of inducing Foxp3 expression pharmacologically has been by treating a population of T cells with the bioactive peptide TGFβ.
- The present inventors have surprisingly discovered a new technique for induction of Foxp3 expression. This new method involves the use of PI3-K inhibitors which have not previously been shown to induce Foxp3 expression.
- A key finding of the present inventors is with regard to the timing of treatments to the target cells. Specifically the inventors have found that the inhibitors (such as PI3K inhibitors) must be added to the cells only after they have been stimulated. Thus the stimulation/activation step must be followed by incubation or a time delay before inhibitors are contacted with the cells. Addition of inhibitors simultaneously with or even before activation does not lead to de novo Foxp3 expression. It is thus a key teaching of the invention that the inhibitors should be added after stimulation/activation. These important timings are discussed in more detail below.
- Although certain PI3-K inhibitors have been shown to inhibit mTOR, there is no evidence of them acting to induce Foxp3 expression. Furthermore, although rapamycin (which acts on mTOR) has been shown to be able to selectively expand CD4+ CD25+Foxp3+ regulatory T cells, there has been no demonstration of any induction of de novo Foxp3 expression using such a technique. Therefore, the discovery made by the present inventors that certain PI3-K inhibitors can directly lead to induction of de novo Foxp3 expression in T cells, and to Treg function, is a surprising and significant advance.
- The present invention is based on these surprising findings.
- Thus, in a first aspect the invention provides a method of inducing Foxp3 expression in a T cell comprising
-
- (i) stimulating a T cell
- (ii) inhibiting signalling via PI3K alpha or PI3K delta or m-TOR or Akt in said T cell, wherein said inhibition is commenced 10 to 22 hours after the stimulation of (i).
- In another aspect, the invention relates to a method of inducing Foxp3 expression in a previously stimulated T cell comprising inhibiting signalling in said T cell via PI3K alpha or PI3K delta or m-TOR or Akt, wherein said inhibition is commenced 10 to 22 hours after the stimulation.
- In another aspect, the invention relates to a method of treating a subject in need of regulatory T cell(s) comprising
-
- (i) removing a sample comprising a T cell from a subject
- (ii) stimulating said T cell
- (iii) optionally withdrawing said stimulation
- (iv) inhibiting signalling via PI3K alpha or PI3K delta or m-TOR or Akt in said T cell, wherein said inhibition is commenced 10 to 22 hours after the stimulation of (i); and
- (v) reintroducing said T cell to said subject.
- Suitably said inhibition is commenced about 17 to 19 hours after the stimulation.
- Suitably said inhibition is commenced about 18 hours after the stimulation.
- Suitably the inhibiting signalling step comprises inhibiting signalling via PI3K alpha or PI3K delta.
- Suitably inhibiting signalling via PI3K alpha or PI3K delta comprises contacting said cell with PI3K inhibitor, and wherein said inhibitor inhibits PI3K alpha and/or PI3K delta.
- Suitably said method(s) further comprise withdrawing said stimulation no later than at the time of inhibiting signalling.
- In another aspect, the invention relates to a method for generating a regulatory T-cell comprising
-
- (i) stimulating a T cell
- (ii) inhibiting signalling via PI3K alpha or PI3K delta or m-TOR or Akt in said T cell, wherein said inhibition is commenced 10 to 22 hours after the stimulation of (i).
- In another aspect, the invention relates to a method for generating a regulatory T-cell comprising treating a stimulated CD8− T cell with
phosphatidyl inositol 3 kinase (PI3K) inhibitor wherein said inhibitor inhibits PI3K alpha and/or PI3K delta. - In another aspect, the invention relates to a method for generating a regulatory T-cell comprising treating a stimulated T cell with
phosphatidyl inositol 3 kinase (PI3K) inhibitor wherein said inhibitor inhibits PI3K alpha and/or PI3K delta. - In another aspect, the invention provides a method for generating a regulatory T-cell comprising treating a stimulated T cell with m-TOR inhibitor. The m-TOR inhibitor may be any known m-TOR inhibitor such as rapamycin (sirolimus), or an analogue thereof such as RAD001 (everolimus), CCI-779 (temsirolimus), AP23573, or a combined m-TOR/p110alpha inhibitor such as PI103. Preferably said m-TOR inhibitor is rapamycin.
- Stimulation may be by any suitable means which renders the T cell sensitive to the action of PI3K inhibitors and/or m-TOR inhibitors for Treg production as described herein. Preferably stimulation of the T cell is by stimulation of the TCR receptor. In some embodiments this stimulation may be a persistent or enduring stimulation, which means that the stimulation is not necessarily withdrawn at the time of action of PI3K and/or m-TOR inhibitors. Preferably a stimulated T cell is a T cell which has been stimulated via the T cell receptor. More preferably stimulation of the T cell is by stimulation of the TCR receptor followed by withdrawal of said TCR receptor stimulation. In another embodiment stimulation may be via CD3. In either case, preferably a costimulatory receptor such as CD28 is also stimulated. Preferably CD28 is stimulated at the same time as stimulation of the TCR or CD3 receptor(s). In a preferred embodiment stimulation is via simultaneous stimulation of TCR and/or CD3, and of CD28, preferably followed by withdrawal of stimulation via TCR and CD3. Withdrawal of stimulation may refer to the simple removal of signal, or may refer to more active methods such as blocking costimulation of CD3/CD28 at the time of addition of inhibitor(s).
- Preferred embodiments of the invention may further comprise a signal deprivation step e.g. as set out in the examples section.
- In another aspect, the invention provides a method for generating a regulatory T-cell comprising (i) stimulating a T cell; (ii) optionally withdrawing said stimulation; and (iii) inhibiting signalling via PI3K alpha or PI3K delta and/or via m-TOR and/or via Akt in said T cell. Preferably step (ii) comprises withdrawing said stimulation.
- Stimulation of said T cell may be via stimulation of the TCR receptor or via CD3, and a costimulatory receptor such as CD28. Preferably stimulation is via the T cell receptor followed by withdrawal of said stimulation via the T cell receptor.
- In another aspect, the invention provides a method of treating a subject in need of regulatory T cell(s) comprising
-
- (i) removing a sample comprising a T cell from a subject
- (ii) stimulating said T cell
- (iii) optionally withdrawing said stimulation
- (iv) inhibiting signalling in said T cell via PI3K alpha or PI3K delta and/or m-TOR and/or Akt; and
- (v) reintroducing said T cell to said subject. Preferably step (iii) comprises withdrawing said stimulation.
- Preferably stimulating said T cell comprises contacting said T cell with anti-TCR or anti-CD3 antibody. Preferably stimulating said T cell further comprises contacting said T cell with anti-CD28 antibody, preferably contacting said T cell with anti-TCR or anti-CD3 antibody, and with anti-CD28 antibody simultaneously. The mode of presentation of such antibodies may be chosen by the operator, for example this may be accomplished using plate-bound antibodies or by using beads coated with antibodies such as anti-CD3/anti-CD28 antibodies, or by any other means of presentation known to the operator.
- In another embodiment stimulation may be by contact of the target cells such as peripheral T cells with antigen presenting cells, such as antigen presenting cells contacted with specific peptide antigen. In these embodiments, as in embodiments involving other modes of stimulation, said stimulation may be enduring or persistent meaning that the stimulation is not withdrawn at the time of m-TOR/PI3K/Akt inhibition. In other embodiments the stimulation may be withdrawn at the time of m-TOR/PI3K/Akt inhibition, may be withdrawn before the time of m-TOR/PI3K/Akt inhibition, suitably the stimulation may be withdrawn at the time of m-TOR/PI3K/Akt inhibition.
- In another aspect, the invention provides a method of inducing Foxp3 expression in a previously stimulated T cell comprising inhibiting signalling in said T cell via PI3K alpha or PI3K delta and/or m-TOR and/or Akt.
- In another aspect, the invention provides a method of inducing Foxp3 expression in a T cell comprising stimulating a T cell; withdrawing said stimulation; and inhibiting signalling in said T cell via PI3K alpha or PI3K delta and/or m-TOR and/or Akt. Preferably said method comprises inducing Foxp3 expression in a T cell by stimulating a T cell via the T cell receptor; withdrawing said stimulation via the T cell receptor; and inhibiting signalling in said T cell via PI3K alpha or PI3K delta and/or m-TOR and/or Akt.
- In another aspect, the invention provides a method as described above wherein inhibiting signalling via PI3K alpha or PI3K delta and/or m-TOR and/or Akt comprises inhibiting signalling via PI3K alpha or PI3K delta. Preferably inhibiting signalling via PI3K alpha or PI3K delta comprises contacting said cell with PI3K inhibitor. Preferably said inhibitor inhibits PI3K alpha and/or PI3K delta.
- When inhibiting signalling via PI3K alpha or PI3K delta or m-TOR or Akt comprises inhibiting signalling via m-TOR, preferably inhibiting signalling via m-TOR comprises contacting said cell with rapamycin.
- In another aspect, the invention provides use of a PI3K inhibitor in the induction of differentiation of a T cell into a regulatory T cell wherein said inhibitor inhibits PI3K alpha and/or PI3K delta.
- In another aspect, the invention provides use of a PI3K inhibitor in the induction of Foxp3 expression wherein said inhibitor inhibits PI3K alpha and/or PI3K delta.
- In another aspect, the invention provides use of a PI3K alpha inhibitor or a PI3K delta inhibitor for the manufacture of a medicament for deficiency of regulatory T cells.
- Preferably the deficiency of regulatory T cells is an autoimmune disorder or an immune pathology. Preferably said deficiency is rheumatoid arthritis or diabetes, preferably type I diabetes, colitis, or a lymphoproliferative disorder where the presence of Treg cells indicates a favourable prognosis, preferably a B cell lymphoma.
- In another aspect, the invention provides a PI3K alpha inhibitor for use in the treatment of a deficiency of regulatory T cells.
- In another aspect, the invention provides a PI3K delta inhibitor for use in the treatment of a deficiency of regulatory T cells.
- In another aspect, the invention provides a M-TOR inhibitor for use in the treatment of a deficiency of regulatory T cells.
- In another aspect, the invention provides an Akt inhibitor for use in the treatment of a deficiency of regulatory T cells.
- In another aspect, the invention provides a kit comprising a TCR stimulant and an inhibitor of PI3K alpha or delta and/or an inhibitor of m-TOR and/or an inhibitor of Akt.
- In another aspect, the invention provides a kit as described above wherein said TCR stimulant comprises anti-TCR or anti-CD3, and anti-CD28. Preferably the anti-TCR/anti-CD3/anti-CD28 agents are antibodies to TCR/CD3/CD28 respectively.
- In another aspect, the invention provides a kit as described above further comprising an m-TOR inhibitor such as rapamycin. A m-TOR inhibitor may be advantageously used in expansion of the Foxp3 expressing T cells generated by use of the TCR stimulant/PI3K inhibitor of the kits of the invention. Furthermore, a m-TOR inhibitor may advantageously increase the efficiency of Foxp3 induction.
- In another aspect, the invention provides a kit as described above further comprising an Akt inhibitor.
- In a most preferred embodiment, the inhibitor is a PI3K inhibitor. Preferably said PI3K inhibitor comprises LY294002; preferably said PI3K inhibitor comprises a class IA PI3K inhibitor such as PIK-90 (alpha/m-TOR), PI-103 (alpha/gamma) or YM-024 (alpha/delta).
- Suitably the starting population of cells (target cells) in which Foxp3 is to be induced are depleted of pre-existing Tregs. Suitably the starting population of cells is depleted of CD25+ cells. If a population of cells comprises less than 1% Tregs we consider it to be depleted of Tregs or effectively free of Tregs. Suitably the starting population of cells does not comprise Tregs. Suitably the method of the invention comprises a further step of such depletion; suitably such step is carried out before stimulation. Suitably the starting population of cells (target cells) in which Foxp3 is to be induced are enriched for naïve T cells. Suitably the starting population is enriched for CD62L cells and/or enriched for CD45Rb cells. Suitably the starting population is enriched for CD62L cells and enriched for CD45Rb cells. Suitably the method of the invention comprises a further step of such enrichment; suitably such step is carried out before stimulation.
- It is a key feature of the invention that activation and inhibition of the cells are chronologically separated. Simultaneous activation and inhibition does not lead to de novo Foxp3 expression. Suitably activation and inhibition are not performed simultaneously according to the present invention. This has happened in the prior art and does not lead to de novo Foxp3 expression. For example, with reference to
FIG. 1C herein, the ‘0’ timepoint is indicative of prior art treatments—this represents 0 hours between stimulation/activation and addition of inhibitors i.e. inhibitors added at the same time as activation/stimulation. It is very clear that this treatment is ineffective at induction of de novo Foxp3 expression. By contrast, treatments according to the present invention involving a delay or incubation between stimulation and inhibition are effective for induction of de novo Foxp3 expression. This does not mean that inhibitors cannot be added with activators still present, but means that activation must precede inhibition or that inhibition must occur after activation. The time of separation can be very important and is a key contribution to the art. The time between activation and inhibition may be specifically chosen for particular application(s) as taught herein. Exemplary timings are when inhibitor treatment is applied approx. 12-18 hours after activation, suitably about 18 hours after activation. This is discussed in more detail below. - Suitably the methods of the invention are applied to induce Foxp3 without a requirement for expansion of the cells.
- It is an advantage of the invention that cells of a desired specificity may be converted to Tregs. It is this capability which provides a number of the advantages set out herein.
- Specialised cell types in multicellular organisms are defined by specific patterns of gene expression. During their differentiation from hematopoietic stem cells, naïve CD4 T cells have undergone considerable restriction of their developmental potential, but a number of options remain open to them, namely Th1, Th2, Th17, and Treg. The choice of Th lineage is important for effective immune responses to specific pathogens, while the balance between effector and regulatory functions is critical to ensure immune competence while avoiding excessive immune pathology and autoimmunity. Natural regulatory T cells are characterised by the expression of the signature transcription factor Foxp3 and persistent expression of Foxp3 is both necessary and sufficient for regulatory T cell function. Tregs arise ‘naturally’ in the thymus and can arise from naive peripheral CD4 T cells. We identify signals that induce Foxp3 expression and regulatory T cell function in naive CD4 T cells. We disclose that Foxp3 expression is induced when newly activated T cells are deprived of TCR signals. In this setting, Foxp3 induction is selectively potentiated by inhibitors of the PI3K/mTOR axis and appears to be independent of TGFbeta, the classical inducer of Treg differentiation.
- In particular the invention provides use of PI3-K/mTOR inhibitors, preferably PI3K inhibitors, which synergise with TCR signal deprivation to induce Foxp3 in newly activated CD4 T cells.
- Activation of naive CD4 T cells reveals their potential to become effector or regulatory T cells (Tregs). While effectors mediate immune responses, Tregs balance effector T cells, maintain homeostasis and prevent immune pathology. We describe novel methods for the stable induction of Foxp3, the signature transcription factor of Tregs, which is initiated when newly activated T cells are deprived of TCR signals, and potentiated by inhibitors of PI3K/mTOR, preferably small molecule inhibitors of PI3K. Selective inhibition of class I PI3K catalytic subunits identifies p111 alpha and p110delta—but not p110gamma or p110beta—as regulators of Foxp3. Foxp3 induction is independent of exogenous TGFbeta and resistant to neutralising TGFbeta antibodies and pharmacological antagonists of Smad signaling. These disclosures enable new approaches to manipulate regulatory T cell differentiation.
- It is to be noted that it is an advantage of the present invention that de novo Foxp3 expression is being induced. This is contrasted with the situation in the prior art where the best effect shown to date has been the expansion of T cells which are already expressing Foxp3. The opportunity to actively induce Foxp3 expression in cells which are not currently expressing it is a significant advantage of the present invention.
- We show that small molecule inhibitors of the PI3K/mTOR pathway rapidly and efficiently induce the de novo expression of Foxp3, the signature transcription factor of the Treg cell lineage. This enables new therapeutic approaches to be applied to clinical settings where the de novo generation of Treg cells is desirable, such as the prevention and the treatment of autoimmune diseases. Many of these diseases are of major clinical significance, such as rheumatoid arthritis and type I diabetes. Thus the industrial application and utility of the invention flow from these significant healthcare applications.
- PI3-K's are a family of enzymes having numerous different individual isoenzymes. In a broad aspect, the invention relates to the use of PI3-K inhibitors, preferably class I PI3K inhibitors, in the induction of Foxp3 expression. However, it is clear from our own data that inhibition of the class IB PI3 Kgamma does not induce Foxp3 expression, and that PI3-Kγ does not act via regulatory T cells. This observation is in contrast with the prior art teachings which say that PI3-Kγ can have modulatory effects. However, as disclosed herein, in fact PI3-Kγ is not exerting its effects by action in regulatory T cells, and therefore inhibition of or inhibitors of PI3-Kγ are specifically disclaimed from the present invention. Preferably references to PI3-K inhibitors should be construed as references to class IA PI3-K inhibitors which are not specific for PI3-Kbeta. Preferably references to PI3-K inhibitors should be construed as not referring to any compound which acts to inhibit PI3-Kγ activity.
- Whether or not a compound acts to inhibit a particular PI3K activity, such as PI3-Kγ activity, may be easily determined. For example, one way in which inhibition of PI3-Kγ may be determined is set out in the examples. Moreover, it may be determined whether a compound is a PI3K isoform specific or selective inhibitor, such as a PI3-Kγ specific or selective inhibitor, by testing according to methods described herein or in the prior art. The standard test is to produce the kinase and to test it in vitro with the inhibitor in a titration experiment with different concentrations of inhibitor and a suitable test substrate capable of being phosphorylated by the kinase being tested. Furthermore, PI3K inhibitors are typically characterised with reference to their specificity by the manufacturer/supplier or in the literature connected with the compound of interest.
- References to PI3-K should be construed as relating to PI3-K's, preferably class I PI3K's, preferably class IA PI3K's, preferably class IA PI3K's except for gamma, most preferably a class IA PI3-K selected from the group consisting of PI3-Kα, PI3-Kβ, PI3-Kδ.
- It is further disclosed herein that PI3-Kβ has a limited role or no role in Foxp3 induction. Therefore, preferably the PI3-K is not PI3-Kα, and preferably the PI3-K inhibitor is not specific or selective for PI3-Kβ.
- Specifically, we show that inhibition of PI3-Kα or PI3-Kδ is particularly advantageous. Therefore, in a preferred embodiment, the PI3-K inhibitor is an inhibitor which is specific for or selective for PI3-Kα. In another preferred embodiment, the PI3-K inhibitor is an inhibitor which is selective for or specific for PI3-Kδ.
- The target cells in which it is desired to produce Foxp3 expression may be any cells. Preferably the cells are haematopoietic cells, preferably the cells are cells of the T cell lineage, preferably the cells are thymocytes or lymphocytes, preferably the cells are a population of lymphocytes such as peripheral lymphocytes (e.g. peripheral blood lymphocytes) comprising a sub-population of mature T cells. Preferably the target cells are T cells, preferably mature naïve T cells. When the cells are thymocytes, preferably the techniques used are the same as for peripheral T cells.
- Preferably the target cells are not CD8+ T cells. CD8+ T cells do not express Foxp3 after activation and PI3K inhibition. Suitably the target cell(s) do not comprise CD8+ T cells. Suitably the target cell(s) are depleted for CD8+ T cells, or are essentially free of CD8+ T cells. Suitably target cells are naïve T cells.
- Preferably the target cells are not transgenic cells. Transgenic cells can be genetically unstable. Transgenic cells can be subject to regulatory problems when contemplating their reintroduction to a subject. Preferably target cells are naturally occurring cells previously collected from a subject of interest.
- When the cells to be treated only comprise a sub-population of target cells (T cells), e.g. when the treatment is conducted on peripheral lymphocytes, then clearly the term ‘target cell’ must be interpreted accordingly to refer to the T cells within the overall population of cells being treated. In other words, in working the invention it may be desired to treat a population of cells to induce Foxp3 expression when in fact only a sub-population of those cells are target cells. For example, a population of peripheral lymphocytes may comprise B cells, T cells and other cells. For convenience the whole population of peripheral lymphocytes may be treated, but of course it will be appreciated by the skilled reader that only a proportion of them (i.e. the T cells) are in fact target cells. Since the aim is typically to generate Tregs, the target cells will be non-Treg cells. Preferably the target cells are T cells which do not express Foxp3 before the treatment(s) of the invention.
- In a broad aspect, the invention relates to taking a population of one or more T cells, treating them with a PI3-K inhibitor, and obtaining regulatory T cells.
- In slightly more detail, preferably the population of T cells are stimulated via the T cell receptor (TCR) or the TCR-associated CD3 complex of signalling proteins. In practice, TCR signal is in fact transmitted via the associated proteins. Thus, to stimulate via the TCR it is possible to target the actual TCR itself (e.g. antigen specific TCR targeting) or to target CD3 (e.g the TCR associated protein(s)). This stimulation is then preferably withdrawn. Following withdrawal of this stimulation, the cells are treated with a PI3-K inhibitor. Following incubation with the PI3-K inhibitor regulatory T cells are obtained. Specifically, treatment of the PI3-K inhibitor induces Foxp3 expression and this leads to a regulatory T cell fate or differentiation into a regulatory T cell.
- Illustrative methods for producing this effect are provided in the examples.
- The timing with regard to TCR stimulation can advantageously be manipulated to improve the effects. Preferably the T cells have been recently activated when they are treated with PI3-K inhibitor. Activation refers to stimulation via the T cell receptor. By “recent” is meant stimulation or activation within the preceding two days.
- Best results are obtained when inhibitor treatment such as PI3-K inhibitor treatment is applied within 48 hours of activation. Preferably inhibitor treatment such as PI3-K inhibitor treatment is provided within 3-47 hours of stimulation, preferably within 47 hours of stimulation, preferably within 30 hours of stimulation, preferably at around 18 hours from stimulation, preferably at 18 hours from stimulation. Preferably inhibitor treatment such as PI3-K inhibitor treatment is provided at least 3 hours after stimulation, preferably at least 4 hours after stimulation, preferably more than 9 hours after stimulation, preferably at least 10 hours after stimulation, preferably about 18 hours after stimulation, preferably at 18 hours after stimulation. The technical benefits of these timings are optimisation and/or maximisation of the Foxp3 induction.
- Preferably the time from stimulation is the time from withdrawal of signalling via the T cell receptor.
- In a preferred embodiment, inhibitor treatment such as PI3-K inhibitor treatment is provided in a range of 3-47 hours from stimulation, preferably from 4-47 hours from stimulation, preferably from 4-30 hours from stimulation, preferably from 10-30 hours from stimulation, preferably from 12-25 hours from stimulation, preferably from 15-25 hours from stimulation, preferably from 17-19 hours from stimulation, preferably at around 18 hours from stimulation, preferably at 18 hours from stimulation. The technical benefits of these timings are optimisation and/or maximisation of the Foxp3 induction.
- In a most preferred embodiment, the inhibitor treatment such as PI3-K inhibitor treatment is provided at a time of 10 to 22 hours after stimulation, preferably 12 to 20 hours after stimulation, preferably 12 to 18 hours after stimulation, preferably 17 to 19 hours after stimulation, preferably about 18 hours after stimulation, preferably 18 hours after stimulation. This has the advantage of excellent Foxp3 induction. Indeed, the technical benefit of these timings is illustrated in the examples section, e.g. with reference to
FIG. 1C . - Regulatory T cells (sometimes referred to as Tregs) are an important component of a healthy immune system. Regulatory T cells are involved in keeping effector T cells in check, and in prevention of “self recognition” which can be a major factor in autoimmune disease.
- Regulatory T cells have numerous acknowledged biomarkers known in the art. These include CD4+, CD25+, and Foxp3+. In particular, according to the present invention a regulatory T cell must show Foxp3 expression (Foxp3+).
- A regulatory T cell must preferably display regulatory function. Exhibition of regulatory function may be determined by any suitable method known in the art. In particular, examples of such tests are set out in the example section. Specifically, the tests embodied in
FIG. 3 are regarded as standard in vitro tests for regulatory T cell function. - In vivo it is widely believed that regulatory T cells need additional factors such as IL-2, TGFbeta, or IL-9 (such as mast cell derived IL-9) for their survival and/or the maintenance of their regulatory functions. Thus, in preferred embodiment, the invention relates to the induction of Foxp3 in T cells together with contacting those T cells with said lymphokines; contacting with said lymphokines may be accomplished by contacting with cells producing said lymphokines such as mast cells. In this embodiment, the cells producing said lymphokines (e.g. mast cells) may be provided in vivo in the subject being treated. It should be noted that PI3 KP110δ knockout animals do not have mast cell dependent responses, and show reduced Treg function.
- The PI3K inhibitors of the invention may be any compound or compounds capable of inhibiting PI3K, preferably class I PI3K, preferably class IA PI3K. In particular, the PI3K inhibitors may be biological macromolecules or may be small organic or inorganic compounds. Preferably the PI3K inhibitors are small organic compounds, preferably synthetic compounds.
- Several small molecule PI3K inhibitors are under evaluation for clinical use—these are preferred inhibitors of the invention. Several small molecule inhibitors of PI3K are approved for clinical use—these are more preferred inhibitors of the invention.
- Of course, some PI3-K inhibitors may act on more than one isoenzyme. If a PI3-K inhibitor happens to act upon one of the PI3-K subtypes which we disclose do not directly cause induction of Foxp3 expression, this does not exclude it from the present invention. The important characteristic of a PI3-K inhibitor as used herein is that it does act to inhibit one of the PI3-K isoenzymes which are disclosed as important for the induction of Foxp3 expression. Therefore, a PI3-K inhibitor according to the present invention must preferably display activity to inhibit the action of PI3-Kα and/or PI3-Kδ. If such an inhibitor also has a subsidiary effect on a different PI3-K isoenzyme such as PI3-Kβ or PI3-Kγ, such an inhibitor should not be regarded as excluded from the present invention. However, clearly it is preferably to choose the PI3-K inhibitor which has as specific an effect as possible in order to simplify administration and to avoid unwanted pleiotropic effects or side effects. Therefore, preferably the PI3-K inhibitor of the invention is specific for a given PI3-K isoenzyine. Preferably the PI3-K inhibitor of the invention is specific for PI3-Kα and/or PI3-Kδ. Preferably the inhibitor is specific for PI3-Kα. Preferably the inhibitor is specific for PI3-Kδ. Inhibitors which reduce the activity of both PI3-Kα and PI3-Kδ are particularly preferred; most preferred are inhibitors which reduce the activity of PI3-Kα and PI3-Kδ but do not reduce the activity of other isoenzymes such as PI3-Kγ and/or PI3-Kβ.
- Most preferably the inhibitor is specific for PI3-Kalpha or delta, preferably the inhibitor is specific for PI3-Kalpha and delta, since these are the predominant activities in regulation of Foxp3.
- Most preferred are PI3K inhibitors which are approved for clinical use and which inhibit PI3K alpha and/or PI3K delta. Even more preferred are such inhibitors which also do not reduce the activity of other isoenzymes such as PI3-Kγ and/or PI3-Kβ.
- In contrast to bioactive peptides purified from biological sources as have been used in the prior art (e.g. TGF beta), small molecule inhibitors of PI3K can be produced synthetically and have superior pharmacological properties (analogous to the difference between insulin and oral antidiabetics). The use of synthetic PI3K inhibitor compounds, such as those with selectivity for individual PI3K isoenzymes, offers the technical advantage that side effects of bioactive peptides can be minimised or eliminated.
- A new generation of PI3-K inhibitors has recently been characterised at the biochemical, structural, and biological level and shown to have selectivity for PI3-K isoenzymes in preference over an extensive range of other kinases (Knight et al., 2006 Cell vol 125 pp 733-747). Selective class IA PI3K inhibitors are preferred inhibitors of the invention. Preferred inhibitors are shown in the examples section; most preferred are the alpha and delta PI3K inhibitors of the examples section.
- m-TOR inhibitors include rapamycin, wortmannin, and synthetic compounds such as PIK-90. Preferred m-TOR inhibitors are disclosed above and in the examples section. Most preferred is rapamycin.
- Protein kinase B or Akt (PKB/Akt—for convenience this is referred to herein simply as ‘Akt’) is a serine/threonine kinase, which in mammals comprises three highly homologous members known as PKB alpha (Akt1), PKB beta (Akt2) and PKB gamma (Akt3). Akt inhibitors include the allosteric inhibitor Akti-1/2.
- Although inhibition of m-TOR signalling (i.e. rapamycin treatment) has been shown to contribute to expansion of Foxp3+Tregs in the prior art, there is no teaching of induction of Foxp3 by rapamycin. The inventors are not aware of any link between m-TOR inhibition and Foxp3 induction in the art. Indeed, the present inventors have investigated this area using biologically relevant starvation/nutrient depletion induced reduction of m-TOR activity. These signals were shown to abolish pS6 as a demonstration of reduced m-TOR activity but do not lead to induction of Foxp3. This elegant dissection of the system illustrates that the methods of the invention provide a new approach to the induction of Foxp3 and further show that prior art approaches acting via m-TOR signalling to produce expansion of Foxp3+ cells do not in fact induce de novo expression of Foxp3 nor differentiation of Tregs.
- Rapamycin is not a PI3K inhibitor. For example, it is demonstrated in the art that ‘no protein kinase tested was inhibited significantly by rapamycin at 1 microM, a concentration 10-20-fold higher than that required to inhibit mTor in cell-based assays (Bioch. J. 351:95-105, 2000)’, the standard work on inhibitor specificity.
- Once Foxp3 expression has been induced according to the invention, it may be advantageous to combine the methods taught herein with methods promoting expansion of those cells. Thus, in a preferred embodiment, preferably regulatory T cells in which Foxp3 expression has been induced are subsequently expanded. Preferably this is accomplished by rapamycin treatment. In particular, this may be accomplished as in Battaglia et al 2005 Blood Volume 105 page 4743.
- The invention finds broad application in clinical settings where the de novo generation of Treg cells is desirable, such as the prevention and/or the treatment of autoimmune diseases.
- m-TOR inhibition may be important for maintenance of in vitro regulatory function.
- The invention finds application in the induction of regulatory T cells for a specific antigen. In this embodiment, the antigen is first selected and then Foxp3 induction takes place in T cells capable of responding to the specific antigen.
- Regulatory T cells control immune systems. In particular, they hold T effector cells in check. Deficiencies in regulatory T cells are associated with auto-immune diseases such as rheumatoid arthritis. Thus, by making regulatory T cells, typically by induction of Foxp3 expression as disclosed herein, such immune damage can be stopped, prevented or reduced.
- The invention may advantageously be applied to the generation of regulatory T cells in vitro. In the prior art, this has been accomplished by treatment with TGFβ. The present invention provides a convenient alternative to this method. Furthermore, the invention provides the advantage of avoiding exposure to the bioactive TGFβ peptide.
- In particular, the invention finds application in the ex vivo production of regulatory T cells. In this embodiment, a population of T cells would be taken from a patient. These would then be treated according to the methods of the present invention to induce regulatory T cells. These regulatory T cells may then be reintroduced into that patient to provide the therapeutic effect.
- The invention finds application in immuno suppression. In particular, immuno suppression may be applied following organ transplantation or graft versus host disease.
- The invention also finds application in autoimmune disease generally. In particular, the invention finds application in autoimmune diseases such as gastritis, thyroiditis, inflammatory bowel disease, ulcerative colitis, autoimmune diabetes, multiple sclerosis or other autoimmune diseases.
- Furthermore, the invention finds application in suppression of allograft rejection, and examples of arthritis such as rheumatoid arthritis or collagen induced arthritis. Moreover, the invention finds application in combating certain cancers, specifically those cancers which are themselves comprised of lymphocytes such as B-cell malignancies (e.g. leukaemia, lymphoma etc.) as discussed herein.
- In another embodiment, preferably methods of the invention are in vitro. Preferably methods of the invention do not involve the human or animal body.
- Suitably references to induction of Foxp3 expression should be understood to mean induction of de novo Foxp3 expression. Suitably enhancement of existing Foxp3 expression, or expansion of cells already expressing Foxp3, are not part of the present invention. Suitably the invention relates to producing Foxp3 expression in cell(s) which were not expressing Foxp3 before the treatments/methods of the invention. Without wishing to be bound by theory, expression of Foxp3 is necessary and sufficient for Treg production from an appropriate target cell. Thus incubation of a cell cause to express Foxp3 de novo according to the present invention leads to Treg production.
- Certain aspects of the invention may be understood with reference to the following numbered paragraphs:
-
- 1. A method for generating a regulatory T-cell comprising treating a stimulated T cell with
phosphatidyl inositol 3 kinase (PI3K) inhibitor wherein said inhibitor inhibits PI3K alpha and/or PI3K delta. - 2. A method for generating a regulatory T-cell comprising
- (i) stimulating a T cell
- (ii) optionally withdrawing said stimulation
- (iii) inhibiting signalling via PI3K alpha or PI3K delta or m-TOR or Akt in said T cell.
- 3. A method of treating a subject in need of regulatory T cell(s) comprising
- (i) removing a sample comprising a T cell from a subject
- (ii) stimulating said T cell
- (iii) optionally withdrawing said stimulation
- (iv) inhibiting signalling in said T cell via PI3K alpha or PI3K delta or m-TOR or Akt; and
- (v) reintroducing said T cell to said subject
- 4. A method of inducing Foxp3 expression in a previously stimulated T cell comprising inhibiting signalling in said T cell via PI3K alpha or PI3K delta or m-TOR or Akt.
- 5. A method of inducing Foxp3 expression in a T cell comprising
- (i) stimulating a T cell
- (ii) optionally withdrawing said stimulation; and
- (iii) inhibiting signalling in said T cell-via PI3K alpha or PI3K delta or m-TOR or Akt.
- 6. A method according to any preceding paragraph wherein stimulating said T cell comprises stimulating said T cell via the T cell receptor (TCR).
- 7. A method according to any preceding paragraph wherein inhibiting signalling via PI3K alpha or PI3K delta comprises contacting said cell with PI3K inhibitor, and wherein said inhibitor inhibits PI3K alpha and/or PI3K delta.
- 8. Use of a PI3K inhibitor in the induction of differentiation of a T cell into a regulatory T cell wherein said inhibitor inhibits PI3K alpha and/or PI3K delta.
- 9. Use of a PI3K inhibitor in the induction of Foxp3 expression wherein said inhibitor inhibits PI3K alpha and/or PI3K delta.
- 10. Use of a PI3K alpha inhibitor or a PI3K delta inhibitor for the manufacture of a medicament for deficiency of regulatory T cells.
- 11. PI3K alpha inhibitor for use in the treatment of a deficiency of regulatory T cells.
- 12. PI3K delta inhibitor for use in the treatment of a deficiency of regulatory T cells.
- 13. A kit comprising
- (i) a TCR stimulant; and
- (ii) an inhibitor of PI3K alpha or delta.
- 14. A kit according to
paragraph 13 wherein said TCR stimulant comprises anti-TCR and anti-CD28 antibody. - 15. A kit according to
paragraph 13 orparagraph 14 further comprising an m-TOR inhibitor. - 16. A kit according to
paragraph 15 wherein said M-TOR inhibitor is rapamycin. - 17. A kit according to any of
paragraphs 13 to 16 further comprising an Akt inhibitor. - 18. A method according to any of
paragraphs 1 to 7, a use according to any of paragraphs 8 to 10, and inhibitor according to paragraph 11 orparagraph 12, or a kit according to any ofparagraphs 13 to 17 wherein said PI3K inhibitor comprises LY294002.
- 1. A method for generating a regulatory T-cell comprising treating a stimulated T cell with
-
FIG. 1 shows TCR signal deprivation induces Foxp3 expression by newly activated T cells in synergy with inhibitors of the PI3-K/mTOR pathway - a) naive CD62LhiCD4+CD25− LN T cells were stimulated with plate bound anti TCR and anti CD28 for 18 hours and cultured for an additional two days in the presence of TCR antibody (continued TCR signalling) or in the absence of TCR antibody (TCR signal deprivation). The expression of Foxp3 RNA was assessed by real time RT-PCR (mean±SD, n=3).
b) naive CD4 T cells were labelled with CFSE and stimulated with plate bound anti TCR and anti CD28 as in a) and transferred to the indicated conditions after 18 hours. The expression of Foxp3 protein was evaluated byintracellular staining 2 days later. CFSE profiles are shown for Foxp3- and Foxp3+ cells.
c) Foxp3 induction is most effective 18 hours after the activation of naive CD4 T cells. -
FIG. 2 shows TCR signaling controls mTOR activity in newly activated CD4 T cells - a) naive LN T cells were stimulated with plate bound anti TCR and anti CD28 for 1 or 18 hours, or for 1 hour with anti CD28 alone (no TCR signaling). Phosphorylation of S6 ribosomal protein was determines at the single cell level using intracellular staining and flow cytometry.
b) naive LN cells were activated as in a). After 18 hours, rapamycin (25 nM) or Ly294002 (10 μM) were added for one additional hour, or the cells were cultured for the indicated time in the absence of anti TCR. pS6 levels were determined as in a). -
FIG. 3 shows induction of Foxp3 by TCR signal deprivation and PI3K/mTOR inhibitors is stable and results in the acquisition of regulatory function. - a) Foxp3 expression was induced in naive CD4 T cells by TCR signal deprivation, rapamycin and Ly294002 and monitored over time. The cells were re-stimulated every 7 days in the presence of IL-2.
b) naive CD4 T cells were activated for 18 hours and cultured for an additional 2 days either with anti-TCR (control, <1% Foxp3+) or without anti-TCR and in the presence of rapamycin and Ly294002 (Foxp3 induced, 28% Foxp3+). Graded numbers of Foxp3 induced or control cells were added to fresh, CFSE labelled CD4 LN T cells in the presence of APC and soluble anti CD3 and the effect on cell division (CFSE profile) was recorded 48 h later. -
FIG. 4 shows Foxp3 expression in response to TCR signal deprivation and PI3-K/mTOR inhibition in vivo - a) naive CD4 T cells were labelled with CFSE and stimulated with plate bound anti TCR and anti CD28 and transferred i.v. to syngeneic, immunocompetent hosts after 18 hours with or without rapamycin and Ly294002 i.p. as indicated. The expression of Foxp3 protein by endogenous (CFSE−) and transferred (CFSE+, the inset displays a greater number of events) CD4+ spleen cells was evaluated 2 days later by intracellular staining.
b) summary of 11 transfer experiments at 18 or 48 hours -
FIG. 5 shows differential involvement of p110 isoenzymes in Foxp3 induction Naive LN cells were activated as inFIG. 1 and PI3-K inhibitors were added after 18 hours. The p110 isoform specificity of each inhibitor at the concentration used is shown (left panel). The percentage of Foxp3+ cells in cultures deprived of TCR signaling (14% in this experiment) was subtracted to indicate the net effect of PI3-K inhibitors (red A values in each scatter plot). Cells were labeled with CFSE prior to activation to monitor cell division (left panel). For each inhibitor, S6 ribosomal protein phosphorylation was determined by intracellular staining after 90 minutes and the percentage of pS6+ cells is shown (black, mean±SD, n=3-5 except TGX-115, n=1, right panel). The percentage of Foxp3+ cells is shown after subtracting the percentage of Foxp3+ cells in cultures deprived of TCR signaling (red, mean±SD, n=4-12). IC50 values determined in vitro (Camps et al., 2005; Knight et al., 2006) are indicated for relevant enzymes (right panel). -
FIG. 6 . Foxp3 induction by inhibitors of PI3K/mTOR signaling is independent of TGFβ - a) naive LN T cells were activated in serum free AIM-V medium (Invitrogen) for 18 hours and whole cell extracts were subjected to SDS gel electophoresis and western blotting after exposure of the cells to TGFβ (1 ng/ml) for (90 minutes, lane 1), TCR signal deprivation (90 minutes, lane 2), or TCR signal deprivation plus rapamycin and Ly294002 (90 minutes,
lane 3 or 8 hours, lane 4). The blot was sequentially probed with anti pSmad2 (S465/467) and anti Smad2/3.
b) naive LN T cells activated as in a) were deprived of TCR signals and TGFβ and PI3-K/mTOR inhibitors were added as indicated below the graph. The percentage of Foxp3 expressing cells was determined 24-48 hours later. Cultures were supplemented with neutralising anti TGFβ (R&D Systems, 3 μg/ml) or the Smad kinase inhibitor SB431542 (Sigma, 20 μM). Foxp3 expression in TCR signal deprived cultures (9.2±5.6%, n=6) was subtracted. Shown is Foxp3 expression in the presence of anti TGFβ (dark grey bars) or SB431542 (light grey bars) normalisesd to control cultures (100%, black bars; TGFβ 22.3±7.0%, n=9; PIK90 36.0±12.9%, n=7; PI-103 35.1±3.8%, n=8; Ly294002 21.5±4.0%, n=4 and rapamycin 28.6±9.0%, n=4). ND: not done. -
FIG. 7 shows TCR signal deprivation and inhibitors of the PI3K/mTOR pathway induce Foxp3 expression by newly activated T cells. - a) naive CD62LhiCD4+ CD25− LN T cells were stimulated with plate bound anti-TCR and soluble anti-CD28 for 18 hours and cultured for an additional two days with TCR antibody (continued TCR signaling) or without TCR antibody (TCR signal deprivation). The expression of Foxp3 RNA was assessed by real time RT-PCR (mean SD, n=3).
b) naive CD4 T cells were labelled with CFSE and stimulated with plate bound anti TCR and anti CD28 as in a) and transferred to the indicated conditions after 18 hours. The expression of Foxp3 protein was evaluated byintracellular staining 2 days later. Cell recovery was between 67 and 108% of input. CFSE profiles are shown for Foxp3− and Foxp3+ cells.
c) naive LN CD4 T cells were activated as in a) for the indicated number of hours, after which the cells were deprived of TCR signals and exposed to rapamycin and LY294002. The percentage of Foxp3 expressing cells was determined 2 days later (mean of 2 experiments).
d) Foxp3 expression was induced in naive CD4 T cells by TCR signal deprivation, rapamycin and LY294002. The cells were re-stimulated weekly in the presence of IL-2 and Foxp3 expression was monitored. Natural Treg cells are shown for comparison.
e) naive CD4 T cells were activated for 18 hours and cultured for an additional 2 days either with anti-TCR (control, <1% Foxp3+) or without anti-TCR and in the presence of rapamycin and LY294002 (Foxp3 induced, 28% Foxp3+). Graded numbers of Foxp3 induced or control cells were added to fresh, CFSE labelled CD4 LN T cells in the presence of APC and soluble anti CD3 and the effect on cell division (CFSE profile) was recorded 48 h later.
f) naive CD45RBhiCD4+ CD25− LN cells were transferred intravenously into syngeneic Rag deficient recipients, either freshly isolated ex vivo, activated under control conditions with continued TCR activation, or deprived of TCR signals and treated with rapamycin and LY294002 after 18 hours. Colitis scores were determined after eight weeks.
g) CD4 single positive, CD25 negative thymocytes were activated, TCR signals were withdrawn, rapamycin/LY294002 added after 18 hours and Foxp3 expression analysed 2 days later as in b). -
FIG. 8 shows differential involvement of p110 isoenzymes in Foxp3 induction - a) naive LN cells were activated as in
FIG. 1 and PI3K inhibitors were added after 18 hours. The p110 isoform specificity of each inhibitor at the concentration used is shown alongside the percentage of Foxp3+ cells.
b) The percentage of pS6+ cells was determined by intracellular staining at 90 min (black, mean±SD, n=3-5 except TGX-115, n=1, right panel). Shown is the increase in Foxp3+ cells over that in cultures deprived of TCR signaling (red, mean±SD, n=4-12). IC50 values determined in vitro are indicated for relevant enzymes. -
FIG. 9 shows Foxp3 induction by PI3K/mTOR signaling is independent of TGFβ. - a) naive LN T cells were activated in serum free AIM-V medium for 18 hours and whole cell extracts were subjected to SDS gel electophoresis and immunoblotting after exposure of the cells to TGFβ (1 ng/ml) for (90 minutes, lane 1), TCR signal deprivation (90 minutes, lane 2), or TCR signal deprivation, rapamycin and LY294002 (90 minutes,
lane 3 or 8 hours, lane 4). The blot was stripped and probed probed with anti pSmad2 (S465/467) and anti Smad2/3.
b) naive LN T cells activated as in a) were deprived of TCR signals and TGFβ and PI3K/mTOR inhibitors were added as indicated. Cultures were supplemented with neutralising anti TGFβ (3 μg/ml) or the Smad kinase inhibitor SB431542. Shown is Foxp3 expression in the presence of anti TGFβ (dark grey bars) or SB431542 (light grey bars) determined 2 days later and normalisesd to control cultures without anti TGFβ and SB431542 (black bars; TGFβ22.3±7.0%, n=9; PIK90 36.0±12.9%, n=7; PI-103 35.1±3.8%, n=−8; LY294002 21.5±4.0%, n=4 and rapamycin 28.6±9.0%, n=4). ND: not done. Foxp3 expression in TCR signal deprived cultures (9.2±5.6%, n=6) was subtracted -
FIG. 10 shows the impact of TCR signaling on the PI3K/mTOR/Akt network in newly activated CD4 T cells. - a) naive LN CD4 T cells were stimulated with plate bound anti TCR and anti CD28 for 1 or 18 hours, or for 1 hour with anti CD28 alone (no TCR signaling). S6 phosphorylation was determined by intracellular staining and flow cytometry.
b) naive LN cells were activated as in a). After 18 hours, rapamycin (25 nM) or LY294002 (10 μM) were added for one additional hour, or the cells were cultured for the indicated time in the absence of anti TCR. pS6 levels were determined as in a).
c) immunoblotting confirmed declining pS6 in response to TCR signal deprivation and rapamycin detected at the single cell level in b). TGFβ also reduced pS6. - pAkt (S473) was visible 1 hour, not 18 hours after T cell activation but reappeared in response to TCR signal deprivation, rapamycin, and TGFβ.
- d) pathway model of the PI3K/mTOR axis. PI3K activates Akt via PDK1, Akt inhibits TSC1/2, this activates mTOR, relieves translational inhibition via 4EBP/eIF4E and stimulates ribosomal activity via S6K1/eIF4E.
e) network models of the PI3K/mTOR axis distinguishes mTORC1 and mTORC2. mTORC1-dependent S6K1 activity blocks the activation of mTORC2 by PI3K via IRS1. Akt activity depends on both PDK1 (T308) and mTORC2 (S473) (Jacinto et al., 2006; Sabatini, 2006).
f) Akt inhibition byAkti 1/2 induces Foxp3 expression. Naive CD4 T cells were activated and Foxp3 expression was evaluated as inFIG. 1 . -
FIG. 11 shows Foxp3 expression in response to TCR signal deprivation and PI3K/mTOR inhibition in vivo. - a) to mimic TCR signal deprivation, CFSE labelled CD62LhiCD4+CD25− LN cells were activated and then transferred intravenously to syngeneic, fully immunocompetent hosts (2-4×106 cells per recipient) with or without intraperitoneal rapamycin (0.5 mg/kg) and LY294002 (15 mg/kg). Foxp3 expression by endogenous (CFSE−) and transferred (CFSE+) CD4 spleen cells was assayed two days later. With 5.3±4.6% (n=11) the frequency of Foxp3+ cells recovered was 3 times higher than in the original inocula (1.5±1.1%). When cell transfer was accompanied rapamycin and LY294002 i.p., the frequency of Foxp3+ cells increased further while Foxp3 expression among endogenous (CFSE−) T cells did not change, demonstrating selectively toxicity to conventional, but not to Foxp3+CD4 T cells.
b) summary of 11 transfer experiments. To address whether the increase in Foxp3 expressing cells was due to the selective recovery of Foxp3+CD4 T cells or to Foxp3 induction we transferred CFSE labelled CD62LhiCD4+ CD25− LN cells after 48 hours of activation, a time when TCR deprivation no longer efficiently induced Foxp3 expression in vitro (seeFIG. 1 c). Under these conditions, 1.3±0.5% of CFSE+ cells expressed Foxp3 after transfer (n=4) and 1.6±0.3% of CFSE+ cells after transfer in the presence of rapamycin and LY294002 (n=3). -
FIG. 12 shows Foxp3 induction by PI3K/mTOR inhibitors in the presence of continued availability of TCR ligands. - Naive CD4 T cells were activated with CD3/CD28 beads (Dynal, 4 μl/106 cells). The indicated PI3K/mTOR inhibitors were added (1 μM) at 18 hours without removing the beads and Foxp3 expression was assessed two days later.
-
FIG. 13 shows Foxp3 induction in response to physiological TCR ligands and PI3K/mTOR inhibition. - CD4 LN cells from Rag1 deficient H2b AND TCR transgenic mice were labeled with CFSE and cultured with BM-derived B10.BR (H2k) antigen presenting cells pre-loaded with the indicated concentrations of pigeon cytochrome-C peptide 81-104. PIK90 (1 μM) was added after 18 hours without removing the antigen presenting cells or the antigenic peptide. Foxp3 expression was analysed two days later.
- The invention is now described by way of example. These examples are intended to be illustrative, and are not intended to limit the appended claims.
- Mouse strains, cell sorting and culture. Animal work was carried out according the Animals (Scientific Procedures) Act, UK. Lymph node (LN) cells were stained, analysed and sorted by flow cytometry as described (Cobb et al 2005 J. Exp. Med. 201: 1367-1373). Intracellular staining for Foxp3 protein was done as advised by the manufacturers (eBiosciences.com). The phosphorylation syatus of S6 ribosomal protein was determined using anti pS6 Ser235/236 (Cellsignaling cat.no. 2211, http://www.cellsignal.com) using the eBioscience Foxp3 staining kit and anti rabbit IgG-FITC or IgG-Cy5 (Jackson Immunoresearch). For induction of Foxp3 expression, sorted LN CD4+ CD25− CD62Lhi T cells were cultured at 1-3×106/ml with plate bound anti-TCRβ (H57, Pharmingen, 200 ng/ml) and anti-CD28 (2 μg/ml, Pharmingen). After 18 hours the cells were either left in place for continued TCR stimulation or moved to uncoated wells with the indicated additives. To assess regulatory function, CD4 T cells cultured as indicated were titrated into round bottom wells containing either 1×105 CFSE labeled total LN cells or 5×104 CFSE labeled CD4+ CD25− T cells and 1×105 mitomycin-C treated (25 μg/ml, 20 min, 37° C.) T cell depleted splenocytes with the indicated concentrations of anti CD3 (2C11, Pharmingen). CD4 T cell CFSE profiles were recorded between 48 and 72 hours later.
- Adoptive transfer experiments. To assess the impact of TCR signal deprivation and PI3-K/mTOR inhibition in vivo, BALB/c CD4+ CD25− CD62Lhi LN T cells were labeled with CFSE, activated for 18 hours as above, and transferred i.v. into untreated syngeneic recipients (2-4×106 cells per recipient). Rapamycin and Ly294002 were given i.p. as indicated. Splenocytes were stained for CD4 and
Foxp3 48 hours later and Foxp3 expression was determined for endogenous (CFSE−) and for transferred (CFSE+) CD4+ cells. - RT-PCR and northern blots. Total RNA was isolated using RNAbee (Tel-Test, Friendswood, Tex.) and reverse transcribed. Real-time PCR analysis was carried out on an Opticon™DNA engine (MJ Research Inc.; 95° C. for 15 min followed by 40 cycles of 94° C. for 15 s, 60° C. for 30 s and 72° C. for 30 s with a plate read at 72° C.) and normalised to the geometric mean of Ywhaz (tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, zeta polypeptide) and Ube2L3 (ubiquitin conjugating enzyme E2L3) as described (Cobb et al 2005 ibid.). Primer sequences (5′ to 3′)
-
Ywhaz forward: CGTTGTAGGAGCCCGTAGGTCAT Ywhaz reverse: TCTGGTTGCGAAGCATTGGG Ubc forward: AGGAGGCTGATGAAGGAGCTTGA Ubc reverse: TGGTTTGAATGGATACTCTGCTGGA Foxp3 forward: ACTCGCATGTTCGCCTACTTCAG Foxp3 reverse: GGCGGATGGCATTCTTCCAGGT - Naive CD4+ CD25− cells were stimulated with plate bound anti-TCR(H57) and anti-CD 28 for 18 hours and then transferred (in their original medium) to plates not coated with TCR antibodies. 48 hours later, real time RT-PCR showed elevated levels of Foxp3 RNA in cells deprived of TCR signals compared to controls exposed to continued TCR signaling (
FIG. 1 a). Intracellular staining showed the expression of Foxp3 protein in a sizeable fraction of newly activated CD4 T cells deprived of TCR signals (10.8±7.6% n=30) (FIG. 1 b), but not in cells left in contact with TCR antibody (1.0±0.8% n=21). - To identify relevant signaling pathways for the induction of Foxp3 we screened activators and inhibitors of signal transduction pathways. These included inhibitors of calcineurin, which block the nuclear translocation of NFAT (cyclosporin A and FK-506), activators and inhibitors of relevant MAPKs (mitogen activated kinases, including JNK/SAPK/p38 and upstream kinases), a wide range of inhibitors and pseudosubstrates of PKC isoenzymes, GSK3 (glycogen synthase kinase-3), HIF-1□(hypoxia inducible factor), Notch (using the β-secretase inhibitor L-685458) and BMP (bone morphogenetic proteins, which are relatives of TGFβ. None of these delectably enhanced the expression of Foxp3 initiated by TCR signal deprivation. In contrast, inhibitors of PI3K and mTOR markedly potentiated Poxp3 induction. The immunosuppressive macrolide antibiotic rapamycin induced the expression of Foxp3 in 26.8±14.4% of cells within 24-48 hours (n=30,
FIG. 1 b). Similarly, the PI3K inhibitors Ly294002 (2-(4-Morpholinyl)-8-phenyl-4H-1-benzopyran-4-one) and Wortmannin induced Foxp3 (26.9±11.4%, n=25 for Ly294002,FIG. 1 b and 17.3±5.3%, n=3, for Wortmannin). The control compound Ly303511 (2-piperazinyl-8-phenyl-4H-1-benzopyran-4-one) is structurally very similar to Ly294002 but does not inhibit PI3-K due to a single atom substitution in the morpholine ring. Ly303511 did not affect Foxp3 expression in our system (6.6±3.0%, n=7). Rapamycin and Ly294002 were maximally effective when used in combination withTCR signal deprivation 18 hours after the activation of naive CD4 T cells, before cell division had occurred (see below). TCR signaling was required for PI3K/mTOR inhibitors to induce Foxp3, and co-stimulation markedly enhanced the efficiency of Foxp3 induction (from 3 to 9% for TCR signal withdrawal, from 7 to 46% for TGFβ, from 10 to 25% for rapamycin and from 4 to 44% for Ly294002, average of two experiments. As a positive control, TGF□ induced Foxp3 in 46.0±15.1% of cells deprived of continued TCR signaling (n=30,FIG. 1 b). To address whether the increased frequency of Foxp3 expressing cells was due to the selective expansion of preexisting Foxp3+ cells, we labelled naive CD4 T cells with CFSE prior to their activation. No cell division had occurred by 18 hours after activation, at the time the cells were placed in the indicated culture conditions (FIG. 1 b). Twenty-four hours later, between 67 and 108% of input cells were recovered. Despite substantially enhancing the frequency of Foxp3 expressing cells, rapamycin and Ly294002 resulted in a slight reduction in the number of cell division, ruling out selective expansion as an explanation for the increased frequency of Foxp3 expressing cells in response to TCR signal deprivation and PI3K/mTOR inhibitors. - Inhibition of PI3-K/mTOR was less effective at inducing Foxp3 at later time points and once cell division had occurred (
FIG. 1 c). - To monitor the activity of the PI3K/mTOR axis in response to TCR signaling, TCR signal withdrawal and treatment with rapamycin and Ly294002, we analysed the level of phosphorylated S6 ribosomal protein (pS6), the target of p70 S6 kinase, which is directly regulated by mTOR. Intracellular staining for pS6 showed at the single cell level that TCR signaling (plate bound H57, 300 ng/ml) combined with anti-CD28 induced high levels of S6 phosphorylation in the majority of naive CD4 T cells (
FIG. 2 a). Anti-CD28 alone had no effect (FIG. 2 a, top panel). S6 phosphorylation persisted in the presence of continued TCR signaling, but was completely removed by rapamycin (25 nM) or Ly294002 (10 μg/ml) within one hour (FIG. 2 b). pS6 declined more gradually when naive CD4 T cells that had been activated for 18 hours with plate bound H57 and anti CD28 were deprived of TCR signals (FIG. 2 b). Hence, Foxp3 induction occurs in response to manipulations that reduce S6 phosphorylation. Importantly, however, reduced S6 phosphorylation is not sufficient for Foxp3 induction. In particular, the inhibition mTOR by nutrient deprivation of newly activated CD4 T cells fails to induce Foxp3 expression. - As described above, Foxp3 expression was induced within 24-48 hours in response to TCR signal deprivation and PI3-K/mTOR inhibitors. We next examined the stability of Foxp3 expression and the functional competence of the Foxp3 induced cells, since transient upregulation of Foxp3 without regulatory function has been described in human CD4 T cells. Foxp3 was robustly expressed by
day 7 after induction and expression was mitotically heritable, since it was stably maintained through several rounds of re-stimulation in IL-2 (FIG. 3 a). To assess whether the induction of Foxp3 by PI3K/mTOR inhibition results in regulatory T cell function, CD62LhiCD4+CD25− LN cells were activated, deprived of TCR signals and cultured in the presence of rapamycin and Ly294002. Graded numbers of the resulting population (28% Foxp3+by intracellular staining) were added to fresh, CFSE labelled CD4 LN T cells and efficiently blocked their response to soluble anti CD3 (2C11, 1□ g/ml) as assessed by the cell division profile (FIG. 3 b, top panel). In contrast, control cells (<1% Foxp3+) did not block anti CD3-induced division of CFSE labeled responder cells (FIG. 3 b, bottom panel). - We used a T cell transfer model of colitis (Powrie et al., 1993) to test whether Foxp3 induction by TCR signal deprivation and PI3K/mTOR inhibition confers the ability to protect from colitis, which is elicited when naive CD4 T cells are transferred to T cell deficient recipients. (Powrie et al., 1993)
- We next addressed whether Foxp3 is induced by TCR signal deprivation and PI3-K/mTOR inhibition in vivo. To mimic TCR signal deprivation, we injected activated, CFSE labelled CD62LhiCD4+CD25− LN cells into the tail veins of syngeneic, fully immunocompetent hosts. Two days later we evaluated Foxp3 expression by endogenous (CFSE−) and transferred (CFSE+) CD4 spleen cells (
FIG. 4 a). With 5.3±4.6% (n=11) the frequency of Foxp3+ cells recovered was 3 times higher than the frequency of Foxp3+ cells contained in the original inocula (1.5±1.1%, summarised inFIG. 4 b). When the i.v. transfer of CFSE labeled activated T cells was accompanied by the i.p. injection of rapamycin and Ly294002, the frequency of Foxp3 expressing cells that were recovered 2 days later increased further, to around 10% (FIG. 4 ). In contrast, the frequency of endogenous (CFSE−) Foxp3+ T cells remained unchanged, excluding the possibility that the inhibitors were selectively toxic to conventional, but not to Foxp3+ CD4 T cells (FIG. 4 ). We next addressed whether the elevated frequency of Foxp3 expressing cells was due to the selective recovery of Foxp3+CD4 T cells or to the induction of Foxp3. We transferred CFSE labelled CD62LhiCD4+CD25− LN cells after 48 hours of activation, a time when TCR deprivation no longer efficiently induced Foxp3 expression in vitro (seeFIG. 1 c). Under these conditions, only 1.3±0.5% of CFSE+ cells expressed Foxp3 after transfer (n=4) and 1.6±0.3% of CFSE+ cells after transfer in the presence of rapamycin and Ly294002 (n=3,FIG. 4 b). - Hence, TCR signal deprivation predisposes newly activated T cells to Foxp3 expression in synergy with inhibition of the PI3-K/mTOR axis, indicating that PI13-K/mTOR signaling antagonises Foxp3 induction in newly activated T cells in vitro and in vivo.
- A new generation of PI3-K inhibitors has recently been characterised at the biochemical, structural, and biological level and shown to have selectivity for PI3-K isoenzymes in preference over an extensive range of other kinases (Camps et al., Nat. Med. 2005, 11:936-943; Knight et al., 2006 ibid.). We utilised these compounds to dissect the role of p110 isoenzymes in the regulation of Foxp3 by titrating them into our T cell differentiation assay. In these experiments, CFSE labeling was used to assess cell cycle progression as a measure of activation and viability, and the induction of Foxp3 was assayed at the single cell level (
FIG. 5 a, b), along with S6 phosphorylation (FIG. 5 b). - p110β and p110γ do not detectably affect Foxp3 expression. TGX115 had a slight impact on Foxp3 expression at 10 μM, where it inhibits both p110β and p110δ. At 0.1 μM, where TGX115 selectively inhibits p110β, it did not affect Foxp3 expression, indicating that p110β plays no significant role in regulating Foxp3 in this setting. Similarly, the p110{tilde over (γ)} specific inhibitor AS-605240 affected Foxp3 only at concentration far in excess of its IC50 for p110γ (0.008 μM), ruling out a role for p110γ in the regulation of Foxp3 (
FIG. 5 a, b). - p110α and p110δ regulate Foxp3 expression in newly activated T cells. The inhibitor IC-87114 induced Foxp3 10-15% of cells over and above TCR deprivation alone down to 0.01 μM. At these concentrations, IC-87114 selectively inhibits p110δ, demonstrating a significant contribution of the p110δ isoenzyme to the regulation of Foxp3. The PI-103 compound strongly induced Foxp3, elevating the frequency of Foxp3 expressing cells by >20% above TCR signal deprivation alone. PI-103 induced Foxp3 at concentrations slightly below its in vitro IC50 for mTORC1 (0.02 μM) and around the IC50 for p110α (0.008 μM), consistent with a role for p110α. The p110{tilde over (α)} specific inhibitor PIK75 could not be used to test this suggestion due to toxicity over the duration of our assay (data not shown). Conclusive evidence came from the analysis of PIK90, which strongly induced Foxp3 at 0.1 μM, where it selectively inhibits p110α and p110γ (
FIG. 5 a, b). Since our experiments with AS-605240 rule out a role for p110γ, this result identifies p110α as the dominant p110 isoenzyme in the regulation of Foxp3. Based on these studies, the role of p110 isoenzymes in the regulation of Foxp3 appears to be selective: p110 and p110γ play no detectable role, p110δ is moderately important, and p110α is predominant. - TGFβis known as a powerful inducer of Foxp3 expression in conventional CD4 T cells in vitro and we therefore asked whether TGFβmediates the induction of Foxp3 by TCR signal deprivation of newly activated T cells and PI3-K/mTOR inhibitors. Since cell culture medium supplemented with FCS contains TGFβ, we carried out the experiments described in this section in serum free lymphocyte culture medium (AIM-V, Invitrogen). Real time RT-PCR detected no increase in TGF-β1, the predominant TGFβ isoform in the immune system, but TGF-β regulation is known to be complex and RNA levels do not necessarily correlate with the amount of secreted protein. The binding of TGFβ binding to ALK5 and TGFβ receptor II (TGFβRII) results in the phosphorylation of receptor-associated Smad2 and -3, which subsequently associate with co-Smads, translocate to the nucleus and act as transcriptional regulators. The phosphorylation of Smad proteins therefore provides a sensitive indicator of TGFβ signaling. Naive LN T cells were activated for 18 hours in serum free medium and then exposed to TGFβ (1 ng/ml) for, TCR signal deprivation, or TCR signal deprivation plus rapamycin and Ly294002. Whole cell extracts were subjected to SDS gel electophoresis and western blotting with anti pSmad2 (S465/467) showed strong phosphorylation of Smad2 in response to TGF□ (
FIG. 6 a lane 1). In contrast, there was no detectable phosphorylation of Smad2 in response to TCR signal deprivation (FIG. 6 a, lane 2), or TCR signal deprivation plus rapamycin and Ly294002 (FIG. 6 a,lanes 3 and 4). The blot was subsequently probed with anti Smad2/3 as a loading control. - Next, we sought to inhibit TGFβ signaling using two independent approaches, neutralising antibodies to TGFβ and SB 431542, an inhibitor of TGFβ activin receptor-like kinases (ALKs). SB-431542 is a potent and specific inhibitor of transforming growth factor-beta superfamily type I activin receptor-like kinase (ALK) receptors ALK4, ALK5, and ALK7. (Inman et al 2002 Mol. Pharmacol. vol 62:65-74). Since cell culture medium supplemented with FCS contains TGFβ, we carried out these experiments in serum free lymphocyte culture medium (AIM-V, Invitrogen). Neutralising TGFβantibodies and SB431542 blocked Foxp3 induction by TGFβ by 85% and 96%, respectively, but had no effect on Foxp3 induction by PI3-K/mTOR inhibitors (
FIG. 6 b). -
TABLE 1 Specificity of the small molecule inhibitors used in FIG. 5 and elsewhere for p100 isoenzymes and other kinases SA- TGX115 IC87114 PIK90 PI-103 605240 p110α 61 >200 0.011 0.008 0.06 p110β 0.13 16 0.35 0.088 0.27 p110δ 0.63 0.13 0.058 0.048 0.3 p110γ 100 61 0.018 0.15 0.008 PI3KC2α >100 >100 0.047 ~1 PI3KC2β 50 >100 0.064 0.026 PI3KC2γ 100 >100 ND ND hsVPS34 5.2 >100 0.83 2.3 PI4Ks PI4KIIα >100 >100 >100 >100 PI4KIIIα >100 >100 0.83 >100 PI4KIIIβ >100 >100 3.1 ~50 PIKKs ATR >100 >100 15 0.85 ATM 20 >100 0.61 0.92 DNA-PK 1.2 >100 0.013 0.002 mTORC1 >100 >100 1.05 0.02 mTORC2 >100 >100 ND 0.083 PIPKs PI4P5KIα >100 >100 >100 >100 PI4P5KIα >100 >100 >100 >100 PI5P4KIIβ >100 >100 >100 >100 Abl 121.2 103.6 103.4 100.8 Abl (T315I) 141.2 99.4 111.3 108.1 Akt1 126.6 122.2 140.2 108.5 − Akt1 (ΔPH) 91.4 89.6 122.4 123.1 Akt2 98.8 116.5 102.0 98.8 FAK 105.5 110.1 100.0 101.8 Fyn 145.7 105.3 126.1 114.2 GRK2 113.5 118.7 120.2 110.3 GSK3β 114.0 104.7 85.6 105.5 (+) Hck 104.9 93.0 94.7 94.9 Insulin R. 108.4 115.7 102.8 106.0 JNK1α1 99.9 88.5 94.2 83.6 − JNK2α1 104.8 107.1 90.5 81.0 − JNK2α2 95.4 87.7 83.1 76.9 IRAK4 112.7 93.1 94.9 105.6 NEK2 125.2 114.3 103.4 120.0 PKA 105.4 108.6 103.1 102.5 − PKCδ 103.9 104.6 100.7 101.2 PKCε 108.9 114.1 105.2 103.4 PDK1 111.2 113.4 110.4 107.5 − PLK1 122.7 109.6 107.6 106.2 p38 101.2 104.1 98.5 99.8 Src 111.7 113.3 103.7 100.6 − Src (T338I) 112.8 95.7 109.5 113.4 WNK1 107.5 109.0 108.6 104.1 Zap70 123.8 110.5 115.8 117.7 − Akt2 (APH) 104.4 117.8 108.5 112.6 Akt3 97.6 111.0 113.3 103.5 CamKII 111.4 115.4 116.1 127.6 − CDK1/cyc. B 103.0 116.0 126.6 142.3 (+) CDK2/cyc. A 105.3 102.4 100.9 98.5 − Chk1 119.9 103.0 102.9 92.3 − CK1 99.7 98.1 97.8 84.8 (+) CK2 103.3 111.7 103.1 108.1 Erk1 96.7 93.7 98.8 92.0 Erk2 107.7 104.7 119.8 114.7 - Summary of Examples 1-7
- We show that TCR signaling and PI3-K/mTOR activity antagonises the induction of Foxp3 in newly activated T cells. Without wishing to be bound by theory, this finding has important implications for understanding immune regulation, as it links the choice between effector and regulatory T cell fate to the termination of TCR signaling. Effective immune responses reduce antigen load and create conditions where the availability of antigen becomes limiting. Our results indicate how immune regulation may be linked to the involution phase of immune responses, which is important for T cell homeostasis and for limiting immune pathology.
- Pharmacological inhibition of the PI3K/mTOR axis potentiates Foxp3 induction triggered by deprivation of TCR signals. The involvement of PI3K/mTOR is selective, since blockade PKC, N-FAT, GSK-3, MAPK, Notch and others does not results in Foxp3 induction in the systems of the examples. PI3-K activity persists for many hours following T cell activation and our findings demonstrate that the PI3K/mTOR axis is critical in preventing the induction of Foxp3 in newly activated T cells. The class I PI3-kinases are subdivided into two groups, A and B, based on the selective involvement of p110 isoezymes, the catalytic subunits of PI3-K. The expression of p110δ and p110γ subunits is mainly restricted to leukocytes, whereas p110α and p110β are ubiquitously expressed and essential for embryonic development. p110γ, the single member of Class IB, is important for T cell development and activation and a major target for the treatment of inflammatory responses and autoimmune disease. The link between PI3K signaling and disease has provided a major driver for the development and introduction into the clinic of selective inhibitors of PI3-K subunits. We have employed extensively characterised selective inhibitors to show selectivity among p110 isoenzymes where p110α and p110δ, but not p110 or p110γ regulate Foxp3. While p110γ is activated by G-protein-coupled receptors, the class IA PI3Ks p110α; p110δ and p110βare typically activated downstream of receptor tyrosine kinases and therefore involved in lymphocyte receptor signalling. Interestingly, the hierarchy among IA PI3Ks in Foxp3 regulation appears to be distinct from their relative contribution to TCR stimulated PI3-K activity. Genetic and pharmacological analysis both point to a prominent role for p110δ in antigen receptor signaling in B and in T lymphocytes, while our data show that p110δ has a significant, but less dominant role in Foxp3 regulation, where p110α appears to dominate. The functional distinction between p110 isoforms in TCR signaling and Foxp3 regulation assists the skilled worker in manipulation of the immune response.
- p110δ deficient mice not only show defects in lymphocyte activation, they also develop inflammatory bowel disease, the hallmark of Treg deficiency. A potential explanation for this is suggested by the dependence of Treg tolerance on mast cell-derived IL-9 and the essential role of p110δ for mast cell function. Consistent with these data, Treg function is impaired in the periphery of p110δ deficient mice. This notwithstanding, the differentiation of Tregs is increased in the p110δ deficient thymus in agreement with our findings.
- Both PI3-K inhibitors and rapamycin have been used to repress unwanted immune responses but the mechanisms by which PI3-K/mTOR inhibitors regulate immunity are largely unknown. A link between PI3-K inhibitors and autoimmunity was suggested by the finding that mice heterozygous for Pten, an antagonist of PI3-K signaling, developed autoimmunity as well as other observations. PI3-Ks regulate numerous processes in multiple cell types and potential mechanisms for the involvement of PI3-Ks in autoimmunity include the increased survival of T cells and the recruitment and activation of antigen presenting cells, mast cells and other inflammatory cell types. Rapamycin had previously been reported to affect regulatory T cell numbers positively or negatively in long term assays. Our findings establish the regulation of Foxp3 as a mechanism by which PI3-K/mTOR inhibitors modulate immunity.
- In contrast to the class IA isoenzymes p110α and δ, the class IB PI3-K isoenzyme p110γ functions predominantly downstream of G protein-coupled receptors (rather than src tyrosine kinases), and PI3-Kγdoes not significantly regulate Foxp3. Nevertheless, PI3-Kγ plays an important role in T cell development and activation and has recently been recognised as a target for the treatment of autoimmune disease. Inhibitors of PI3-Kγ are effective drugs in the prevention and in the treatment of autoimmunity, but—as we demonstrate—not via the induction of Foxp3 in newly activated T cells.
- Earlier studies had linked rapamycin to deletion or the protracted expansion of pre-existing Tregs, especially in combination with growth factor withdrawal, but rapamycin appeared to have no effect on the de novo induction of Foxp3. Here we show rapid de novo induction of Foxp3 by rapamycin in combination with TCR signal deprivation.
- TGFβ is a potent inducer of Foxp3 in naive CD4 T cells and we therefore asked whether TGFβ is involved in the induction of Foxp3 by TCR signal deprivation of newly activated T cells and PI3-K/mTOR inhibitors. We found no evidence that newly activated T cells increase TGFβ production in response to TCR signal deprivation and inhibition of PI3K/mTOR. Foxp3 induction was efficient in serum free medium, which excludes a requirement for serum-derived TGFβ. Our findings show that TCR signal deprivation and PI3-K/mTOR inhibitors do not result in detectable phosphorylation of Smad2 and that Foxp3 induction by TCR signal deprivation and PI3-K/mTOR inhibitors is independent of exogenous TGFβ resistant to neutralising anti-TGFβ and resistant to SB431542. They are therefore consistent with a model in which PI3-K/mTOR inhibitors induce Foxp3 by a pathway independently of TGFβ.
- In summary, we have identified a novel, TGFβ independent pathway of Foxp3 induction in newly activated naive T cells. Our findings highlight the importance of TCR signaling for the choice between effector fate and Treg function and we describe new approaches to drive regulatory T cell differentiation by small molecule inhibitors of PI3K/mTOR signaling in situations where the manipulation of immune responses is desirable.
- We teach that activation of naive CD4 T cells creates a window of opportunity for the induction of Foxp3 expression, controlled by PI3K/mTOR signaling.
- Overview: Activation reveals the potential of naive CD4 T cells to differentiate towards a range of T helper (Th) cell types, or, alternatively, to adopt a regulatory T cell (Treg cell) fate. How the effector versus regulatory cell fate choice is controlled is largely unknown in the prior art. We show that expression of the Treg cell signature transcription factor Foxp3 is induced when naive CD4 T cells are deprived of TCR signals soon after activation. Foxp3 induction is controlled by
phosphatidyl inositol 3 kinase (PI3K) catalytic subunits p110α and p110δ, Akt and mTOR. These findings link TCR signal transduction pathways to the choice of Treg cell fate. The invention provides new approaches for the experimental and therapeutic manipulation of regulatory T cell differentiation. - Introduction: Specialised cell types in multicellular organisms are defined by specific patterns of gene expression. During their differentiation from multipotent hematopoietic stem cells, developing T cells undergo considerable restriction of their lineage potential. Options that remain open to naive CD4 T cells include several distinct Th subsets (such as Th1, Th2 and Th17) and the Treg cell fate. The choice of Th lineage is important for effective immune responses to specific pathogens, while the balance between effector and regulatory functions is critical to ensure immune competence while avoiding excessive immune pathylogy and autoimmunity. Natural regulatory T cells are characterised by the expression of the signature transcription factor Foxp3 and stable high level expression of Foxp3 is both necessary and sufficient for regulatory T cell function. Treg cells arise in the thymus and from naive peripheral CD4 T cells. TGFβ instructs Foxp3 expression in vitro but, like IL-2, is important for the maintenance of Treg cells in vivo rather than for Treg cell differentiation. Since the molecular basis of the choice between effector and regulatory T cell fate is unknown in the prior art, we set out to identify signals that induce Foxp3 expression and regulatory T cell function in naive CD4 T cells.
- Experimental: Naive CD4+ CD25− cells are activated with plate bound anti-TCR and soluble anti-CD28 for 18 hours and then moved to fresh wells with soluble anti-CD28 only. Two days later, real time RT-PCR showed elevated expression of Foxp3 RNA in cells deprived of TCR signals compared to controls exposed to continuous TCR signals (
FIG. 7 a) and Foxp3 protein was detected 10.8±7.6% (n=30) of cells deprived of TCR signals, but only in 1.0±0.8% (n=21) of cells left in contact with TCR antibody (FIG. 7 b). To identify pathways that control Foxp3 downstream of TCR signaling we screened small molecule inhibitors of enzymes involved in signal transduction. Inhibitors of PI3K and mTOR markedly potentiated Foxp3 induction (FIG. 7 b), whereas inhibitors of calcineurin/NFAT (cyclosporin A and FK-506), mitogen activated kinases (MAPKs JNK, SAPK, p38 and upstream kinases), protein kinase-C isoenzymes, glycogen synthase kinase-3, hypoxia inducible factor, and γ-secretase/Notch did not. The mTOR inhibitor rapamycin induced Foxp3 in 26.8±4.4% of cells (n=30,FIG. 7 b). Similarly, the PI3K inhibitors LY294002 and Wortmannin induced Foxp3 in 26.9±11.4% (n=25,FIG. 7 b) and 17.3±5.3% of cells, respectively (n=3,). The LY294002 derivative LY303511 does not inhibit PI3K due to a single atom substitution in the morpholine ring and did not induce Foxp3 expression. TGFβ was used as a positive control (FIG. 7 b). To address whether increased Foxp3 expression resulted from the selective expansion of pre-existing Foxp3+ cells, we labelled naive CD4 T cells with CFSE prior to activation. No cell division had occurred after 18 hours, when the cells were exposed to inhibitors. Rapamycin and LY294002 slightly reduced the number of cell divisions that occurred during the next 24-48 hours, yet substantially enhanced the frequency of Foxp3 expression (FIG. 7 b) and Foxp3 was expressed in many cells that had not undergone cell division (FIG. 7 b). Hence, TCR signal deprivation and PI3K/mTOR inhibitors induce Foxp3 expression in naive CD4 T cells. - T cell activation was required for Foxp3 induction (
FIG. 7 c) and costimulation markedly enhanced its efficiency. - Costimulation markedly enhanced the efficiency of Foxp3 induction in response to TCR signal deprivation and PI3K/mTOR inhibition:
-
TCR signal depriv. rapamycin LY294002 anti-TCR 3 % Foxp3 +10% Foxp3+ 4% Foxp3+ anti-TCR + 9 % Foxp3 +25% Foxp3+ 44% Foxp3+ anti-CD28 - To explore the temporal relationship between T cell activation and Foxp3 induction, we withdrew TCR stimulation and inhibited PI3K/mTOR at different times (
FIG. 7 c). Foxp3 induction was maximal when T cells were activated for 18 hours prior to PI3K/mTor inhibition. Earlier addition of inhibitors blocked cell division and resulted in less efficient induction of Foxp3. Similarly, Foxp3 induction was inefficient when at later time points, once cell division had occurred (FIG. 7 c). We conclude that T cell activation creates a window of opportunity for Foxp3 induction. - Once induced, Foxp3 expression was mitotically heritable and maintained through several rounds of restimulation (
FIG. 7 d). Foxp3 expression was accompanied by regulatory T cell function, since Foxp3-induced cells (36% Foxp3+) efficiently blocked cell division of CFSE labelled CD4 LN T cells in response to soluble anti CD3 (FIG. 7 e, top panel), while control activated cells (1% Foxp3+) did not (FIG. 7 e, bottom panel). Resting or control activated CD45RBhi CD4 T cells cause colitis when transferred to lymphocyte deficient (Rag−/−) mice whereas colitis was markedly less severe when Foxp3 had been induced in a proportion of CD45RBhi CD4 T cells (28% Foxp3+) prior to transfer (FIG. 7 f). - While peripheral CD4 T cells can give rise to ‘adaptive’ Treg cells, their physiological relevance compared to Treg cells that arise ‘naturally’ in the thymus is an area of interest. To address whether manipulations of TCR signal transduction drive Foxp3 expression in thymocytes, we activated CD4 single positive, CD25 negative thynocytes for 18 hours and added PI3K/mTOR inhibitors (
FIG. 7 f). Analysis ofFoxp3 expression 2 days later demonstrated the induction of Foxp3 in a sizeable fraction of thymocytes. - A new generation of PI3K inhibitors have recently been characterised at the biochemical, structural, and biological level. Selectivity of these compounds for PI3K isoenzymes has been extensively validated by in vitro kinase assays and cell-based experiments (see Table 1) and by directly comparing the effects of pharmacological and genetic ablation on insulin signaling and lymphocyte activation. We utilised these compounds to define the involvement of PI3K catalytic subunits in the control of Foxp3. The TGX115 compound had a slight impact on Foxp3 expression at 10 μM, where it inhibits both p110β and p110δ but did not affect Foxp3 expression at 0.1 μM, where it selectively inhibits p110β. Similarly, the p110γ-specific inhibitor AS-605240 affected Foxp3 only at concentrations far in excess of its IC50 for p110γ (0.008 μM; indicating that p110δ and p110γ play no significant role in regulating Foxp3 in this setting (
FIG. 5 a, b). The IC-87114 compound consistently induced Foxp3 in 10-15% of cells over and above TCR deprivation alone at concentrations where it selectively inhibits p110δ (0.01 μM), demonstrating a significant contribution of p110δ to the regulation of Foxp3. The PI-103 compound strongly induced Foxp3, elevating the frequency of Foxp3 expressing cells by >20%. PI-103 induced Foxp3 at concentrations slightly below its in vitro IC50 for mTOR (0.02 μM) and around the in vitro IC50 for p110α (0.008 μM), consistent with a role for p110α. The p110α-specific inhibitor PIK75 could not be used to test this suggestion due to toxicity over the duration of the assay. Conclusive evidence for a role of p110α came from the analysis of PIK90, which strongly induced Foxp3 at 0.1 μM, where it selectively inhibits p110α and p110γ (FIG. 8 a, b). Since p110γ inhibition did not affect Foxp3 induction (see above) this result identifies p110α as the dominant p110 isoenzyme in this setting. This hierarchy of p110 isoenzymes (α>δ>>>β and γ) appears to set Foxp3 regulation apart from lymphocyte activation, where p110δ is considered as dominant. - Of course in vitro IC50 values must be treated as guidance for cellular IC50s; cellular values are typically somewhat higher because of competition from ATP. IC87114 is extremely p110δ selective, esp. at 1 μM, so the 15% induction at that concentration is clearly due to 6. TGX-115 has very little effect even at 10 μM (where minor 6 inhibition is obtained), so beta is likely of limited or peripheral importance. The a
inhibitors - TGFβ is a powerful inducer of Foxp3 expression in conventional CD4 T cells in vitro and we addressed its role in our system. The binding of TGFβ binding to ALK5 and TGFβ receptor 11 (TGFβRII) results in the phosphorylation of receptor-associated Smad2 and -3, which provides a sensitive indicator of TGFβ signaling. pSmad2 (S465/467) was readily detectable in response to TGFβ (
FIG. 9 a lane 1) but not in response to TCR signal deprivation (FIG. 9 a, lane 2), or PI3K/mTOR inhibition (FIG. 9 a,lanes 3 and 4). Neutralising TGFβ antibodies and SB 431542, which blocks TGFβ activin receptor-like kinases, reduced Foxp3 induction by TGFβ (by 85% and 96%, respectively), but had no effect on Foxp3 induction by PI3K/mTOR inhibitors (FIG. 9 b), demonstrating that TGFβ is dispensable for the induction of Foxp3 by TCR signal deprivation and PI3K/mTOR inhibition. - To monitor the activity of the PI3K/mTOR axis in newly activated CD4 T cells we analysed phosphorylation of S6 ribosomal protein (pS6), a target of the mTOR-regulated p70 S6 kinase S6K1. TCR/CD28 signaling (but not anti-CD28 alone) induced high levels of pS6 (
FIG. 10 a). The maintenance of mTOR activity in 18 hour activated T cells required continued TCR signaling, since S6 phosphorylation declined when TCR signals were withdrawn (FIG. 10 b). S6 phosphorylation was completely removed by rapamycin or LY294002 (FIG. 10 b). The serine/threonine protein kinase Akt/PKB is rapidly phosphorylated in response to signaling through TCR/CD28 but, in contrast to pS6, pAkt (S473) was no longer detected 18 h after initiation of TCR/CD28 signaling (FIG. 10 c). Akt (S473) phosphorylation was restored, however, when 18 h activated T cells were deprived of TCR signals, which resulted in increasing levels of pAkt at 1, 3, and 8 hours and a reciprocal decline in pS6 levels (FIG. 10 c). Exposure to rapamycin for 1 hour had a similar effect. Increased Akt phosphorylation in response to TCR signal deprivation and rapamycin treatment is incompatible with a traditional linear signaling pathway (FIG. 10 d) but consistent with a network model in which Akt activity is controlled both by PDK1 and by mTORC2. In this model, mTORC2 (mTOR/rictor/Sin1) is under negative feedback control of mTORC1 (mTOR/raptor) via S6K1, which phosphorylates and inhibits IRS1 (insulin receptor substrate 1) and reduces Akt activation via PI3K, PDK1 and mTORC2 (FIG. 10 e). Applied to our data, withdrawal of TCR signaling lowers mTORC1 and S6K1 activity (FIG. 10 b), which reduces feedback inhibition of mTORC2 and explains the observed increase in pAkt (S473) (FIG. 10 c). Similarly, short-term treatment with rapamycin blocks mTORC1-dependent feedback inhibition of mTORC2, resulting in Akt (S473) phosphorylation (FIG. 10 c, e). Interestingly, TGFβ also results in reduced pS6 and increased pAkt S473, and in this regard mimics TCR signal deprivation and mTOR inhibition (FIG. 10 c). - Reduced S6 phosphorylation alone was not sufficient to induce Foxp3 expression, since nutrient deprivation of 18 hour activated CD4 T cells inhibited pS6 but did not induce Foxp3 (continued TCR signaling: 2% Foxp3′; TCR signal deprivation 11% Foxp3+; raparnycin: 25% Foxp3+; IMDM culture medium with 0.1% FCS: 4% Foxp3+; PBS with 10% FCS: 5% Foxp3+; PBS with 0.1% FCS: 2% Foxp3+). It remains open whether the induction of Foxp3 by TCR signal deprivation is due to increased Akt activity following the loss of mTORC1-mediated feedback inhibition, or, alternatively, to the eventual loss of Akt activity, which occurs when long term exposure to rapamycin interferes with the assembly of mTORC2, and consequently with the phosphorylation of Akt (S473). To address this question, we used an allosteric inhibitor, Akti-1/2. Akti-1/2 enhanced Foxp3 expression in recently activated T cells at concentrations around its IC50 for Akt1 and Akt2 (58 nM and 210 nM, respectively), demonstrating that Akt inhibition, not Akt activation drives Foxp3 induction (
FIG. 10 f). - In summary, we have shown that activation creates a window of opportunity for the induction of Foxp3 in naive CD4 T cells. Foxp3 induction appears independent of TGFβ and is antagonised by PI3K/mTOR/Akt signaling. This finding has important implications for understanding immune regulation, as it links the choice between effector and regulatory T cell fate to TCR signal transduction pathways. Consistent with our finding that p110δ regulates Foxp3 expression, higher than normal numbers of Treg cells are generated in the thymi of p110δ deficient mice. In the longer term, p110δ deficiency impairs Treg cell maintenance and function, possibly because p110δ is important for other cell types such mast cells, which in turn affect Treg cells. These considerations, together with the differential role of p110 isoenzymes in Foxp3 regulation we have demonstrated enable new strategies for manipulating the immune response. A potential obstacle to the generation of antigen specific Treg cells by PI3K/mTOR inhibition is if the approach requires the removal of TCR ligands to allow Foxp3 induction. However, we show that PI3K/mTOR inhibitors induce Foxp3 in a sizeable proportion of naive CD4 T cells in the continued presence of anti CD3/CD28 beads (
FIG. 12 ). Foxp3 was also inducible by PI3K/mTOR inhibition in Rag1 deficient AND TCR transgenic CD4 LN cells stimulated by antigen presenting cells and specific peptide, demonstrating that it is advantageously now possible to generate antigen specific Treg cells using PI3K/mTOR inhibitors. - Interestingly, compromised PI3K/mTOR/Akt signaling not only favours Treg cell differentiation, but Akt signaling is reportedly compromised in Treg cells and their targets, raising the possibility that regulatory T cell function involves alterations in PI3K/mTOR/Akt signaling.
- Lack of sustained TCR engagement or compromised TCR signaling may occur in situations relevant to immune regulation, such as antigen presentation by non-professional APCs, low antigen dose during the involution phase of immune responses or mosaic antigen expression. This is consistent with the selection of Treg cells by epithelial cells ectopically expressing tissue-specific antigens in the thymus and in lymph nodes.
- Materials and Methods for Example 8 Mice, cell sorting and culture. Animal work was carried out according to the Animals (Scientific Procedures) Act, UK. Lymph node (LN) cells or thymocytes from wild type were stained, analysed and sorted by flow cytometry as described (Thompson et al., 2007 Immunity Vol 26 pp 335-344) from wild type (C57BL/6, BALB/c or C57BL/6×129) mice or from Rag1 deficient H2b AND TCR transgenic mice. Antigen presenting cells were derived from bone marrow in the presence of GM-CSF and incubated with antigenic peptide. Intracellular staining for Foxp3 protein was done as advised by the manufacturers (eBiosciences.com). The phosphorylation status of S6 ribosomal protein was determined using anti pS6 Ser235/236 (Cell Signaling cat.no. 2211, http://www.cellsignal.com) using the eBioscience Foxp3 staining kit and anti rabbit IgG-FITC or IgG-Cy5 (Jackson ImmunoResearch). For induction of Foxp3 expression, sorted
LN CD4 + CD25−CD62Lhi T cells were cultured at 1-3×106/ml with plate bound anti-TCRβ (H57, Pharmingen, 200 ng/ml) and soluble or plate-bound anti-CD 28 (2 μg/ml, Pharmingen). After 18 hours the cells were either left in place for continued TCR stimulation or moved to uncoated wells with the indicated additives. To assess regulatory function, CD4 T cells cultured as indicated were titrated into round bottom wells containing either 1×105 CFSE labeled total LN cells or 5×104 CFSE labeled CD4+ CD25− T cells and 1×105 mitomycin-C treated (25 μg/ml, 20 min, 37° C.) T cell depleted splenocytes with the indicated concentrations of anti CD3 (2C11, Pharmingen). CD4 T cell CFSE profiles were recorded between 48 and 72 hours later. - Adoptive transfer experiments. CD4+ C125− CD45RBhi naive CD4 cells were transferred into lymphocyte deficient (Rag−/−) hosts and colitis was scored as described (Powrie et al., 1993 Int. Immunol. Vol S pp 1461-1471).
- RT-PCR and northerns and immunoblots. Total RNA was isolated using RNAbee (Tel-Test, Friendswood, Tex.) and reverse transcribed. Real-time PCR analysis was carried out on an Opticon™ DNA engine (MJ Research Inc.; 95° C. for 15 min followed by 40 cycles of 94° C. for 15 s, 60° C. for 30 s and 72° C. for 30 s with a plate read at 72° C.) and normalised to the geometric mean of Ywhaz (tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, zeta polypeptide) and Ube2L3 (ubiquitin conjugating enzyme E2L3) as described (Thompson et al., 2007 above). Primer sequences (5′ to 3′)
-
Ywhaz forward: CGTTGTAGGAGCCCGTAGGTCAT; Ywhaz reverse: TCTGGTTGCGAAGCATTGGG; Ubc forward: AGGAGGCTGATGAAGGAGCTTGA; Ubc reverse: TGGTTTGAATGGATACTCTGCTGGA; Foxp3 forward: ACTCGCATGTTCGCCTACTTCAG; Foxp3 reverse: GGCGGATGGCATTCTTCCAGGT - Immunoblots were done as described (Thompson et al., 2007 above).
- All publications mentioned in the above specification are herein incorporated by reference. Various modifications and variations of the described aspects and embodiments of the present invention will be apparent to those skilled in the art without departing from the scope of the present invention. Although the present invention has been described in connection with specific preferred embodiments, it should be understood that the invention as claimed should not be unduly limited to such specific embodiments. Indeed, various modifications of the described modes for carrying out the invention which are apparent to those skilled in the art are intended to be within the scope of the following claims.
Claims (22)
1. A method of inducing Foxp3 expression in a T cell comprising
(i) stimulating a T cell
(ii) inhibiting signalling via PI3K alpha or PI3K delta or m-TOR or Akt in said T cell, wherein said inhibition is commenced 10 to 22 hours after the stimulation of (i).
2. A method of inducing Foxp3 expression in a previously stimulated T cell comprising inhibiting signalling in said T cell via PI3K alpha or PI3K delta or m-TOR or Akt, wherein said inhibition is commenced 10 to 22 hours after the stimulation.
3. A method of treating a subject in need of regulatory T cell(s) comprising
(i) removing a sample comprising a T cell from a subject
(ii) stimulating said T cell
(iii) optionally withdrawing said stimulation
(iv) inhibiting signalling via PI3K alpha or PI3K delta or m-TOR or Akt in said T cell, wherein said inhibition is commenced 10 to 22 hours after the stimulation of (i); and
(v) reintroducing said T cell to said subject.
4. A method according to claim 1 wherein said inhibition is commenced about 17 to 19 hours after the stimulation.
5. A method according to claim 4 wherein said inhibition is commenced about 18 hours after the stimulation.
6. A method according to claim 1 wherein the inhibiting signalling step comprises inhibiting signalling via PI3K alpha or PI3K delta.
7. A method according to claim 6 wherein inhibiting signalling via PI3K alpha or PI3K delta comprises contacting said cell with PI3K inhibitor, and wherein said inhibitor inhibits PI3K alpha and/or PI3K delta.
8. A method according to claim 1 further comprising withdrawing said stimulation no later than at the time of inhibiting signalling.
9. A method according to claim 1 wherein stimulating said T cell comprises stimulating said T cell via the T cell receptor (TCR).
10. A method of inducing of a T cell into a regulatory T cell comprising contacting said T cell with a PI3K inhibitor wherein said inhibitor inhibits PI3K alpha and/or PI3K delta.
11-14. (canceled)
15. A kit comprising
(i) a TCR stimulant; and
(ii) an inhibitor of PI3K alpha or delta.
16. A kit according to claim 15 wherein said TCR stimulant comprises anti-TCR and anti-CD28 antibody.
17. A kit according to claim 15 further comprising an m-TOR inhibitor.
18. A kit according to claim 17 wherein said m-TOR inhibitor is rapamycin.
19. A kit according to claim 15 further comprising an Akt inhibitor.
20. A method for generating a regulatory T-cell comprising
(i) stimulating a T cell
(ii) inhibiting signalling via PI3K alpha or PI3K delta or m-TOR or Akt in said T cell, wherein said inhibition is commenced 10 to 22 hours after the stimulation of (i).
21. A method for generating a regulatory T-cell comprising treating a stimulated CD8− T cell with phosphatidyl inositol 3 kinase (PI3K) inhibitor wherein said inhibitor inhibits PI3K alpha and/or PI3K delta.
22. A method according to claim 1 wherein said PI3K inhibitor comprises LY294002.
23. A method according to claim 20 wherein said PI3K inhibitor comprises LY294002.
24. A method according to claim 10 wherein said PI3K inhibitor comprises LY294002.
25. A kit according to claim 15 wherein said PI3K inhibitor comprises LY294002.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12/518,739 US20100034786A1 (en) | 2006-12-14 | 2007-12-13 | Use of PI3K M-TOR and Akt Inhibitors to Induce FOXP3 Expression and Generate Regulatory T Cells |
Applications Claiming Priority (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US87468306P | 2006-12-14 | 2006-12-14 | |
GB0624999A GB0624999D0 (en) | 2006-12-14 | 2006-12-14 | Methods and users |
GB0624999.9 | 2006-12-14 | ||
US91244807P | 2007-04-18 | 2007-04-18 | |
GB0707609.4 | 2007-04-19 | ||
GB0707609A GB0707609D0 (en) | 2007-04-19 | 2007-04-19 | Methods and uses |
PCT/GB2007/004784 WO2008071974A2 (en) | 2006-12-14 | 2007-12-13 | Use of pi3k m-tor and akt inhibitors to induce f0xp3 expression and generate regulatory t cells |
US12/518,739 US20100034786A1 (en) | 2006-12-14 | 2007-12-13 | Use of PI3K M-TOR and Akt Inhibitors to Induce FOXP3 Expression and Generate Regulatory T Cells |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/GB2007/004784 A-371-Of-International WO2008071974A2 (en) | 2006-12-14 | 2007-12-13 | Use of pi3k m-tor and akt inhibitors to induce f0xp3 expression and generate regulatory t cells |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/527,044 Continuation US9314485B2 (en) | 2006-12-14 | 2014-10-29 | Use of PI3K M-TOR and AKT inhibitors to induce FOXP3 expression and generate regulatory T cells |
Publications (1)
Publication Number | Publication Date |
---|---|
US20100034786A1 true US20100034786A1 (en) | 2010-02-11 |
Family
ID=39048069
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/518,739 Abandoned US20100034786A1 (en) | 2006-12-14 | 2007-12-13 | Use of PI3K M-TOR and Akt Inhibitors to Induce FOXP3 Expression and Generate Regulatory T Cells |
US14/527,044 Expired - Fee Related US9314485B2 (en) | 2006-12-14 | 2014-10-29 | Use of PI3K M-TOR and AKT inhibitors to induce FOXP3 expression and generate regulatory T cells |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/527,044 Expired - Fee Related US9314485B2 (en) | 2006-12-14 | 2014-10-29 | Use of PI3K M-TOR and AKT inhibitors to induce FOXP3 expression and generate regulatory T cells |
Country Status (5)
Country | Link |
---|---|
US (2) | US20100034786A1 (en) |
EP (1) | EP2094837B1 (en) |
JP (1) | JP2010512738A (en) |
GB (1) | GB2444853B (en) |
WO (1) | WO2008071974A2 (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011126806A1 (en) * | 2010-04-08 | 2011-10-13 | The Trustees Of The University Of Pennsylvania | Methods to expand a t regulatory cell master cell bank |
WO2014068070A1 (en) | 2012-10-31 | 2014-05-08 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for preventing antiphospholipid syndrome (aps) |
US10092597B2 (en) | 2014-01-14 | 2018-10-09 | The University Of Hong Kong | Human CD8+ regulatory T cells inhibit GVHD and preserve general immunity in humanized mice |
WO2019234221A1 (en) | 2018-06-08 | 2019-12-12 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for stratification and treatment of a patient suffering from chronic lymphocytic leukemia |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2011529920A (en) * | 2008-07-31 | 2011-12-15 | ジェネンテック, インコーポレイテッド | Pyrimidine compounds, compositions and methods of use |
WO2010151517A2 (en) * | 2009-06-25 | 2010-12-29 | The Regents Of The University Of Michigan | Antigen-specific long-term memory t-cells |
WO2011078990A1 (en) * | 2009-12-14 | 2011-06-30 | Benaroya Research Institute At Virginia Mason | Hydrogels comprising hyaluronan and at least one t cell induction agent |
WO2013050596A1 (en) | 2011-10-06 | 2013-04-11 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Method of maintaining foxp3 expression in expanded t regulatory cell |
UY35675A (en) | 2013-07-24 | 2015-02-27 | Novartis Ag | SUBSTITUTED DERIVATIVES OF QUINAZOLIN-4-ONA |
RS60106B1 (en) | 2014-04-25 | 2020-05-29 | Bluebird Bio Inc | Mnd promoter chimeric antigen receptors |
NZ726989A (en) * | 2014-06-06 | 2020-08-28 | Bluebird Bio Inc | Improved t cell compositions |
US10383929B2 (en) | 2014-12-12 | 2019-08-20 | Bluebird Bio, Inc. | BCMA chimeric antigen receptors |
WO2017099712A1 (en) | 2015-12-07 | 2017-06-15 | Bluebird Bio, Inc. | Improved t cell compositions |
US11413309B2 (en) | 2016-01-20 | 2022-08-16 | Fate Therapeutics, Inc. | Compositions and methods for immune cell modulation in adoptive immunotherapies |
US11096964B2 (en) * | 2016-01-20 | 2021-08-24 | Fate Therapeutics, Inc. | Compositions and methods for immune cell modulation in adoptive immunotherapies |
WO2018106595A1 (en) | 2016-12-05 | 2018-06-14 | Fate Therapeutics, Inc. | Compositions and methods for immune cell modulation in adoptive immunotherapies |
JP7206212B2 (en) * | 2017-03-06 | 2023-01-17 | タラリス・セラピューティクス・インコーポレイテッド | Methods and compositions for determining efficacy of therapeutic cell compositions |
CN115698266A (en) * | 2020-05-15 | 2023-02-03 | 博迪贺康(北京)生物技术有限公司 | T cell and preparation method and application thereof |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030026802A1 (en) * | 2000-09-26 | 2003-02-06 | Markovitz David M. | Novel methods for inhibition of HIV replication |
US20040072766A1 (en) * | 1994-04-29 | 2004-04-15 | The United States Of America As Represented By The Secretary Of Navy | Methods for modulating T cell responses by manipulating intracellular signal transduction |
US6734001B1 (en) * | 1997-03-17 | 2004-05-11 | Medical Research Council | 3-phosphoinositide-dependent protein kinase |
US20040126781A1 (en) * | 1999-07-28 | 2004-07-01 | Genetics Institute, Inc. | Methods of preventing immune-mediated abortion by inhibiting a CD28-mediated costimulatory signal |
US20040241162A1 (en) * | 2000-02-24 | 2004-12-02 | Xcyte Therapies, Inc. | Activation and expansion of cells |
US20050032725A1 (en) * | 2002-10-09 | 2005-02-10 | Toerrx, Inc. | Molecules preferentially associated with effector T cells or regulatory T cells and methods of their use |
US20050261317A1 (en) * | 2000-04-25 | 2005-11-24 | Icos Corporation | Inhibitors of human phosphatidylinositol 3-kinase delta |
US20070048293A1 (en) * | 2005-05-31 | 2007-03-01 | The Trustees Of The University Of Pennsylvania | Manipulation of PTEN in T cells as a strategy to modulate immune responses |
US7344870B2 (en) * | 1997-03-17 | 2008-03-18 | Medical Research Council | 3-phosphoinositide-dependent protein kinase |
-
2007
- 2007-12-13 US US12/518,739 patent/US20100034786A1/en not_active Abandoned
- 2007-12-13 GB GB0724319A patent/GB2444853B/en not_active Expired - Fee Related
- 2007-12-13 EP EP07848526A patent/EP2094837B1/en not_active Not-in-force
- 2007-12-13 JP JP2009540860A patent/JP2010512738A/en active Pending
- 2007-12-13 WO PCT/GB2007/004784 patent/WO2008071974A2/en active Application Filing
-
2014
- 2014-10-29 US US14/527,044 patent/US9314485B2/en not_active Expired - Fee Related
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040072766A1 (en) * | 1994-04-29 | 2004-04-15 | The United States Of America As Represented By The Secretary Of Navy | Methods for modulating T cell responses by manipulating intracellular signal transduction |
US6734001B1 (en) * | 1997-03-17 | 2004-05-11 | Medical Research Council | 3-phosphoinositide-dependent protein kinase |
US7344870B2 (en) * | 1997-03-17 | 2008-03-18 | Medical Research Council | 3-phosphoinositide-dependent protein kinase |
US20040126781A1 (en) * | 1999-07-28 | 2004-07-01 | Genetics Institute, Inc. | Methods of preventing immune-mediated abortion by inhibiting a CD28-mediated costimulatory signal |
US20040241162A1 (en) * | 2000-02-24 | 2004-12-02 | Xcyte Therapies, Inc. | Activation and expansion of cells |
US20050261317A1 (en) * | 2000-04-25 | 2005-11-24 | Icos Corporation | Inhibitors of human phosphatidylinositol 3-kinase delta |
US20030026802A1 (en) * | 2000-09-26 | 2003-02-06 | Markovitz David M. | Novel methods for inhibition of HIV replication |
US20050032725A1 (en) * | 2002-10-09 | 2005-02-10 | Toerrx, Inc. | Molecules preferentially associated with effector T cells or regulatory T cells and methods of their use |
US20070048293A1 (en) * | 2005-05-31 | 2007-03-01 | The Trustees Of The University Of Pennsylvania | Manipulation of PTEN in T cells as a strategy to modulate immune responses |
Non-Patent Citations (2)
Title |
---|
Chen et al., 2003, Conversion of Peripheral CD4+CD25- Naïve T cells to CD4+CD25+ Regulatory T cells by TGF-beta Induction of Transcription Factor Foxp3, The Journal of Experimental Medicine, 198(12): 1875-1886. * |
Peterson et al., 2001, Coupling of the TCR to Integrin Activation by SLAP-130/Fyb, Science, 293: 2263-2265. * |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011126806A1 (en) * | 2010-04-08 | 2011-10-13 | The Trustees Of The University Of Pennsylvania | Methods to expand a t regulatory cell master cell bank |
WO2014068070A1 (en) | 2012-10-31 | 2014-05-08 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for preventing antiphospholipid syndrome (aps) |
US10092597B2 (en) | 2014-01-14 | 2018-10-09 | The University Of Hong Kong | Human CD8+ regulatory T cells inhibit GVHD and preserve general immunity in humanized mice |
US10653722B2 (en) | 2014-01-14 | 2020-05-19 | The University Of Hong Kong | Human CD8+ regulatory T cells inhibit GVHD and preserve general immunity |
WO2019234221A1 (en) | 2018-06-08 | 2019-12-12 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for stratification and treatment of a patient suffering from chronic lymphocytic leukemia |
Also Published As
Publication number | Publication date |
---|---|
WO2008071974A2 (en) | 2008-06-19 |
US20150147304A1 (en) | 2015-05-28 |
GB2444853B (en) | 2010-02-24 |
JP2010512738A (en) | 2010-04-30 |
EP2094837B1 (en) | 2012-04-25 |
US9314485B2 (en) | 2016-04-19 |
GB0724319D0 (en) | 2008-01-30 |
EP2094837A2 (en) | 2009-09-02 |
WO2008071974A3 (en) | 2008-10-30 |
GB2444853A (en) | 2008-06-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9314485B2 (en) | Use of PI3K M-TOR and AKT inhibitors to induce FOXP3 expression and generate regulatory T cells | |
Tang et al. | Transplant trials with Tregs: perils and promises | |
Xu et al. | Glycolytic ATP fuels phosphoinositide 3-kinase signaling to support effector T helper 17 cell responses | |
Kim et al. | Role of PI3K/Akt signaling in memory CD8 T cell differentiation | |
Huynh et al. | Signals and pathways controlling regulatory T cells | |
McMurchy et al. | Moving to tolerance: clinical application of T regulatory cells | |
Benhamron et al. | Direct activation of mTOR in B lymphocytes confers impairment in B‐cell maturation andloss of marginal zone B cells | |
US9532997B2 (en) | Compositions and methods for promoting intestinal stem cell function | |
AU2006232374A1 (en) | Preventing rejection of transplanted tissue using regulatory T cells | |
Ren et al. | Tolerogenic dendritic cells modified by tacrolimus suppress CD4+ T-cell proliferation and inhibit collagen-induced arthritis in mice | |
Chong et al. | Regulation of alloantibody responses | |
Lin et al. | Differential mTOR and ERK pathway utilization by effector CD4 T cells suggests combinatorial drug therapy of arthritis | |
Bi et al. | mTOR regulates T-cell differentiation and activation in immunity and autoimmunity | |
Muthukumarana et al. | Evidence for functional inter-relationships between FOXP3, leukaemia inhibitory factor, and axotrophin/MARCH-7 in transplantation tolerance | |
US8951796B2 (en) | Methods and compositions for expanding and stabilizing natural regulatory T cells | |
ES2386082T3 (en) | Use of PI3K and AKT inhibitors to induce FOXP3 expression and generate regulatory T cells | |
US20100297123A1 (en) | Combination therapy to inhibit t cell effector function | |
Bickerstaff et al. | Allograft Acceptance Despite Differential Strain-Specific Induction of TGF-Ƴ/IL-10-MediatedImmunoregulation | |
Xie et al. | IL-21 prevents expansion of CD8+ CD28− T cells stimulated by IL-15 and changes their subset distribution | |
Shrestha | PTEN signaling in regulatory T cells and inflammatory disease | |
Yang | The Developmental Heterogeneity of NK Cells and Its Alteration in Mice with Conditional Raptor-or Rictor-deficiency and a Patient With GATA 2T354M Mutation | |
Chang | The role of Erk MAPK pathway in CD4 T cell proliferation and differentiation | |
Geiger et al. | Uncoupling of IL-2 Signaling from Cell Cycle | |
Kim | SIGNALING AND TRANSCRIPTIONAL BASES OF T CELL HOMEOSTASIS AND DIFFERENTIATION | |
Chandrasekaran | Phospholipase D Signaling in T Cells |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: MEDICAL RESEARCH COUNCIL,UNITED KINGDOM Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:MERKENSCHLAGER, MATTHIAS MICHAEL;REEL/FRAME:023420/0337 Effective date: 20090710 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |